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Abstract 
Human African Trypanosomiasis (HAT), commonly known as Sleeping Sickness, is 
endemic in over 36 countries in sub-Saharan Africa.  It is caused by the parasitic 
subspecies Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense, which is 
transmitted to humans by the tsetse fly. The World Health Organisation estimates that 0.5 
million people are currently infected with the disease, with a further 60 million at risk. 
HAT is lethal if left untreated and there is no vaccine available. There are only four 
accessible drugs, which are all inadequate and highly toxic. Thus there is a vital need for 
novel anti-parasitic agents. 
Compounds interfering with polyamine biosynthesis or function have shown potential use 
as anti-cancer, anti-HIV, anti-fungal and antiparasitic agents. The overall aim of this work 
was to synthesise novel macrocyclic polyamines containing different substituents to 
increase the toxicity against T. brucei. 
Twenty racemic substituted tetraazamacrocycles B have been synthesised using an iron 
template method in good yields (54-100%) from triethylenetetraamine and aromatic 
glyoxal derivatives A. The R-groups were aromatic or heteroaromatic and were selected to 
give compounds with varying electronic demand and a broad range of log P values. Two 
derivatives contain parasite-specific recognition motifs were also prepared. The 
compounds were tested against T. brucei and several of the analogues displayed high 
activity. 
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Some of these azamacrocycles were also tested for activity against the malarial parasite 
Plasmodium falciparum, and for oligopeptidase B (OPB) inhibition, with a number of 
compounds exhibiting promising results. 
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Fmoc   9-fluorenylmethoxycarbonyl 
g   gram 
h   hours 
HAT   Human African Trypanosomiasis 
HDM2   Human Double Minute gene 2 
HEK   Human Embryonic Kidney 
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Hz   Hertz 
IC50   concentration of a drug to inhibit 50% of enzyme activity 
ICR   Institute for Cancer Research 
IR   infra red 
J   NMR spectra coupling constant 
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kg   kilogram 
Km   binding constant of P2 transporter 
L   litre (or ligand in TETA complex with FeCl3) 
µL   microlitre 
LEC   lowest effective concentration 
LiHMDS  lithium hexamethyldisilazane 
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LRMS   low resolution mass spectrometry 
m   multiplet 
M   molar (or metal in TETA complex with FeCl3) 
µm   micromole 
µM   micromolar 
λmax   maximum ultraviolet-visible absorbance 
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MDM2  Mouse Double Minute gene 2 
Me   methyl 
Mel B   melarsoprol 
MeOH   methanol 
mg   milligram 
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ROS   reactive oxygen species 
rt   room temperature 
s   singlet 
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1 Human African Trypanosomiasis 
1.1 Human African Trypanosomiasis (HAT) 
HAT, also known as sleeping sickness, is a vector-borne parasitic disease that is endemic 
in 36 countries in sub-Saharan Africa (see Figure 1). The World Health Organisation 
(WHO) estimate that over 60,000 people die annually from sleeping sickness, although 
many more infections and deaths go unreported.1 Half a million people are currently 
infected and 60 million are at daily risk. HAT is one of the major factors constraining 
Africa’s social and economic development. A subsistence farmer speaking at the 28th 
meeting of the International Scientific Council for Trypanosomiasis Research and Control, 
summed up the HAT problem: “My child is dying of malaria, but it is African 
trypanosomiasis that is killing us.”2 
 
Figure 1 
1.1.1 HAT Transmission 
The parasites, named trypanosomes, are transmitted to humans and animals through the 
bite of the tsetse fly of the genus Glossina (Figure 2). Tsetse flies inhabit the vast savannah 
across sub-Saharan Africa, breeding in warm humid areas of vegetation along rivers, lakes, 
forests and scrubland.1,3 Man, cattle and wild animals act as reservoirs of the parasite, and 
the tsetse fly feeds on their blood. The disease can be passed on in other ways; parasites 
can cross the placenta and infect the foetus causing abortion or perinatal death. Accidental 
infections in laboratories through handling infected blood are uncommon, and there is only 
one reported case of sexually transmitted sleeping sickness.4 
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Figure 2 
1.1.2 HAT History 
Trypanosomiasis was first recorded in the 14th century in the country of Mali. However the 
destructive force of this disease was not recognised until an epidemic in Uganda and the 
Congo Basin (1896-1906) killed half a million people.1 The parasite was identified by two 
English doctors in 1902, Ford and Dutton, working in the Gambia, and the tsetse fly was 
recognised as the vector by Sir David Bruce (after whom T. brucei are named) in 1903.5 
There have been another two major epidemics in Africa since then, one affecting several 
countries in 1920, and one in 1970, which is still progressing today.1 
1.1.3 Current Situation of HAT 
Sleeping sickness is a daily threat, affecting rural and remote areas where the population is 
dependent on agriculture, fishing and hunting. These areas generally have little or no 
available health system, and the disease also follows social and economic problems such as 
poverty, displacement of population, political instability and war. The disease has a 
devastating impact on these areas by decreasing the labour force and hampering work 
capacity and production.6 The disability adjusted life years lost due to sleeping sickness are 
two million.7 In countries such as Sudan and Angola, the ability to deal with the epidemic 
situation of the disease has been surpassed, and the prevalence of the disease is greater than 
20% of the population.6 
Other subspecies of the parasite cause animal trypanosomiasis, for example domestic cattle 
suffer from Nagana (Figure 3). Nagana can cause a 25% decrease in milk production, a 
20% decrease in calving as well as approximately three million livestock deaths per year, 
which also has a devastating effect on the community.8 
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Figure 3 
1.2 The Trypanosome 
Trypanosomes are protozoa of the family Trypanosomatidiae. The genus Trypanosoma 
may be divided into two groups, the stercoraria and the salivaria, which are both infective 
parasites (Figure 4). The stercoraria include the species T. cruzi that causes South 
American trypanosomiasis known as Chagas’ disease. The salivarian group includes T. 
brucei gambiense and T. brucei rhodesiense, which are parasites of the subgenus 
Trypanozoon.9 
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Figure 4 
There are two human forms of sleeping sickness, a chronic form and an acute form. The 
chronic form of the disease is caused by T. brucei gambiense and it affects Western and 
Central Africa with the disease lasting up to several years. Acute sleeping sickness, caused 
by T. brucei rhodesiense, is found in countries of Eastern and Southern Africa and lasts 
several weeks. Both forms if left untreated lead to death.1,6 The two species are 
morphologically indistinguishable, and their body length range is 14-33 µm (Figure 5).10 
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Figure 5 
1.3 Trypanosome Life Cycle 
During a blood meal, metacyclic trypomastigotes are injected into the host’s skin by the 
fly. The parasites enter the lymphatic system and pass to the bloodstream. In the blood, the 
parasites are transformed into bloodstream trypomastigotes. These are replicated and are 
carried to other sites in the body, reaching other blood-fluids such as spinal and lymph 
fluid. A tsetse fly becomes infected with bloodstream trypomastigotes by taking a blood 
meal, and the parasites then transform into procyclic trypomastigotes in the fly’s midgut. 
These proliferate via binary fission, leave the midgut and then convert into epimastigotes, 
which reach the fly’s salivary glands. It is at this stage that the cycle begins again, with the 
cycle in the fly taking around three weeks (see Figure 6).10 
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Figure 6 
1.4 Disease and Diagnosis 
The symptoms of first stage HAT are non-specific; fever, headaches, weakness, joint pain 
and itching. The parasite also invades the lymph system causing lymph nodes to swell up. 
Gradually the immune system is exhausted and the symptoms become more pronounced; 
anaemia, cardiovascular, endocrine and kidney disorders, abortion and oedema appear.1 
The parasite will then invade the central nervous system (CNS) and second stage 
symptoms begin. Depending on acute or chronic infection this can take as little as a few 
weeks, or several years after initial inoculation. At this time, the patients experience severe 
neurological and psychiatric problems. They lose the ability to concentrate and are prone to 
unpredictable and sudden mood swings, leading to confusion, violence and lethargy. Due 
to this torpor, eating, speaking and walking becomes a tremendous effort. One of the 
disease’s most prominent symptoms is the inability to sleep at night, but exhaustion and 
times of sleep-like unconsciousness during the day. Eventually the disease leads to coma 
and death.1 
Diagnosis is dependent on locating trypanosomes within the blood, lymphatic or 
cerebrospinal fluids of the patients. Early diagnosis of patients is rare due to the non-severe 
early symptoms plus sparse and inadequate health care. Therefore prognosis of the disease 
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is normally when the parasite has already invaded the CNS and the patient is displaying 
symptoms. The parasitaemia can be very low and difficult to detect and so techniques are 
used to concentrate (centrifugation or mini anion-exchange) and find parasites. Another 
way to detect infection is by measuring the presence of above normal levels of leukocytes 
(>5 cells/mL) or protein (>37 mg/100mL) within the CNS, or by the detection of low red 
blood cell count or by carrying out antibody and antigen tests.9 These methods are invasive 
and difficult to use in resource-poor centres. Highly trained staff are also required for 
accurate results. 
1.5 Prevention and Control 
The WHO has set up a programme with three parts to give the most effective approach to 
sleeping sickness control. Of the 36 countries in which HAT is endemic, 22 are actively 
involved in this programme.1 
The first and most crucial part is mobile medical monitoring with specialised staff using 
effective diagnostic equipment. Case-by-case screening is not practically possible in highly 
endemic regions and so systematic screening within identified foci is the best approach. 
Patients attend centres to determine what stage of the disease they are at, and what 
treatment is best. Patients then attend post-therapy follow-up care.1 
Secondly, the availability of fixed-post medical services at hospitals, health centres and 
dispensaries is important, where blood samples are taken before analysis at reference 
centres.1 
Finally, the most cheap and ecologically accepted method is vector control. In theory this 
is the most effective as the female flies only produce ten larvae in their short life span. 
Spraying the tsetse’s habitat with insecticide from the ground and air, and destroying 
bushland are traditional schemes. Another way is to bait the flies using livestock that are 
sprayed with insecticide. These methods however require commitment and financial 
backing from the local government and community, which cannot be guaranteed in all 
areas. The most simple and effective form of control is using nets and traps for the flies.1 
The epidemic in 1920 sparked the employment of control campaigns, mobile health teams 
and administration structures that screened millions of people at risk. The drug 
pentamidine was used as a preventative, with each person receiving one injection as it was 
wrongly thought that a low dose of this drug gave six months protection from the disease. 
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By the start of African independence in the 1960s, the disease had almost disappeared. 
However, after the initial success, effective monitoring ceased and so the disease 
reappeared in endemic form.1 
1.6 Treatment 
An editorial in Science titled “Trypanosomes at the Gates” highlights that T. brucei is one 
of the species that causes one of the most major region-specific human diseases.11 The 
disease has been studied for over a century but it still relies upon some of the most highly 
toxic and inadequate drugs. These drugs were invented almost 100 years ago! The reason 
for this is simple; the victims of the disease being among the world’s poorest people, and 
there has been a lack of investment by the pharmaceutical industry.12 
There is no vaccine against HAT due to an immuno-protective process using antigenic 
variation to protect the parasite. Trypanosomes have a variable surface glycoprotein (VSG) 
coat on their surface. The VSG has over 1000 different genes encoding for proteins, and it 
undergoes constant antigenic variation in order to evade the host’s immune systems.13 
However, there are a handful of drugs available but they all come with serious side effects 
and drug resistance is on the increase. Four drugs are currently licensed to treat HAT 
which are all stage-specific.5,14 
1.6.1 Suramin 
Developed in 1916 by Oskar Dressel as a by-product in the German dye company Bayer, 
suramin 1 is a colourless polysulfonated symmetrical naphthalene derivative. It was first 
used an anti-sleeping sickness drug in 1922 after it had been observed that a number of 
naphthalene dye substances had trypanosomidal activity.15 Suramin is a highly charged 
compound, containing six negative charges at physiological pH, and so it does not cross 
the blood-brain barrier. Suramin inhibits many enzymes by electrostatic interactions: For 
example, it inhibits reverse transcriptase, a key enzyme of the Human Immunodeficiency 
Virus (HIV).16 The drug has also been tested against a variety of cancers, where it has been 
used in clinical trials against hormone-refractory prostate cancer.17 However, suramin’s 
mode of action has not been elucidated, although some suggestions are that it acts using an 
anti-angiogenesis effect along with interaction with growth factor receptors.18,19 
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Suramin 1 is used in early stage HAT and it the preferred drug for use in East Africa. It is 
used in West Africa for the treatment of onchoceriasis (River blindness) and not for 
sleeping sickness. The drug is administered in 20 mg per kg body weight doses to patients 
by intravenous injection, and it circulates the blood associated with low-density 
lipoproteins and serum albumin. It is then taken up slowly by the parasite and host via 
receptor mediated endocytosis.5 
1.6.2 Pentamidine 
Pentamidine 2 is from a class of drugs called the diamidines, which were developed during 
the 1930s from the lead compound synthalin 3 which is a hypoglycaemic agent.20 
Pentamidine, also known as lomidine, is an aromatic diamidine which works directly 
against the parasites independent of the host. This drug, like suramin, is also used to treat 
early stage HAT because it doesn’t cross the blood-brain barrier. It is active against T. 
brucei gambiense and it shouldn’t be used against T. brucei rhodiense due to primary 
resistance in many areas of Africa.5 Pentamidine is also used against antimony refractory 
leishmania and Pneumocystis carinii pneumonia.12 The mode of action of diamidines has 
not been established, although their amphipathic character with charge and hydrophobicity 
makes them very like polyamines as they have the ability to interact with negatively 
charged intracellular components.20 The interaction of pentamidine with intercatenated 
circular DNA molecules is extremely close, and these DNA units make up the 
mitochondrial genome of all kinetoplastid flagellates.12 A number of alternative cellular 
targets have been proposed, however as the drug concentrates within the cells to mM 
levels, it is thought that its toxicity may arise simply by the inhibition of many cellular 
targets.12 The recommended dose is seven intramuscular injections daily at 4 mg/kg body 
weight.5 
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1.6.3 Melarsoprol 
Despite being known as “the king of poisons”, arsenic-containing compounds have been 
used as therapeutics since 2000 B.C. when arsenic trioxide (As2O3) was used as a drug and 
a poison in the Far East and India. In 400 B.C. Hippocrates and Aristotle administered 
orpiment (As2S3), and realger (AsS) as a treatment for ulcers. From the late 18th century 
until the 1950s, arsenic was used in Fowler’s solution (1% KAsO2) in Europe and America 
as a remedy for asthma, syphilis, rheumatism, skin disorders and was the first 
chemotherapeutic drug against leukaemia.21,22 
Thomas and Breinl observed in 1905 the trypanolytic activity of the aromatic arsenical 
atoxyl 4. Paul Ehrlich developed the first clinically effective arsenical for the treatment of 
syphilis in 1910. This drug, named salvarsan 5, or ‘606’, is often considered to be the 
prototypic chemotherapeutic agent.23 At this time, Ehrlich wrongly believed that 
trypanosomes and the venereally transmitted T. equiperdum (a spirochaete) were related. 
Tryparsomide 6, developed in 1919 by Jacobs and Heidelberger, was the first clinically 
effective arsenical against HAT.20 
H2N As ONa
OH
O
As
HO
NH2
HN As
OH
OH
O
H2N
O
4 5 6
As
NH2
OH
 
Freidheim’s melaminophenyl arsenicals were developed in the 1940s, culminating with 
melarsoprol 7 (arsobal, Mel B) in 1947,24 which is a drug that remains today as the most 
widely used trypanoside.20 However, Mel B often has lethal side effects. A doctor working 
for Médecins Sans Frontièrs (MSF) in Uganda states, “Melarsoprol is a terrible drug – you 
don’t feel proud injecting it. It is caustic, it burns, and you don’t know if you are going to 
save your patient or kill him”.3 
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Melarsoprol is very effective in the treatment of both early and late stages of HAT in both 
the Eastern and Western countries of Africa, against both the acute and chronic forms of 
the infection. The treatment consists of several series of injection using 3.6 mg/kg, with 
each series separated by at least a week.5 However Mel B is only ever used in late stages of 
the disease due to its risks. Treatment using this drug is linked with acute, reactive 
encephalopathy (affects functions of the brain) in 5-10% of the patients, which results in 
paralysis, brain damage and in some cases (10-70%) death.1,5 
Again, it is not fully understood how Mel B 7 or other arsenicals are toxic against 
trypanosomes, although it is understood that the drug is accumulated in the parasite using 
an unusual amino-purine transporter.25 The loss of this transporter leads to drug resistance 
(see Chapter 1.8).20,25 The trivalent oxidation state is more toxic than the pentavalent state, 
and trivalent arsenicals react aggressively and reversibly with vicinal dithiols in proteins 
and therefore, a number of proteins are inhibited by these compounds (Figure 7).20 
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Figure 7 
When treated with Mel B in vitro, the parasite quickly loses its motility, which is rapidly 
followed by lysis, resulting in cell death. It would therefore seem that Mel B has an effect 
on the cell’s metabolism and membrane integrity.20 Successful trials against leukaemia and 
myeloma using melarsoprol in vitro reached clinical trials although unfortunately the same 
reactive encephalopathy was observed.26,27 
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1.6.4 DL-α-Difluoromethylornithine 
DL-α-Difluoromethylornithine 8 (DFMO), also known as eflornithine, is the only new 
drug to be developed in the last fifty years. Developed in the 1970s by Albert 
Sjoerdsmanot with clinical trials in the 1980s, DFMO is known as the ‘resurrection drug’ 
due to its effectiveness against late stage T. brucei gambiense infections that are resistant 
to Mel B.28 Comatosed patients have been known to wake up rapidly and resume their 
usual activities on DFMO injection. 
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DFMO is not recommended as a treatment against the acute form of the disease as many T. 
brucei rhodiense are naturally resistant strains.20 Therefore DFMO is efficiently used to 
treat early and late stages of West African sleeping sickness. Eflornithine was originally 
developed as an anticancer agent, however it remains at the trial stages as clinicians are 
still determining which malignancy it suits best.22 
DFMO 8 is an analogue of ornithine, which is a specific suicide inhibitor of the enzyme 
ornithine decarboxylase (ODC). ODC is the first enzyme in the pathway of trypanosome 
polyamine synthesis (see Chapter 2.3.2). DFMO inhibits ODC with a similar affinity in 
both the trypanosome and mammalian host enzymes. However this drug is more specific to 
the parasite’s enzyme because trypanosomes have an ODC that is degraded and reformed 
within the cells at a much lower rate than in mammals. DFMO therefore deprives the 
parasites of ODC resulting in delayed polyamine synthesis for a longer time than in the 
mammals. The growth-arrested parasites are then removed by a functional immune-
system.12 
In 1990, the drug was approved by the United States Food and Drug Administration 
(FDA), but unfortunately the company responsible for its production, Aventis, stopped its 
production in 1999. However, in 2001, Aventis signed a long-term agreement to 
manufacture and donate the drug, in association with MSF and WHO.1,3 
Eflornithine must be given in large quantities due to its rapid excretion. A full treatment 
contains 400 g taken over a period of two weeks, via an infusion followed by oral 
administration in fruit juice.22 
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1.6.5 Additional Drugs 
There are a number of experimental nitroheterocyclic trypanoside compounds that are 
being investigated for the treatment of HAT. The first is nifurtimox 9, which is a drug 
currently in use against Chagas’ disease.29 The nitro group of the compound is pivotal to its 
activity. Parasite death is thought to be via the one-electron reduction of the nitro group, 
which generates a free radical, which goes on to produce oxygen metabolites such as 
hydrogen peroxide, hydroxyl free radicals and superoxide.30 Nifurimox has shown limited 
success against arsenical refractory T. brucei in trials within West Africa.31 This drug is not 
very parasite-specific as it is thought to enter cells by passive diffusion.12 
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The second experimental nitro heterocyclic compound is called megazol 10, which is a 5-
nitroimidazole that shows good efficacy against T. cruzi and T. brucei.32,33 Megazol enters 
the parasite by passive diffusion although the compound possesses a structural motif 
recognised by the amino-purine transporter responsible for the uptake of other 
trypanosomidal drugs.25 T. cruzi is an intracellular parasite and therefore megazol activity 
indicates that the drug is specific to the parasite via a target of activation by the parasites.12 
Drugs for the treatment of Nagana are ethidium 11, isomethamidium 12 (samorin) and 
berenil 13.5 These treatments are effective but are suspected mutagens and teratogens 
because of their ability to intercalate DNA, and so cannot be used to treat HAT. A water-
soluble analogue of melarsoprol called cymelarsen 14 has also recently been introduced.20 
Treated cattle may only be slaughtered for consumption several months after the end of the 
treatment, to ensure there are no drug residues in the meat. 
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1.7 Drug Uptake by Trypanosomes 
Trypanosomes live and move freely in the bloodstream and cerebral-spinal fluid of their 
host, and do not become intracellular. Therefore drugs to target these parasites only have to 
cross one membrane to reach the interior, and this gives us an opportunity to target drugs 
selectively to these cells.14 
Hydrophobic drugs in general can directly enter the cells of trypanosomes and their 
mammalian host via passive diffusion across the lipid bilayer, but there is no selective 
accumulation within the parasite. Hydrophilic drugs on the other hand can only cross the 
cell’s lipid membranes by means of active transport using specific channels or transporters. 
Drugs can therefore be chosen to exploit any differentiating uptake process between the 
host and parasite.14 
1.7.1 Trypanosome Transporters 
As early as 1938, studies by Hawking suggested that parasites actively accumulated some 
arsenical compounds.34 He noticed that drug-resistant parasites did not accumulate drugs. 
In 1959, Williamson discovered that compounds containing the melamine motif could 
antagonise the anti-parasite action of known trypanosides, the diamidines and 
melaminophenyl arsenicals.35 This was the birth of the idea that trypanosomes have a 
‘melamine receptor’ on their surface. It was known that melaminophenyl arsenicals acted 
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intracellularly, and it was therefore proposed that the melamine ring facilitated the uptake 
of the drug from the extracellular environment into the interior. Melamine has similarities 
to a number of natural metabolites as it is a nitrogen rich heterocycle, and it was thought 
that the ‘melamine receptor’ would be a transporter for specific growth nutrients.35 
However, back in the early 20th century when Ehrlich developed the first arsenicals, he 
also noticed that they were the first drugs to experience resistance.23 He observed that 
cross-resistance between different classes of arsenical corresponded to the side chains on 
the aromatic ring and not on the arsenic moiety. Ehrlich proposed a theory of drug action 
based on the haptophore-toxophile biphasic mechanism of melarsen oxide 15 (Figure 8).23 
The ‘anchorer’ or haptophore (blue) part of the compound targets a specific cell receptor 
while independently the ‘poisoner’ or toxophile (red) moiety performs cytotoxic activity 
on the target. It is now known that the drug target receptors of the haptophore are cellular 
components such as membrane transport systems, cell wall components or intracellular 
targets such as enzymes. 
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Figure 8 
The genome of T. brucei has been decoded and around 5-10% of the genes encode 
membrane transporter, which gives around 400 different genes.36 Several classes of 
transporters of T. brucei have been characterised and exploited to target toxic chemicals 
specifically to this parasite.36 
1.7.1.1 Purine Transporters 
It wasn’t until 1993 that it was discovered that the amino-purines and adenosine strongly 
inhibited lysis of trypanosomes. It was then proposed that the ‘melamine receptor’ 
introduced by Williams was actually an amino-purine carrier.25 
T. brucei have a number of purine transporters in their plasma membrane (Figure 9). Two 
of these transporters identified by Carter and Fairlamb are adenosine transporters, the first 
is called P1 and it carries adenosine, guanosine and inosine. The second is called P2, and it 
carries adenosine and its nucleoside adenine.25 P1 transporter functions as a general purine 
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nucleoside transporter whereas the P2 transporter also interacts with melaminophenyl 
arsenicals and diamidines due to the ability of these reagents to inhibit adenosine uptake.37 
Trypanosomes resistant to sodium melarsen were found to have lost their P2 transporter.25 
These data indicated that in wild-type T. brucei the P2 transporter is responsible for the 
uptake of melamine-based arsenicals and diamidines. Pentamidine however has been found 
to penetrate trypanosomes via alternative routes.14 In 1999 both the genes for P1 and P2 
transporters were cloned and the mutations linked to drug resistance were identified.38,39 
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Figure 9 
There is a recognition motif shared between diamidines 2, melamine-based arsenicals 15 
and amino-purines 16 (Figure 10).20,37 Grafting this motif onto compounds that normally 
are not taken up into trypanosomes has facilitated the introduction of novel drugs into 
cells. The P2 recognition motif has been built into polyamine analogues with the result of 
inhibiting adenosine uptake by cells, plus incurring trypanocidal activity. This method has 
previously been used to introduce toxic tin and nitro-containing compounds into 
parasites.40,41 
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Figure 10 
In addition to these amino-purine transporters, a number of purine nucleobase transporters 
have been identified.42,43 Trypanosomes are heavily dependent on these systems due to 
their inability to synthesise their own purines. The investigation and characterisation of all 
the different purine transporters may lead to the elucidation of other unusual substrate 
recognition motifs. 
1.7.1.2 Glucose Transporters 
Glucose transporters from several trypanosomatids have been identified and characterised 
in order to exploit then as a means to target drugs.44,45 Trypanosomes in their bloodstream 
form are highly dependent on substrate-level phosphorylation through glycolysis to 
produce adenosine triphosphate (ATP). Glycolysis occurs in trypanosomes within special 
organelles called glycosomes. 
Trypanosomes are unique in that their different glucose transporters adapt depending on 
their environment, from the insect vector to the mammalian host. T. brucei has two 
transporters, one with low affinity and high capacity which functions in the bloodstream 
form where they are exposed to high glucose concentrations.46 The second receptor is a 
high affinity transporter for use in the tsetse fly where glucose is rare. The genes of these 
receptors have been cloned and expressed in different systems. It was found that one could 
carry D-fructose as well as D-glucose,47 plus a D-glucose analogue bearing substituents at 
the C2 and C6 positions.48 The analogue carrying a C2 substituent exhibits competitive 
glucose-uptake inhibition. These analogues however are not taken up into the parasite 
interior despite binding to the receptor.49 It is also understood that due to the blood glucose 
level being 5000 times higher than the adenosine concentration, using glucose transporters 
is not a key route for targeting anti-trypanosomiasis drugs.49 
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1.7.1.3 Amino Acid Transporters 
There are a number of amino acids present in blood plasma in low millimolar 
concentrations.50 Amino acids contain a vast range of ligands and therefore their 
transporters offer a potential portal of entry for drug molecules into cells. Proline is the 
main source of carbon and energy in procyclic trypanosomes, and its transporter has been 
studied extensively. Similarly the amino acid aspartic acid has been studied in depth, as it 
is the amino acid with the lowest plasma concentration. Aspartic acid does not have a high 
affinity transporter. Methionine was found to have a specific affinity transporter and its 
characterisation is currently underway. Targeting amino acid transporters may be a future 
route to tackling the HAT drug problem.14 
1.7.2 Non-carrier-mediated uptake 
As mentioned previously, passive diffusion (non-carrier-mediated uptake) is a major route 
to parasite drug entry due to the amphipathic nature of many drug compounds. The 
compound megazol has shown activity against T. brucei in rodent and primate infection 
models and shows potential as a novel HAT treatment.51 Megazol 10 contains the 
recognition motif accepted by the P2 purine transporters, which inhibits adenosine P2 
transportation and removes arsenical-induced lysis of the parasites in vitro. These data 
indicate that megazol could not be useful against HAT resistant to arsenicals (where P2 
activity is altered). However, parasites selected for P2 deficiency that are resistant to 
melaminophenyl arsenicals and diamidine drugs showed no resistance to megazol.52 
Therefore megazol must have another major route of entry, and this is non-carrier mediated 
uptake. 
It was found that even with a high concentration of adenosine and P2 transporters, megazol 
uptake was unaffected. The uptake was found to be biphasic, starting with rapid 
equilibration of the drug across the membrane simply due to passive diffusion. This was 
followed by slow accumulation over time due to metabolism of the drug intracellularly.52 
1.8 Drug Resistance 
There is an emerging threat of T. brucei becoming naturally resistant to the few available 
HAT treatments.20 Drug resistance can be considered as the natural response of the parasite 
to the selective pressure of the drug. Resistance to other trypanocides is also on the 
increase and this threatens the current medical and vetinary treatment of these diseases. It 
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is vital to understand the current drugs’ mode of action plus the mechanism of resistance, 
to give an insight into how chemotherapeutic strategies can be designed to overcome or 
reverse this problem. Doing this can also help to increase the therapeutic activity of current 
treatments by providing a basis for combination drug therapy, as it can reduce the toxicity 
of treatments and help decrease the rate at which resistance is appearing.20 
In a Gambiensian disease report from Uganda in 1999, it was found that 30% of people 
treated for HAT using melarsoprol relapsed within two years,53 and in an Angolan focus 
(2001) 25% of patients relapsed within 30 days.54 Currently any resistance to the early 
stage treatments pentamidine and suramin are not considered a serious risk as any 
treatment failure may be due to misjudgement during stage-diagnosis. The innate 
resistance to DFMO by T. brucei rhodesiense has been demonstrated although this drug is 
effective against T. brucei gambiense. This is due to a difference in ODC turnover rates 
between the two species.55 
Resistance to melarsoprol was initially introduced in laboratory strains of parasites, 
however it is now being observed in the field. This development of resistance to arsenicals 
and cross-resistance (tolerance to a usually toxic substance as a result of exposure to a 
similarly acting substance) to diamidines is thought to be due to the loss of the function of 
the P2 transporter as described earlier.25 The melarsen arsenical resistant line created by 
Fairlamb and co-workers named T. brucei 427 cRU15 had reduced P1 activity and no P2 
activity. This resistant strain also showed cross-resistance to some diamidines. 
1.8.1 Molecular Basis of Drug Resistance 
The gene that encodes the P2 transporter TbAT1, was discovered in 1999.38 TbAT1 encodes 
a 463 amino acid hydrophobic polypeptide with 11 transmembrane α-helices, a cytosolic 
loop, an extracellular carboxy terminus and a cytosolic amino terminus (Figure 11). 
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Figure 11 
The P2 transporters from an arsenical resistant strain of T. brucei were cloned and 
expressed and it was found that the resistant strain had ten nucleotide alterations, which 
resulted in six changes at the amino acid level. The process in which the P2 transporter is 
altered is unclear, however it is likely to be due to either a point mutation within the gene, 
which alters Km, νmax, or both of the P2 transporter. Alternatively it may be due to the 
transporter being down-regulated.56 A study of patients from north-western Uganda also 
found this mutation of TbAT1 in trypanosomes of early stage infection and relapse patients. 
It was noted that many of the point mutations found in the wild species were the same as 
those generated in the laboratory.57 
1.8.2 Mechanisms of Drug Resistance 
Antimicrobial agents generally act through an interaction with a drug target and drug 
resistance can arise in a number of ways: i) as a consequence of a change in drug level; ii) 
by a change in the target; or iii) both of these ways (see Table 1).25 
Drug Level Target Level 
By exclusion 
Decreased drug import 
Increased drug export 
By sequestration 
Drug-binding molecule 
Drug compartmentalisation 
By metabolism 
Pro-drug not activated 
Increased drug inactivation 
Modified 
Decreased target affinity 
Amplified 
Increased drug sequestration 
Increased enzyme activity above threshold 
Missing 
Target bypass 
Repaired/protected 
Increased damage repair 
Protected by substrate 
 
Table 1 
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Drug resistance can also be linked with the treatment of animal cases of trypanosomiasis. 
A publication in 2001 reported that the re-stocking of an area of Uganda with cattle from 
out-with the surrounding area resulted in an outbreak of T. brucei rhodiense HAT. This 
suggests that the cattle acted as a reservoir of the human infective parasites, and then the 
native tsetse flies spread the disease to the local population.58 
The increase in drug resistance can be due to a number of factors; the drug’s widespread 
use, the use of the drug as a prophylactic, self-administration, inappropriate dosing and 
exposing the parasite to sub-curative levels of the treatment.58 The treatment of Nagana 
with berenil 13 is a classic case of all of these factors. Berenil was used as a prophylactic, 
bought on the black market and administered by farmers when it should be purchased and 
authorised by pharmacies. The black market products have been found to contain between 
0 and 90% of the active ingredient, and therefore the doses varied widely. Farmers also 
underestimated the weight of their cattle and so did not give the correct dose, and were 
found to only treat animals that showed signs of illness. This also resulted in the 
probability of the trypanosome encountering sub-curative doses of the drug allowing 
resistance to grow.59 
It is simple to select for cross-resistance in vivo and in vitro between berenil and 
melarsoprol. Cross-resistance has now been observed in the field with human infective 
trypanosomes infecting cattle, developing a resistance to berenil, and then being carried 
back to the human population with a cross-resistance to melarsoprol.20 
1.9 Future of HAT Treatment 
When Aventis ceased the production of DFMO in 1995 due to its lack of profit, the future 
of HAT treatment looked bleak. However the agreement made in 2001 between WHO, 
MSF and Aventis after years of international pressure, found Aventis agreeing to donate 
enough DFMO, pentamidine and melarsoprol to cover global needs for five years.3 They 
also agreed to financially support WHO’s programmes for sleeping sickness research and 
treatment, plus providing technical assistance and technology to potential long-term 
manufacturers of the drugs. At this time the company Bayer announced that they would 
restart the production of two sleeping sickness drugs, and Bristol-Myers Squibb also 
became involved by paying for part of the first years supply of DFMO after they launched 
an eflornithine-based product for the removal of women’s facial hair.3 
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Although this was an excellent turnaround for the drug companies, the value of Aventis’ 
donation at around $5 million was still small in comparison to the $40 million per year cost 
for an effective pan-Africa HAT control programme.3 
In early 2006, an announcement was made that the Bill and Melinda Gates Foundation was 
giving a $22.6 million grant to the University of North Carolina (UNC) at Chapel Hill 
which leads an international research consortium. The grant is to support the phase III 
clinical trial of a highly promising new drug for the treatment of sleeping sickness, which 
is the final step required before receiving approval from the US Food and Drug 
Administration.60 
The new drug DB289 17, recently named pafuramidine, is far less toxic and more 
appropriate for use in the rural areas of Africa as it is an orally administered prodrug. In 
preliminary studies, DB289 had activity against Pneumocystis carnii in animal models, in 
HIV patients with Pneumocystis pneumonia and also against strains of Plasmodium 
(malaria) and Cryptospiridium parvum (another parasitic protozoan).61 DB289 was tested 
for the first time in early stage sleeping sickness in a phase II trial in 2001 in Angola and 
the Democratic Republic of Congo which compared the activity of DB289 with 
pentamidine. Results indicated that DB289 was significantly safer than pentamidine 
although the treatment failure rate was higher than expected.62 
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The phase III trials are currently underway and the UNC are conducting research into a 
paediatric formula for use in children under six years old and studying pafuramidine in 
children aged six to 12 years. UNC will also start an expanded access programme, along 
with studying the effectiveness of pafuramidine in treating the East African form of 
sleeping sickness.60 
Therefore DB289 17 is the first orally administered drug for the treatment of sleeping 
sickness and it is the first new HAT drug for over 50 years. Although test results look very 
promising for DB289, there is still a vital need for new sleeping sickness drugs to tackle 
the increasing problem of resistance and cross-resistance of current drugs, and their innate 
toxicity. 
32 
2 Polyamine Metabolism 
Polyamines are ubiquitous organic cations of low molecular weight found in all living cells 
examined to date. Most cells contain significant amounts of the polyamines putrescine 18, 
spermidine 19 and spermine 20, and their concentrations within cells are highly 
regulated.63 
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2.1 Functions of Polyamines 
Although their full physiological function has been much debated and has not yet been 
fully elucidated, polyamines are crucial for cell growth and differentiation. They are 
positively charged at physiological conditions and can interact covalently with many 
cellular molecules, and during in vitro experiments, they have altered reaction rates and the 
dissociation of sub-cellular components.64 Their polybasic character allows them to bind 
strongly to nucleic acids, and they can stabilise DNA by decreasing the repulsion between 
the strands by neutralising the negative charges on the phosphate groups. Polyamines can 
also influence protein synthesis by interaction with RNA, and assist the association of 
ribosomal subunits by binding to ribosomes. Polyamines also interact with receptor 
proteins such as the K+ channel pore.65 
Studies have indicated that rapidly growing and differentiating cells have higher 
concentrations of polyamines than those of quiescent cells, and the inhibition of polyamine 
biosynthetic enzymes can lead to cell growth cessation and even cell death.65 Abnormal 
polyamine metabolism has also been found to influence the development of tumours.65 
2.2 Polyamine History: Discovery and Elucidation 
Putrescine and its homologue cadaverine were first discovered in the late 19th century by 
German chemists and medics studying the products of bacterial fermentation. Even as late 
as 1945 it was still thought that the presence of these amines in human tissues and fluids 
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was due to bacterial action.66 Between 1920 and the 1940s, bacteria were studied and 
found to metabolise some amino acids, and these extracts were able to decarboxylate L-
ornithine and L-lysine to putrescine 18 and cadaverine 21, respectively.66 Similarly, the 
presence of spermine 20 was first reported by Leeuwenhoek as a crystalline phosphate in 
human seminal fluid in the 17th century, but it wasn’t until 1917 that Mary Rosenheim 
proved the presence of spermine in eukaryotic cells. Otto Rosenheim, Mary’s husband, 
then carried out the proof of structure and chemical synthesis of spermine. He also 
discovered and synthesised the triamine spermidine 19.66 After this, little further research 
was carried out on the diamines, triamines or tetraamines until the end of World War II. At 
this time, Herbst and Snell found that a strain of influenza required putrescine for growth, 
and this led Herbst to carry out separations and investigations of various bacterial 
polyamines. This began 40 years of prolific research into the function and cellular 
metabolism of polyamines.66 
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Microbiology was established in the 1950s and 1960s that allowed the clarification of the 
activity and specificity of the amine oxidases. By 1980 the entire polyamine cycle, 
including the synthesis and degradation of compounds, and the numerous side branches 
yielding metabolic products, had been established.66 
2.3 Polyamine Biosynthesis 
Polyamine synthesis is unique and not dependent on an external supply, but is entirely 
controlled by the cell.64 Mammalian cells synthesise putrescine 18, spermidine 19 and 
spermine 20, whereas many bacteria and protozoa synthesise only putrescine and 
spermidine. Some microorganisms and higher plants can produce putrescine from 
agmatine (produced by the decarboxylation of arginine). However mammalian cells, fungi 
and protozoa do not have arginine decarboxylase and so they synthesise putrescine using 
the enzyme ornithine decarboxylase (ODC).63 
2.3.1 Mammalian Polyamine Biosynthesis 
Figure 12 shows the general pathway for polyamine biosynthesis in mammals, although 
they can also occasionally be obtained from the diet. Polyamines are derived from arginine 
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and methionine. Putrescine is formed from L-ornithine using ODC. Ornithine in 
mammalian cells is found in the plasma, or formed within the cells from arginine and the 
arginase enzyme.63 ODC and arginine decarboxylase are pyridoxal phosphate-dependent 
enzymes. ODC is a homodimer with two active sites, and is found in very small 
concentration in inactive cells and is regulated by an ODC inhibitor. The activity of ODC 
can be increased by stimuli such as hormones, drugs and growth factors.63 
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Figure 12 
Putrescine is converted into spermidine and spermine via the action of two aminopropyl 
transferases followed by spermidine synthase (SpdSyn) and spermine synthase (SpmSyn), 
respectively. These enzymes are specific to their acceptor but both use decarboxylated S-
adenosylmethionine 22 (dcSAM) as the aminopropyl donor.65 The enzyme S-
adenosylmethionine decarboxylase (SAMDC) then decarboxylates S-adenosylmethionine 
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23 (SAM). The cell concentration of dcSAM in mammalian cells is normally low, and its 
availability regulates the activity of aminopropyltransferases. The second product in the 
system of transferring an aminopropyl group from dcSAM to putrescine or spermidine is 
1,5’-methylthioadenosine 24 (MTA). MTA is then degraded via the methionine recycling 
pathway using MTA phosphorylase to 5’-methylthioribose-1-phosphate and adenine, and 
the adenine is then converted into 5’-adeninemonophosphate using adenine phosphoribosyl 
transferase. 5’-Methylthioribose-1-phosphate is also converted back into methionine, and 
thus, the aminopropyl groups for the synthesis or spermidine and spermine are derived 
from methionine.65 
The enzymes polyamine oxidase (PO), spermidine N1-acetyltransferase and spermine N1-
acetyltransferase degrade spermidine and spermine back to putrescine. This 
interconversion is a regulatory response when the levels of spermidine and spermine reach 
certain limits, and is induced by exposure to spermidine, toxic agents, and by fasting.65 
2.3.2 Trypanosome Polyamine Biosynthesis 
Trypanosome polyamine metabolism differs in several ways from that of their mammalian 
hosts with respect to their half-life, turnover, substrate specificity and regulation of 
enzymes, both within the main polyamine biosynthetic pathway and the related pathway of 
transmethylation.64 African trypanosomes contain putrescine and spermidine, but not 
spermine. The spermidine content of trypanosomes varies from 10-30 nmol per 108 cells, 
and putrescine makes up 20-30% of the total polyamine content. The putrescine analogue 
cadaverine is not found in these parasites; however they do contain an unusual glutathione 
25 derivative of spermidine which is N1,N8-bis(glutathionyl)spermidine, now known as 
trypanothione 26. Trypanothione was characterised by Cerami and Fairlamb in 1992, and 
is a complex compound that replaces glutathione in the biosynthetic pathway and 
maintains the intracellular reducing environment, while performing the usual glutathione 
function as the trypanosomes' antioxidant.67 Trypanothione is found at relatively constant 
levels in bloodstream trypanosomes at 1-2 nmol per 108 cells.68 It has been found that 
trypanosome enzymes are specific to trypanothione and do not catalyse glutathione 
reactions.66 Spermidine is essential in trypanosomes and its function is well defined. These 
protozoa have a specific trypanothione reductase (TR) enzyme that has been crystallised 
and its active sites analysed in the search for inhibitors as targets for chemotherapy.66 
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The starting point of polyamine biosynthesis in trypanosomes is ornithine and methionine 
(Figure 13). Ornithine is decarboxylated to putrescine using ODC, and methionine is 
transformed into SAM using ATP and SAM synthetase, before it is decarboxylated to 
dcSAM using SAMDC. The putrescine then accepts an aminopropyl group from dcSAM 
to form spermidine. The by-product MTA is phosphorylated via MTA phosphorylase to 
give adenine and methylthioribose-1-phosphate, and eventually to methionine and SAM 
using the methionine recycling pathway.64 
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Figure 13 
2.4 Polyamine Metabolism as a Therapeutic Target 
Pharmacological intervention that inhibits polyamine biosynthetic enzymes prevents cell 
growth, and causes cell death in almost every polyamine pathway studied.69 Polyamine 
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pathways have been successfully exploited to design chemotherapeutics against a number 
of parasitic diseases and in cancer chemotherapy against a range of tumour cell lines.69 The 
inhibition of key biosynthetic enzymes and polyamine transport as well as replacing 
naturally occurring polyamines with synthetic analogues are ways of directing drug 
design.69 
2.4.1 Polyamine Metabolism as a Target for Cancer 
Chemotherapy 
Polyamines that perturb polyamine biosynthesis and functionality have been shown to 
inhibit the growth of tumours efficiently.69,70 Cancerous cells have an enhanced 
requirement for polyamines and so targeting their transport systems is an attractive vector 
for drug design.65,66,69 
It was realised early on in the research into the activity and structures of polyamines that 
the enzyme ODC is the fundamental rate limiting and controlling step in the biosynthetic 
pathway.70,71,72 In the 1970s DFMO 8, a drug created by the Merrell-Dow research 
institute, was found to be the most active suicide inhibitor of ODC.63,64 Over the last 40 
years, DFMO has been used extensively as a tool in the elucidation of the synthesis and 
catabolism mechanisms of polyamines; in the polyamine mechanism of cells' proliferation 
and differentiation; and in the inhibition of cell growth as well as a number of other 
approaches to cancer chemotherapy.66,70,73 Another key enzyme in the pathway is SAMDC 
and a drug discovered in 1963 called methylglyoxal bis(guanylhydrazone) 27 (MGBG) 
(Table 2) was found to be a potent inhibitor of eukaryotic SAMDC, resulting in the death 
of cancer cells.66,74 This antileukaemic agent unfortunately showed some non-specific 
cytotoxic effects such as blocking the metabolism of fatty acids which resulted in damage 
to the mitochondrial membranes.74 More recently however, an enzyme-activated SAMDC 
inhibitor which is an analogue of SAM called 5’-{[(Z)-4-amino-2-butenyl]-methylamino}-
5’deoxyadenosine 28 (MDL73811) was synthesised, which showed low mammalian 
toxicity while being highly specific with significant antitumour activity.75 
Caroline M. Reid, 2006  Chapter 2, 38 
28
N
NN
N
NH2
O
OHOH
N
CH3
H2N
 
From the early work, it was established that mammalian cells contain four key enzymes in 
the polyamine synthetic pathway, ODC, SAMDC, SpdSyn and SpmSyn, and a multitude 
of powerful specific inhibitors have been found for all of these enzymes.69 Several hundred 
polyamine synthesis inhibitors, catabolism stimulators and other polyamine derivatives 
have been tested against cancer cells.66,69,70 These drug compounds focus mainly on these 
crucial enzymes but they also target the polyamine uptake/transport systems and other 
enzyme pathways in an attempt to stop cancer cell growth by decreasing the intracellular 
levels of putrescine, spermidine and spermine. Table 2 contains a selection of some 
inhibitors/activators of polyamine related enzymes. 
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Table 2 
Unfortunately these drugs do not completely inhibit cell growth as most mammalian cells 
(including cancer cells) have polyamine uptake and transport systems, which import 
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polyamines from neighbouring cells when polyamine concentrations are low. Mammalian 
cells have a rapid ODC turnover and have the ability to unblock the polyamine pathway by 
converting any spermine into spermidine via an acetylation pathway. To obtain maximum 
inhibition of cancer cells, a combination of inhibitors must be used.70 For example DFMO 
8 is relatively non-toxic and so can be used in conjunction with other drugs. DFMO and 
MGBG 27 together have shown success in tissue cultures, animal models and human trials. 
DFMO is first used to inhibit ODC and deplete the cells of polyamines before MGBG (a 
polyamine derivative) is administered. This is rapidly imported into cells to inhibit 
SAMDC. This drug combination has shown 99% proliferation inhibition in cell 
cultures.69,76,77 
Polyamine transport systems are not strictly specific and a variety of synthetic polyamine 
derivatives and analogues can use them. In tumour cells, the activity of these systems is 
higher than in normal cells, and studies have shown that tumours take up higher amounts 
of radio-labelled polyamines than normal cells.66,69 These systems can therefore be used to 
direct cancer chemotherapy in two ways: drugs can be designed to inhibit the system by 
preventing polyamine uptake; and uptake of potent polyamine analogues can interfere with 
or block key proliferation events.70,78 
Structural analogues of polyamines are considered to be the compounds with the highest 
potential for interfering with polyamine action, and this has been investigated thoroughly 
in cancer cells.66,69,70 One of the main advantages is that analogues disrupt the biosynthetic 
pathway in a number of ways, acting as polyamine antagonists that prevent growth related 
functions. Analogues including N1,N12-diethyl homospermidine 31 (BE-4-4-4) and N1,N12-
bis(ethyl)spermine 32 (BE-3-4-3) have been shown to induce N’-AcSpm which leads to a 
loss in the polyamine content of treated cells.79 These analogues also repress ODC and 
SAMDC activity in the same way as spermine. Therefore the uptake of BE-3-4-3 and BE-
4-4-4 can result in a complete loss of normal polyamine activity and lead to cytotoxicity.69 
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2.4.2 Polyamine Metabolism as a Target for Trypanocide Design 
In the design of drugs to be used against African trypanosomiasis, the progress in the 
search for anti-cancer drugs has been harnessed. The three main enzyme targets of 
trypanosomes are ODC, SAMDC and MTA phosphorylase.80 
2.4.2.1 ODC Inhibition 
After the success of DFMO 8 anti-cancer activity on a range of tumour cell lines, in the 
1980s Bacchi and co-workers demonstrated that DFMO had an effect on the growth of the 
trypanosome. DFMO was used to cure acute infections of T. brucei in mice.81 Infected 
animals were treated with 4% DFMO for 12 to 36 hours, and it was found that DFMO 
interrupted a number of areas of parasite metabolism. ODC was inactivated, while 
ornithine, spermine, putrescine and trypanothione levels were decreased by up to 95% and 
RNA and DNA production was reduced.82 DFMO also blocked the synthesis of the VSG 
and other proteins. It was also found that SAM and dcSAM levels increase up to 400-fold 
which was an observation not seen in mammalian experiments. This difference has critical 
implications, as there are several biochemical distinctions between mammals and 
trypanosomes. The parasite has a long ODC half-life (four hours) and slow turnover, 
whereas mammals have a rapid ODC turnover with a half-life of 10-60 minutes. The 
trypanosomes' inability to synthesise spermine due to their lack of putrescine and 
spermidine transport is also a key difference.64 
2.4.2.2 SAMDC Inhibition 
The success of targeting cancer cells with the SAMDC inhibitor by blocking spermidine 
and spermine synthesis led to the investigation of SAMDC as a target in the search for 
antiparasitic drugs.64 The trypanosome enzyme is unlike the mammalian version in a 
number of ways: its solubility and ionic properties are unique; and it does not cross react 
with human SAMDC. SAMDC is inhibited using the trypanosides berenil and 
pentamidine.83 
2.4.2.3 MTA Phosphorylase Inhibition 
The third potential enzyme target is MTA phosphorylase, which is present in mammalian 
cells and some protozoa. This enzyme catalyses the conversion of MTA into adenine and 
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methylthioribose-1-phosphate. MTA analogues were synthesised to contain ribose moieties 
which on interaction with the enzyme, would block methionine recycling.84 
2.5 Previous Approaches Towards Antiparasitic Agents 
within the Robins Group 
L. Slater reported in her 1998 Ph.D thesis the synthesis of a number of putrescine 
analogues.85 33 was the lead compound as it displayed promising anti-malarial activity 
with a lowest effective concentration (LEC) against a culture of P. falciparum of 18-36 
µM. Analogues had varying carbon chains and substitution patterns on the nitrogens, 
however the only compound to show any improved activity was the N,N’-bisbenzyl 
compound 34 (LEC
 
3-15 µM) although its activity in vivo was poor. 
NH2Bn
BnH2N 2Cl
34
NH
NH 2Cl
33
 
Slater then went on to prepare a number of spermine analogues with 35 showing the best 
result in vitro with a LEC value of 1-2 µM. 
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NH2N N
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Later in 2003, L. Parker synthesised a number of polyazamacrocycles on the route to 
nitrogen mustard analogues. A selection of these compounds was tested against L. 
mexicana and T. brucei by Dr M. Barrett (University of Glasgow).86 N-Substituted 
polyazamacrocycles had previously shown biological activity, displaying anti-tumour, anti-
HIV, anti-malaria, anti-microbial, and anti-fungal properties.86,87,88 The antiparasitic 
activity of polyazamacrocycles however, had not been published. Table 3 contains a 
number of the compounds tested with 39 displaying the best in vitro activity. There are no 
trends in the results with the activity profile of the macrocycles being different between the 
two parasite species. 
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Table 3 
This early work was the foundation for the synthesis of further analogues of 1,4,7,10-
tetraazacyclododecane 36 (cyclen) with aromatic substituents in an attempt to increase the 
antiparasitic activity of polyazamacrocycles. 
43 
3 Synthesis and Evaluation of 
Tetraazamacrocycles as Antiparasitic Agents 
3.1 Aims of this Work 
Some investigation has been carried out within the Robins group to determine if the size, 
shape and heteroatom content of aza and oxoaza macrocycles affects their activity as 
antiparasitic agents.85,86,89 The next endeavour was to vary the electronic demand on 
1,4,7,10-tetraazacyclododecane 36 (commonly known as cyclen) by attaching various aryl 
groups at the C-2 position 40. A number of analogues containing parasite-specific 
recognition motifs at the C-2 position were selected for preparation, and all compounds 
were to be tested in vitro for antiparasitic activity against Trypanosoma brucei. Cyclen 36 
was chosen as our basic ring structure due to its promising activity in other biological test 
systems.86 It was used as a reference in all the biological in vitro assays, as well as the 
starting material for the synthesis of anti-cancer alkylating agents (Chapter 5). 
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3.2 Synthesis of 1,4,7,10-Tetraazacyclododecane (Cyclen) 
This first section describes an investigation to find the optimum strategy for the synthesis 
of cyclen 36. As with other cyclisation reactions, the synthesis of polyazamacrocycles is 
notoriously tricky. There are numerous ways to prepare macrocycles ranging from high 
dilution reactions to metal or carbon templated cyclisations. In each case, the reaction 
conditions are designed to encourage intramolecular cyclisation over intermolecular 
oligomerisation.90,91,92,93 
Cyclen is a 12-membered tetraazamacrocycle, which has become an important 
intermediate for the synthesis of diagnostic and therapeutic pharmaceutical agents.94,95 In 
particular, one of the fastest growing medicinal uses of cyclen is in the development of 
magnetic resonance imaging contrast agents,96 and more recently cyclen-based bifunctional 
chelating agents are being investigated for use as therapy against targeted cancer agents.97 
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Therefore there is an increasing demand for 36 on both a research and commercial scale, 
and considerable effort is being made towards efficient synthetic strategies. This first 
section focuses on the search for the best method to produce large quantities of high purity 
36 in good yields. 
3.2.1 Richman Atkins 
Up until the early 1970s the most efficient method for the synthesis of polyazamacrocycles 
was by Stetter and Roos. This used high dilution conditions to condense terminal halides 
with bis-sulfonamide sodium salts.92,98 This method gave moderate yields of macrocyclic 
sulfonamides. Richman and Atkins then developed their synthesis of polyazamacrocycles 
which didn’t employ high dilution or template effects.90 Their simple and adaptable 
preparation was used for the synthesis of nine to 21 membered rings containing three to 
seven heteroatoms, all with moderate to good yields. In this early publication 36 was 
synthesised by treating a stirred solution of 41 in DMF at 100 oC with one equivalent of 42 
(where R is a different leaving group, OTs, OMs, Cl, Br, I) in DMF over one to two hours 
(Scheme 1). Addition of water to the cooled solution gave 1,4,7,10-tetrakis-(toluene-4-
sulfonyl)-1,4,7,10-tetraazacyclododecane 43 in 80% yield. Hydrolysis to remove the tosyl 
protecting groups was carried out by heating 43 at 100 oC with concentrated sulfuric acid 
for 48 hours, which gave a 90% yield of cyclen after work-up. It was found that the 
sulfonate ester leaving groups on 42 along with the dipolar aprotic solvent removes the 
requirement for high dilution conditions. 
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Scheme 1 
More recently, this reaction has often been carried out by the reaction of the dianion of a 
bis-toluenesulfonamide with a suitable bis-tosylated analogue in anhydrous DMF. The 
tosylamide salt can be formed by the reaction of sodium hydride in DMF or sodium 
ethoxide in ethanol, but more commonly it is formed in situ by the presence of caesium 
carbonate in the reaction mixture.99 The caesium salt exhibits reactivity characteristics that 
have been dubbed the “caesium effect” due to two synthetic phenomena.100 Firstly it 
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applies to the readiness with which caesium salts dissolved in DMF can be alkylated with 
alkyl halides, but the term also refers to the way that many macrocycles including very 
large rings and relatively apolar chain components can be synthesised via intramolecular 
anionic nucleophilic substitution of the precursor (Figure 14). In this case the 
intermolecular substitution is suppressed relative to the intramolecular process. 
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Figure 14 
The tosyl groups serve two functions: firstly by rendering the secondary amine sufficiently 
acidic for salt formation under mild conditions; and secondly they protect the nitrogen 
allowing monoalkylation only.101 In addition it has also been shown that the steric bulk of 
the p-toluenesulfonyl groups confer a pseudo-Thorpe-Ingold (gem-dialkyl) effect that 
encourages intramolecular reaction (Figure 15).102,103 It is thought that the tosyl 
functionalities decrease the angle between the reacting termini, positioning them closer 
together and increasing the chance of reaction. 
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Figure 15 
3.2.2 Phase Transfer Conditions 
In 1988, Lukyanenko and co-workers described the synthesis of aza- and oxoaza- 
macrocycles using a biphasic system.104 This procedure involves reacting bis-sulfonamide 
analogues with dibromides or ethylene glycol bis-(toluene-p-sulfonates) in aqueous alkali-
toluene in the presence of quaternary ammonium salts as phase transfer catalysts. 
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This interphase reaction is presented in Scheme 2. Deprotonation of the sulfonamide 
groups with the alkali probably occurs successively (reactions i and iv). In the absence of 
catalyst (QY) no alkylation of sulfonamide occurs after the deprotonation of the first 
sulfonamide group (reaction i), however if catalyst is present, exchange takes place 
(reaction ii). The ionic pair that has been formed then undergoes alkylation in the organic 
phase (reaction iii). Deprotonation of the alkylated product results in the formation of a 
highly lipophilic anion (reaction iv) and this is able to solvate alkaline metal cations to 
form a cation-associated precursor. Intramolecular alkylation completes the process 
(reaction v).104 
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Scheme 2 
This strategy was used to synthesise cyclen 36 in two ways. 
3.2.2.1 Route I 
N,N’,O,O’-Tetra(p-toluenesulfonyl)-N,N’-bis(2-hydroxyethyl)-ethylenediamine 44 and 
ditosylated ethylenediamine 45 dissolved in toluene were added to a stirred mixture of 
tetrabutylammonium bromide and aqueous lithium hydroxide in toluene heated under 
reflux (Scheme 3) for 20 hours. The organic layer was then separated and dried to leave 43 
as a pale yellow solid in 79% yield. 
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Scheme 3 
3.2.2.2 Route II 
Using the same method, 43 was prepared from N,N’,N’’-tri(p-toluenesulfonyl)diethylene 
triamine 46 and N,O,O’-tri(p-toluenesulfonyl)diethanolamine 47. In this case the reaction 
mixture was stirred and heated under reflux for seven days (Scheme 4). After work-up, 43 
was obtained as a white solid in 98% yield. 
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Scheme 4 
3.2.3 Facile Route Utilising Bis-imidazoline 
By far the best method we found for the preparation of 36 on a large scale involved the use 
of a modern simple synthesis by Athey and Kiefer.105 Around the time of this publication 
in the early 2000s, several new synthetic routes towards cyclen had been reported.106-110 
This method is a three-step route via bis-imidazoline 48 that can be carried out on a 
multigram scale (Scheme 5). The first step uses the reactivity of formamide acetals, 
previously known for converting primary amines and amides into amidines and acylated 
amidine respectively.111 Bis-imidazoline 48 was prepared from triethylenetetraamine 
(TETA) and N,N-dimethylformamide dimethyl acetal under neat reaction conditions. Bis-
imidazoline 48 can be recrystallised from THF although it can be taken onto the next step 
without further purification. Macrocyclisation of 48 with the dielectrophilic substrate 1,2-
dibromoethane in acetonitrile with potassium carbonate gives the monoimidazolinium 
compound 49 in quantitative yield. Hot alkali hydrolysed 49 to afford 47 g of 36, which is 
a 70% yield in three steps over two days. 
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Scheme 5 
A possible stepwise mechanism for the generation of 49 from 48 is seen in Scheme 6. Bis-
imidazoline 48 is alkylated by 1,2-dibromoethane producing imidazolinium intermediate 
50. 50 then loses hydrobromic acid to form carbene 51, which undergoes an intramolecular 
carbene carbon-hydrogen insertion. This process will eventually lead to the electronically 
neutral intermediate 52. This amidine may then readily displace the remaining bromine to 
form 49. In comparison to the Richman-Atkins cyclisation, which goes through a 12-
membered transition state for final macrocyclic ring closure, the mechanism from 52 to 49 
passes through a conformationally favourable six-membered transition state. 
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Scheme 6 
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3.2.4 Tosylation of Cyclisation Precursors 
The starting materials for both the Richman-Atkins style cyclisation and the phase transfer 
conditions require tosyl protection of the corresponding amine or diol. Three different 
methods were investigated for the tosylation of the commercially available starting 
materials. Three trial reactions were carried out with N,N’-bis(2-hydroxyethyl)-
ethylenediamine and the best method was then used to prepare all other tosylated reagents. 
3.2.4.1 Route I 
A previous member of the Robins group, F. Anderson, prepared N,N’-di(p-
toluenesulfonyl)ethylenediamine 45. Ethylenediamine was tosylated with p-
toluenesulfonyl chloride in water, sodium hydroxide and diethyl ether (Scheme 7).112 
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Scheme 7 
This method previously gave excellent yields but it was not so high yielding in our 
tosylation reactions. In the protection of N,N’-bis(2-hydroxyethyl)-ethylenediamine, this 
method achieved only 11% yield of product 44 (Scheme 8). 
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Scheme 8 
3.2.4.2 Route II 
Another method reported by F. Anderson was used to synthesise 44.112 A solution of p-
toluenesulfonyl chloride in dichloromethane was added slowly to a stirred solution of 
N,N’-bis(2-hydroxyethyl)-ethylenediamine in dichloromethane (Scheme 9). A phase 
transfer catalyst benzyl triethylammonium chloride (TEBACl) was then added, followed 
by aqueous sodium hydroxide with vigorous stirring. After four hours at room temperature, 
the solution was poured onto water and the organic layer separated. Work-up gave the 
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product in good yields, however the product contained some non-tosylated starting 
material. 
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Scheme 9 
3.2.4.3 Route III 
The most successful method for the synthesis of tosylated precursors followed a 
straightforward preparation by Dale et al.113 The N,N’-bis(2-hydroxyethyl)-
ethylenediamine was dissolved in dry pyridine at 0 oC, and a solution of p-toluenesulfonyl 
chloride in a small volume of dry pyridine was then added dropwise with stirring (Scheme 
10). The reaction mixture was then stirred at room temperature overnight then poured into 
ice-water. The solid 44 was collected and recrystallised from ethanol in very high yields 
with excellent purity. This method was used to prepare 46 and 47 in 70% and 59% yields 
respectively. 
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3.2.5 Tosyl Deprotection Strategies 
In the case of cyclisation under phase transfer or Richman-Atkins conditions, the final step 
towards cyclen is the deprotection of the tosyl groups. There are a variety of methods 
described in the literature which include using concentrated sulfuric acid,114 
sodium/mercury amalgam,115,116 potassium fluoride on alumina,117 lithium aluminium 
hydride,118 and hydrobromic acid of different concentrations in acetic acid with 
phenol.101,104 However these harsh conditions result in very low yields (maximum 45%)101 
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and this makes the overall cyclisation method towards cyclen uneconomical. Two routes 
were employed to liberate the secondary amines of cyclen 36. 
3.2.5.1 Route I 
In this method, 43 was heated at 110 oC in concentrated sulfuric acid for 40 hours before 
the flask was cooled in an ice bath and water was slowly added (Scheme 11).101 Potassium 
hydroxide pellets were added to reach pH 13, then ethanol was added and the resulting 
precipitate was dissolved in hydrochloric acid and extracted with dichloromethane. The 
aqueous phase was basified with potassium hydroxide and extracted with chloroform. The 
combined organics were dried to yield a colourless oil. Recrystallisation from acetone gave 
cyclen 36 in 88% yield. 
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Scheme 11 
3.2.5.2 Route II 
A second method using hot sulfuric acid was more rapid (Scheme 12).101 The sulfuric acid 
was heated to 165 oC before 43 was added. The solution was stirred vigorously at this 
temperature for six minutes before the flask was quickly cooled in an ice bath. The black 
liquid was added to a stirred flask of ethanol then diethyl ether was added and the solution 
was cooled to 0 oC. After filtration, a small volume of hot water and hydrobromic acid was 
added to the filtrate. Filtration removed the precipitated hydrobromide salt and the filtrate 
was concentrated in vacuo to give the tetrahydrobromide salt 53 in a modest 42% yield. To 
form the free base, 53 was stirred in an aqueous sodium hydroxide solution with toluene 
under reflux. A Dean-Stark apparatus was used to remove the water, and the toluene 
solution containing cyclen 36 can be decanted from the precipitated sodium bromide.89 
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Scheme 12 
3.3 General Strategy Towards C-Functionalised 
Derivatives of Cyclen 
3.3.1 Efficient Metal-Templated Synthesis 
Our goal was to find a route to C-substituted cyclen derivatives, and as in the preparation 
of other polyazamacrocycles, this normally requires high dilution syntheses using 
tosylamide cyclo-alkylation methodologies.119-125 These reactions involve at least six steps 
with overall yields of 5-18%. However, a publication by Edlin and co-workers in 1996 
reported that 12-membered tetraaza ring derivatives could be prepared using an efficient 
metal-templated strategy.126 
Triethylene tetraamine (TETA) forms well-defined cis-[MLCl2] complexes with a range of 
first-row transition metals, and cyclo-co-condensation reactions with 1,2-dicarbonyl 
compounds are feasible.127 The first step of the synthesis was to prepare the cis-[FeLCl2]Cl 
complex by slowly adding a solution of TETA in methanol to a stirred solution of iron (III) 
chloride in methanol at room temperature (Scheme 13).128 The diimine formed is likely to 
exist in the cis-conformation shown 54, with the two terminal nitrogen atoms positioned in 
close proximity that would allow macrocyclisation. An aromatic glyoxal 55 was then 
added drop-wise in methanol, and the mixture was stirred for two hours. The intermediate 
56 formed was generally a brown to green colour. After this time, an excess of sodium 
borohydride was added carefully to reduce the metal centre from iron (III) to iron (II). 
After heating and stirring the solution under reflux for four to 24 hours, acidic work-up 
removed the coordinated iron (II) ion. The racemic free base 40 was extracted using a 
chlorinated solvent in a high yield as an orange to dark brown viscous oil. 
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Scheme 13 
3.3.2 Synthesis of 1,2-Dicarbonyl Compounds 
Although phenylglyoxal is commercially available, the other glyoxal derivatives required 
for the cyclisation process had to be prepared from the corresponding acetophenone. This 
was carried out by a simple preparation involving selenium dioxide oxidation in 1,4-
dioxane and water using the commercially available acetophenones (Scheme 14).129 These 
reactions could be followed to completion by thin layer chromatography and took up to 24 
hours. Table 4 contains the glyoxal analogues prepared and the yields obtained. 
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Scheme 14 
A publication in 2002 by Paul and co-workers showed that the same reactions could be 
completed using solvent-free microwave technology in seven to 10 minutes.130 However in 
a number of test reactions it was found that microwave irradiation only gave partial 
conversion into the glyoxal and the microwave apparatus available could only be used to 
carry out reactions on a maximum 1.0 g scale. It was therefore more practical to use the 
traditional method. 
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The mechanism of α-oxidation of aldehydes and ketones by selenium dioxide has not been 
completely elucidated, and attack at both the carbon and oxygen of the enol has been 
proposed. The ketoselenic acid 57 formed in each case undergoes a Pummerer 
rearrangement, which gives the α-dicarbonyl compound 55 (Scheme 15).131 
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Scheme 15 
Once the dicarbonyl was formed, it was converted to the di-hydrate compound 58 by 
heating and stirring in water (Scheme 16).132 This often gave a crystalline products which 
were easier to handle than the glyoxal oils. 
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Scheme 16 
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3.4 Synthesis and Biological Evaluation of C-
Functionalised Derivatives of Cyclen 
3.4.1 Synthesis of First Library 
Six aromatic glyoxal derivatives were prepared (59 – 65), and using the metal-templated 
strategy in Chapter 3.3, six substituted macrocycles (66 – 72) were synthesised (Table 4). 
Three of these compounds (66, 71, 72) have been made previously for lanthanide 
complexation.126 No tetraazamacrocycles of this kind have been tested for antiparasitic 
activity. 
NH HN
HNNH
R
R
O
H
O
TETA
FeCl3
NaBH4
MeOH
R
O
SeO2
1,4-dioxane
H2O
 
R Glyoxal 
R
O
H
O
 
Yield 
(%) 
Macrocycle 
NH HN
HNNH
R
 
Yield 
(%) 
Novel? Est. 
log P 
 
59 100 66 84 no126 -0.19 
OMe
 
60 100 67 83 yes -0.11 
OMe
OMe
 
61 100 68 81 yes -0.55 
F
 
62 100 69 80 yes 0.01 
CF3
 
63 100 70 64 yes 0.77 
NO2
 
64 80 71 67 no126 -0.37 
 
65 42 72 100 no126 1.83 
Table 4 
Caroline M. Reid, 2006  Chapter 3, 56 
3.4.1.1 Log P 
The estimated log P value for each compound is also included in Table 4. These were 
calculated using an online program.133  Log P measurements show the degree to which the 
compound is partitioned between water and a non-miscible solvent such as octanol. P is the 
partition coefficient and it is defined as the ratio of concentration of the compound (as the 
neutral molecule) in aqueous phase to the concentration in the immiscible solvent. In 
practice the log P will vary according to the conditions under which it is measured and the 
choice of partitioning solvent. However, using this programme, we can get a general 
understanding about the variation in these values between the different analogues. 
Relationships between log P and biological activity are often found in series of 
compounds. Hansch in 1964 showed that these relationships are often parabolic, leading to 
an optimum value for the log P for a desired activity.134 For both CNS and gastric 
absorption the relationship appears to be parabolic with an optimum log P value of around 
2 ± 1 (Figure 16).134,135 
Log P
Absorbance
21 3
 
Figure 16 
3.4.2 Biological Evaluation of 66 - 72 
Compounds 66 - 72 were tested for antiparasitic activity against Trypanosoma brucei along 
with non-substituted cyclen 36 as reference using an Alamar Blue assay. Cultures of the 
parasites are treated with serial concentrations of the compounds and left for 48 hours at 26 
oC before staining with Alamar Blue for 24 hours. Alamar Blue is a redox indicator that 
monitors the reducing environment of the cells.136 When added to the cells, Alamar Blue is 
in the resazurin form 73 that is a deep purple colour. If the parasites are alive, the 
compound is converted to resorufin 74, which is colourless. 
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The IC50 values were calculated from the spectrophotometric data taken using a 
fluorimeter, and two compounds (70 and 72) were found to have activity at a concentration 
< 7 µM (Table 5). Interestingly the compounds with the highest activity correspond to 
those with the log P value in the range for optimum in vivo absorption. 
NH HN
HNNH
R
 
 R Est. log P T. brucei IC50 (µM) HEK IC50 (µM) 
36 H -1.83 >200 5.0 
66 
 
-0.19 >200 >200 
67 OMe
 
-0.11 >200 >200 
68 OMe
OMe
 
-0.55 >200 >200 
69 F
 
0.01 >200 >200 
70 CF3
 
0.77 6.8 73 
71 NO2
 
-0.37 >200 >200 
72 
 
1.83 2.6 26.0 
Table 5 
To discover if these compounds have any parasite-selectivity, another Alamar Blue assay 
was carried out using Human Embryonic Kidney (HEK) cells. A selective drug would be 
active against the parasite but not against human cells. There is no dramatic parasite 
specificity observed between the results in Table 5, and therefore these compounds would 
Caroline M. Reid, 2006  Chapter 3, 58 
not make ideal antiparasite drugs. However, the outstanding activity of 72 prompted the 
synthesis of further analogues in an attempt to increase the activity and selectivity of the 
macrocycles against T. brucei. 
3.4.3 Synthesis of Further Analogues 
A further nine analogues were prepared, containing different heterocycles, larger aromatic 
moieties and a non-aromatic substituent, using the same methodology (Table 6). 
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NH HN
HNNH
R
R
O
H
O
TETA
FeCl3
NaBH4
MeOH
R
O
SeO2
1,4-dioxane
H2O
 
R Glyoxal 
R
O
H
O
 
Yield 
(%) 
Macrocycle 
NH HN
HNNH
R
 
Yield 
(%) 
Novel? Est. 
log P 
CF3
CF3
 
75 100 84 54 yes 1.73 
Br
 
76 100 85 71 yes 0.70 
Cl
 
77 100 86 78 yes 0.77 
N
 
78 100 87 72 no126 -0.65 
O
 
79 75 88 54 yes -0.82 
S
 
80 95 89 79 yes -0.37 
 
81 83 90 77 yes 0.98 
 
82 43 91 79 yes 2.16 
 
83 100 92 63 yes -0.05 
Table 6 
3.4.4 Biological Evaluation of 84 - 92 
Compounds 84 – 92 were tested in vitro in the same way against T. brucei and HEK cells 
using Alamar Blue assays, and their IC50 values were calculated (Table 7). 
Caroline M. Reid, 2006  Chapter 3, 60 
NH HN
HNNH
R
 
 R Est. log P T. brucei IC50 (µM) HEK IC50 (µM) 
84 CF3
CF3
 
1.73 6.8 61.0 
85 Br
 
0.70 21.8 >200 
86 Cl
 
0.77 2.8 181.2 
87 N
 
-0.65 >200 >200 
88 O
 
-0.82 127.8 >200 
89 S
 
-0.37 72.3 >200 
90 
 
0.98 6.9 >200 
91 
 
2.16 1.26 24.9 
92 
 
-0.05 133.0 >200 
Table 7 
Again, compounds with a log P value within the optimum range have shown the highest 
activity against T. brucei and HEK cells. 91 has the best antiparasite activity so far with an 
IC50 value of 1.26 µM. This permitted some in vivo testing that was carried out using mice 
infected with T. brucei. 91 was administered interperitoneally in 20mg/kg doses and an 
experiment using melarsoprol in 5mg/kg doses served as a control. Melarsoprol 7 cured all 
mice at 5 mg/kg, however 91 given at 20 mg/kg did not. 
A number of compounds demonstrated some parasite-specificity: 85, 86 and 90 are more 
active against T. brucei than the human cell line, however their activity is not potent 
enough to warrant further testing in animal models.  
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3.4.5 Unsuccessful Syntheses 
In addition to the compounds produced in Chapters 3.4.1 and 3.4.3, the synthesis of other 
substituted tetraazamacrocycles was unsuccessfully attempted. 
3.4.5.1 Amine Analogues 
To complete the library of compounds, the synthesis of some nitrogen-containing 
compounds would be advantageous (Scheme 17). Unfortunately the amine function of the 
acetophenone starting materials was also oxidised by the selenium dioxide, resulting in 
degraded material. No product or starting material could be isolated in any case. 
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Scheme 17 
3.4.5.2 Non-Aromatic Analogue 
The synthesis of another non-aromatic analogue 102 was attempted, however the methyl 
ketone does not form a stable glyoxal 101 (Scheme 18). In the case of 83 however, we 
were able to form the glyoxal due to stabilisation by the tertiary carbon. Interestingly in 
Edlin’s report of the metal-templated synthesis of tetraazamacrocycles, it was suggested 
that an aryl group was necessary to stabilise the diimine cyclisation intermediate.128 
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Scheme 18 
3.4.5.3 Pyrene Derivative 
The biological results indicate that the compounds with a log P value within the optimum 
range demonstrate the greatest toxicity. It was therefore desirable to synthesis the pyrene 
derivative 104 that has an estimated log P value of 2.82. It was postulated that it would 
also have high antiparasitic activity if it could cross the lipid bilayer of the parasite cell 
membrane by passive diffusion. 1-Acetylpyrene was successfully transformed into glyoxal 
103 using selenium dioxide in quantitative yield, however the insolubility of 103 in 
methanol prevented the cyclisation (Scheme 19). 
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Scheme 19 
3.4.5.4 Hydroxyl Analogue 
The synthesis of the substituted aromatic derivative bearing a hydroxyl group was 
attempted (Scheme 20). 4’-Hydroxyacetophenone was successfully converted into (4-
hydroxy-phenyl)-oxo-acetaldehyde 105 using selenium dioxide in a good yield. The 
cyclisation step to form the macrocycle 106 however was unsuccessful for unknown 
reasons. 
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Scheme 20 
3.5 Synthesis of Parasite-Specific Analogues 
The next synthetic aim was to prepare tetraazamacrocycles derivatives that contain parasite 
P2 recognition motifs, which are found in the HAT drugs pentamidine 2 and melarsoprol 7 
(see Chapter 1).20,35,37 Synthesising compounds with melamine or benzamidine motifs may 
increase the specificity and toxicity of these cyclen analogues. 
2
H2N
NH
O O
NH2
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N
N
N
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H2N NH
As S
S OH
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3.5.1 Melamine Derivative 
Target compound 107 was retrosynthesised to commercially available 4’-
aminoacetophenone and 2-chloro-4,6-diamino-1,3,5-triazine (Scheme 21). The first step in 
the synthesis would require oxidation of the acetyl to a 1,2-dicarbonyl, however it has been 
previously shown that this is not possible as the selenium dioxide destroys the amine group 
(Chapter 3.4.5). Therefore a protecting group strategy was designed to protect the amine 
during the oxidation and cyclisation steps. Selective removal of the protecting group 
should allow the coupling of the melamine group to form 107. 
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Scheme 21 
3.5.1.1 Test Coupling 
Firstly a trial coupling reaction was carried out using 2-chloro-4,6-diamino-1,3,5-triazine 
and 4’-aminoacetophenone under basic aqueous conditions to give 109 as a white solid 
(Scheme 22).41,137,138 
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Scheme 22 
3.5.1.2 Amine Protection 
A number of different protecting groups were used to protect the amine functionality with 
varying success (Scheme 23). 
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Scheme 23 
Trityl 
The first protecting group used was the trityl group. Amine 110 was synthesised from 4’-
acetylbenzylamine and triphenylmethyl chloride in a good yield (Scheme 23).139 The 
oxidation using selenium dioxide however was unsuccessful as the trityl group was 
removed under these conditions resulting in degradation of the compound. No starting 
material or product was isolated from this reaction. 
Aniline was also trityl-protected to confirm that the selenium dioxide deprotects the trityl 
group and oxidises the amino group. 120 was formed in excellent yield under the same 
conditions, and then reaction with selenium dioxide gave triphenylmethyl hydroxide 121, 
and signs of degraded aniline (Scheme 24). 
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Scheme 24 
tert-Butoxycarbonyl 
Using one equivalent of di-tert-butyl dicarbonate to protect 4’-aminoacetophenone gave 
Boc-protected amine 111 in a good yield after purification by flash chromatography 
(Scheme 23).140 111 was then successfully oxidised to give 116 in a quantitative yield. 
Benzyloxycarbonyl 
112 was synthesised in an excellent yield using benzylchloroformate however the Cbz 
group did not survive the oxidation step (Scheme 23).141 
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Tosyl 
p-Toluenesulfonyl chloride was used to protect 4’-aminoacetophenone to give 113 
(Scheme 23),113 and then oxidation gave 118 in a very low yield. 
9-Fluorenylmethoxycarbonyl 
9-Fluorenylmethylchloroformate was used to protect the amine in moderate yields 114 
(Scheme 23).142 Due to time constrains towards the end of this project, the oxidation was 
attempted but the product was not isolated. Thin layer chromatography of the reaction 
mixture showed only starting material after stirring and heating for a number of days, and 
there were also signs of degraded amine. 
3.5.1.3 Cyclisation 
The only groups that survived the oxidation step from the five different protecting 
strategies were Boc and tosyl. The next cyclisation step using the metal-template strategy 
however was not successful and no product was isolated in either case (Scheme 25). It is 
thought that the harsh reduction conditions followed by work-up using concentrated 
hydrochloric acid may have removed the protecting group resulting in the product being 
too polar to extract into the chlorinated solvent. 
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Scheme 25 
3.5.1.4 Another Route 
Although the protecting group strategy was not successful, another way to synthesise an 
amino-derivative is by reducing the nitrile derivative 87 prepared earlier. This was done 
using borane, to give 124 in a good yield as a cream, viscous oil (Scheme 26).143 When the 
coupling reaction was carried out under the same conditions as before using 2-chloro-4,6-
diamino-1,3,5-triazine,41,137,138 the target material 125 could not be isolated. At this stage 
we moved away from the melamine-based compounds as their solubility in test reactions 
was a problem. It is unlikely that 125 would dissolve in water or DMSO for in vitro 
testing. 
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Scheme 26 
3.5.2 Benzamidine Derivative 
The amidine functionality has been found in many natural products, and amidine-
containing compounds are often a critical part of many biological processes. Substituted 
amidines are useful intermediates in the synthesis of many heterocyclic compounds, and 
consequently a plethora of methods has been developed for their preparation.111,144 The 
most common route for synthesis are from amides, nitriles or thioamides.145-149 This 
section describes the strategies attempted for the preparation of benzamidine-substituted 
macrocycles. 
3.5.2.1 Pinner 
The Pinner reaction is an organic reaction of a nitrile with an alcohol under acid 
catalysis.150 If hydrochloric acid is used for example, the product formed is the 
hydrochloric acid salt of an imino ester or an alkyl imidate 126. These “Pinner salts” can 
react with an excess of alcohol to form the ortho-ester, with water to form an ester 127, or 
with ammonia or an amine to form an amidine 128 (Scheme 27). A. Pinner developed this 
reaction and studied the nature of imidates in the late 19th century.151,152 The reaction is 
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normally carried out at 0 oC in an anhydrous solvent such as chloroform or diethyl ether, 
although an excess of alcohol can also be used as the diluent in some cases.111,144,150 
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Scheme 27 
A trial reaction under Pinner conditions was carried out using benzonitrile (Scheme 28).153 
Benzonitrile was dissolved in dry dichloromethane and two equivalents of absolute ethanol 
were added. The solution was cooled to -8 oC using a sodium chloride-ice bath, and then 
the solution was saturated with anhydrous hydrochloric acid. Addition of diethyl ether led 
to a precipitate that was extracted from the basic solution to give an oil. Ammonium 
chloride in aqueous methanol was added and the mixture was heated under reflux for six 
hours. After work-up, benzamidine 129 was achieved as a white solid in good yield. 
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Scheme 28 
Before this reaction was carried out with macrocycle 87, another test reaction was carried 
out using an amine. 4’-Aminobenzonitrile was under the same conditions as before, 
however 100% starting material was recovered (Scheme 29). It is understood that the first 
step using hydrochloric acid formed the salt of the amine, which precipitated out of 
solution and the imidate did not form. Thus work-up just produced the free base of the 
starting material. This reaction was repeated a number of times using alcohol as the solvent 
in an attempt to dissolve the amine salt formed, and the volume of hydrochloric acid 
bubbled through the solution was increased, however we did not isolate any 4’-amino 
benzamidine 130. 
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Scheme 29 
In the paper “The Chemistry of Imidates”, Roger and Neilson mention that if the nitriles 
have an amino group it should be protected (using p-toluenesulfonyl chloride) to prevent 
precipitation of the aminonitrile hydrohalide.150 Protecting the amines in our macrocyclic 
starting material is possible, however it adds an extra two steps into the synthesis, and as 
mentioned previously, tosyl protecting groups are notoriously difficult to remove. 
 Baksheev and Gavrilov published the successful preparation of imido esters of amino 
acids by using methanol saturated with hydrochloric acid to react with aminonitrile 
hydrochlorides.154 Using an adapted method we attempted the synthesis of our target 
compound 131 (Scheme 30).155 87 was cooled to -8 oC in absolute ethanol, and 
hydrochloric acid was bubbled through the solution for 25 mins. The concentrated product 
in ethanol was heated at 60 oC with ammonium chloride and the yellow solid obtained after 
work-up consisted mainly of ammonium chloride and starting material but no target 
material. The Pinner strategy towards our target material 131 was therefore unsuccessful. 
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Scheme 30 
3.5.2.2 LiHMDS 
A number of pentamidine and other amidine-containing analogues needed for biological 
activity have been prepared by the conversion of a nitrile functional groups into amidines 
using lithium hexamethyldisilazide (LiHMDS).156,157 LiHMDS is a strong base which is 
employed as a metallating agent. LiHMDS can be prepared in situ from n-BuLi and 
1,1,1,3,3,3-hexamethyldisilazane in THF,158 however we used the commercially available 
reagent. A number of successful test reactions were carried out with benzonitrile and 4’-
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acetobenzonitrile using two equivalents of LiHMDS at -78 oC (Scheme 31). Following 
work-up, both benzamidine 129 and 4’-acetyl benzamidine 132 were isolated in good 
yields with high purity. 
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Scheme 31 
This method was then attempted using macrocycle 87, however a number of modifications 
were required to complete the reaction. Using two equivalents of LiHMDS gave only 
starting material, and increasing the number of equivalents to 5.5 only produced a small 
amount of product. After a number of unsuccessful attempts involving changing the 
amount of reagents, temperature and reaction time, amidine 131 was synthesised in 
excellent yield (Scheme 32). Five equivalents of LiHMDS were used at -78 oC and the 
worked up product was treated with hydrochloric acid in diethyl ether. The product was 
recrystallised from ethanol and diethyl ether to give 131 as a pentahydrochloride salt. This 
extremely hygroscopic product had to be handled carefully under anhydrous conditions. 
Characterisation of the product was problematic as the product could only be identified by 
13C NMR spectroscopic data. The nitrile quaternary carbon of 87 comes at δ 111.2 (Figure 
17) and the amidine quaternary carbon of 131 comes at δ 163.3 (Figure 18). 
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Scheme 32 
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Figure 17 
 
Figure 18 
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3.5.2.3 Buchwald-Hartwig Amination 
Another target benzamidine compound is 133, which can be retrosynthesised to 
macrocycle 86 and commercially available 4’-aminobenzamidine (Scheme 33). 
NH HN
HNNH
NH HN
HNNH
Cl
133 86
H
N
NH
NH2
H2N
NH2
NH
+
 
Scheme 33 
A publication by Huang et al. in 2003 described how a range of different compounds can 
undergo palladium-catalysed amination reactions.159 A test reaction was carried out to 
synthesise methyl 3-phenylaminobenzoate 134 (Scheme 34). This reaction was done in a 
Schlenk tube using Pd2(dba)3 and the XPhos ligand under argon in a modest yield.159,160 
H
N CO2MePh
CO2MeCl
Aniline
Pd2(dba)3
XPhos
NatBu
t-BuOH
25% 134
 
Scheme 34 
In Huang’s publication, this strategy had been successfully used to couple Boc-protected 
amines without removing the protecting group (Scheme 35).159 
N
Cl
Morpholine
Pd2(dba)3
XPhos
NatBu
t-BuOH
81%135
NHBoc
NHBoc
O
136
 
Scheme 35 
The aim therefore was to couple macrocycle 86 with Boc-protected 4’-aminobenzamidine 
under these conditions before removing the Boc group to give the benzamidine compound. 
The hydrochloride salt of 4’-aminobenzamidine was Boc-protected using di-tert-butyl 
dicarbonate under basic conditions (Scheme 36). The primary amine of the benzamidine is 
Caroline M. Reid, 2006  Chapter 3, 73 
the most reactive and so the Boc protecting group was chosen to allow C-N bond 
formation at the aromatic amine.161 Both the mono- 137 and di-Boc 138 protected amines 
were prepared,161,162 however mono-protected 137 was used in all coupling reactions. 
NHBoc
NH
H2N
N(Boc)2
NH
H2N
NH2
NH
H2N 2.HCl
137 138
1 eq Boc2O
1M NaOH
THF
H2O
66%
2.5 eq Boc2O
1M NaOH
THF
H2O
65%
 
Scheme 36 
Unfortunately amination reactions carried out with 4’-chloroacetophenone and 137 
(Scheme 37), and 86 with 137 (Scheme 38), were both unsuccessful and therefore this 
amination route was abandoned. 
137
Pd2(dba)3
XPhos
NatBu
t-BuOH
139
Cl
O
N
H
O
NHBoc
NH
 
Scheme 37 
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NH HN
HNNH
Cl
86
 
Scheme 38 
3.5.2.4 Amide Coupling 
The benzamidine moiety may also be coupled to the macrocycle via an amide bond. Target 
material 141 can be retrosynthesised to carboxylic acid 142 and 4’-aminobenzamidine 
(Scheme 39). 
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Scheme 39 
A test reaction to find the optimum conditions for amide coupling was carried out using 
aniline and benzoyl chloride to give benzanilide 143 (Scheme 40).163 
N
H
O
Cl
O
DMAP
pyridine
CH2Cl2
90% 143
H2N
 
Scheme 40 
A trial reaction was also carried out to find the best conditions for the hydrolysis of a 
nitrile to a carboxylic acid functional group. This was done with benzonitrile using 
potassium hydroxide (Scheme 41).164 Work-up gave beautiful white crystals of benzoic 
acid 144 in a good yield. 
144
N
KOH (s)
EtOH
H2O
77%
OH
O
 
Scheme 41 
142 was prepared directly from 87 under the same conditions in an excellent yield, before 
142 was converted into the acid chloride 145 using thionyl chloride (Scheme 42).165 
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Scheme 42 
Another route toward carboxylic acid was studied (Scheme 43). 4’-Acetyl benzoic acid 
was protected using benzyl bromide to give 146 in a good yield before carrying out an 
oxidation using selenium dioxide.166 It was thought that glyoxal 147 could be cyclised and 
then deprotected to give 142. This route was undesirable for a number of reasons: the 
starting material was reasonably expensive; glyoxal 147 required further purification by 
flash chromatography that resulted in low yields; and the overall scheme required the extra 
protection and deprotection steps which were time consuming. This route was therefore 
incomplete and not used for the production of 142. 
NH HN
HNNH
OH
O
142
O
HO
O
O
BnO
O
O
BnO
O
H
O
BnBr
NEt3
THF
72%
SeO2
1,4-dioxane
H2O
146 147
 
Scheme 43 
Acid chloride 145 was carried straight onto the next step without purification or 
characterisation and reacted with 137 using DMAP (Scheme 44). Unfortunately after 
work-up the 1H and 13C NMR spectroscopic analysis revealed only the Boc-protected 
starting material 137, and the aqueous phase contained the macrocycle 145. This route 
towards a benzamidine derivative was therefore discarded. 
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Scheme 44 
3.5.2.5 Four Benzamidine Moieties 
Another benzamidine-containing target compound 149 is a non-substituted azamacrocycle 
with four benzamidine moieties connected through the nitrogen atoms.  
149
N N
NN
R
R R
R = NH
NH2
HN
O
R
 
Using a method used to prepare a number of trypanocides, Boc-protected 137 was coupled 
with chloroacetyl chloride using triethylamine in dichloromethane in a good yield (Scheme 
45).161 The coupling of 150 with cyclen 36 was unsuccessful. We were unable to obtain 
any analysis from the product despite numerous recrystallisations from various solvent 
systems. Due to time constraints this route was also discarded. 
NHBoc
NH
N
H
O
Cl137
Cl Cl
O
NEt3
CH2Cl2
59% 150
149
 
Scheme 45 
3.5.3 Guanidine Derivative 
A guanidine derivative 152 (which also contains the P2 recognition motif) was prepared 
using amine 124, N,N’-di-Boc-1H-pyrazole-1-carboxamidine and N,N-
diisopropylethylamine (Scheme 46).167 The Boc protecting groups were removed from 151 
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using hydrochloric acid. The yellow residue was recrystallised from methanol and diethyl 
ether in excellent yield to give the hexahydrochloride salt 152 as a white solid. 
NH HN
HNNH
NH2
NH HN
HNNH
N
H
NH2
NH
N
N
BocN
NHBoc
DIPEA
MeOH
100%
6M HCl
99%
NH HN
HNNH
N
H
NHBoc
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124 151
152
.6HCl
 
Scheme 46 
3.5.4 Biological Evaluation of Parasite-Specific Analogues 
Two tetraazamacrocycles containing a trypanosome P2 purine transporter recognition 
motif were prepared (131 and 152), along with two other novel macrocycles (124 and 142). 
These four compounds were tested for antiparasite activity, and toxicity against HEK cells 
(Table 8). 
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NH HN
HNNH
R
 
 R Est. log P T. brucei IC50 (µM) HEK IC50 (µM) 
131 
NH2
NH
 
-1.44 22.0 >200 
152 
N
H
NH2
NH
 
-1.64 41.2 >200 
124 NH2
 
-1.12 >200 >200 
142 
OH
O
 
-0.31 >200 >200 
Table 8 
Compounds 124 and 142 unsurprisingly show no activity against trypanosomes or the 
human cell line, as their log P values suggest that they would not be taken up in vitro. 131 
and 152 however show trypanocidal activity but are ineffective against the HEK cells. 
Both compounds have log P values outwith the optimum range for passive diffusion, 
therefore the P2 recognition motif has caused the parasites to transport the compounds 
actively across the cell wall. The absence of a P2 transporter in the mammalian cells means 
that they are unaffected by the drug dose of 131 and 152. 
3.6 Summary of Synthetic Achievements 
Cyclen 36 was prepared in large quantities for synthesis of anti-cancer alkylating agents, 
and as a standard compound for all biological testing. Twenty racemic C-substituted 
analogues were prepared using an iron-template method. Fourteen of these are novel, 
including two analogues containing a P2 recognition motif required for parasite-specific 
activity. The synthesis of a number of other parasite-specific analogues was investigated 
without success. 
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3.7 Biological Evaluation 
All 20 compounds were tested as their hydrochloride salts against T. brucei and HEK cells 
along with non-substituted cyclen 36. They were also tested against the malarial parasite 
Plasmodium falciparum, and a handful were tested for oligopeptidase B (OPB) inhibition. 
Table 9 contains the full list of compounds and their biological test results. Fluorescence 
experiments and a study of the effects of polyamines were also carried out later in an 
attempt to elucidate the mode of antiparasitic action. 
NH HN
HNNH
R
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 R Est. 
log P 
T. brucei  
IC50 (µM) 
HEK  
IC50 (µM) 
P. falciparum 
IC50 (µM) 
OPB 
IC50 (µM) 
36 H -1.83 >200 5.0 >100 0.19 
66 
 
-0.19 >200 >200 26.0 - 
67 OMe
 
-0.11 >200 >200 26.0 - 
68 OMe
OMe
 
-0.55 >200 >200 >100 - 
69 F
 
0.01 >200 >200 24.0 - 
70 CF3
 
0.77 6.8 73 5.0 - 
71 NO2
 
-0.37 >200 >200 13.0 - 
72 
 
1.83 2.6 26.0 1.3 0.24 
84 CF3
CF3
 
1.73 6.8 61.0 4.8 - 
85 Br
 
0.70 21.8 >200 5.8 - 
86 Cl
 
0.77 2.8 181.2 2.3 - 
87 N
 
-0.65 >200 >200 >100 - 
88 O
 
-0.82 127.8 >200 >100 5.08 
89 S
 
-0.37 72.3 >200 46.7 - 
90 
 
0.98 6.9 >200 1.7 0.27 
91 
 
2.16 1.26 24.9 <1.5 0.27 
92 
 
-0.05 133.0 >200 >100 - 
124 NH2
 
-1.12 >200 >200 >100 - 
142 
OH
O
 
-0.31 >200 >200 >100 - 
131 
NH2
NH
 
-1.44 22.0 >200 >100 0.36 
152 
N
H
NH2
NH
 
-1.64 41.2 >200 >100 - 
Table 9 
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3.7.1 Trypanosoma brucei 
In general from the test results it can be hypothesised that the log P value plays a large part 
in the activity of the compound. In general, those compounds with a log P value within the 
optimum range for gastric and CNS absorption have the most striking activity. 72, 86 and 
91 showed the greatest toxicity. Figure 19 contains an example IC50 curve, which 
represents the activity of 91. 
10-5 10-4 10-3 10-2 10-1 1 101 102
180
Response
[Inhibitor]
 
Figure 19 
Incorporating the trypanosome P2 purine recognition motif onto 131 and 152 has allowed 
the parasites to uptake compounds which otherwise could not have passively diffused into 
the cells. Adding the recognition motif did not however improve on the toxicity of 91. 91 
was tested in vivo against T. brucei by Dr Vanessa Yardley (London School of Hygiene 
and Tropical Medicine), however a dose of 20 mg/kg of 91 did not cure trypanosomiasis. 
3.7.2 Human Embryonic Kidney (HEK) Cells 
Alamar Blue assays determining the activity of the compounds against HEK cells 
highlights any selectivity of the compounds towards the parasites. A selective drug should 
have toxicity against T. brucei at less than 1-2 µM, but would be inactive against human 
cell lines. The most active drugs (72, 86 and 91) against T. brucei also show high activity 
against HEK cells, and the compounds with the greatest parasite-selectivity are 84, 85, 90, 
131 and 152. The compounds with the P2 recognition motif (131 and 152) display parasite 
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selectivity, but their activity against the trypanosomes is not high enough to permit in vivo 
testing. 
3.7.3 Plasmodium falciparum (Malaria) 
Plasmodium flaciparum is one of four species of Plasmodium protozoa that cause malaria. 
Malaria is a parasitic disease transmitted by the Anopheles mosquito, which affects 
approximately 300 million people worldwide, with at least 90% of cases occurring in 
tropical Africa. Every year between 1 and 1.5 million people die from malaria.168 
E.-M. Patzewitz from the group of Prof. S. Muller (University of Glasgow) tested all 21 
tetraazamacrocycles against P. falciparum. The results in Table 9 show that analogues with 
large aromatic moieties, and electronegative heteroatoms, have the greatest activity. 91 
displayed the best activity with an IC50 value lower than 1.5 µM, and this assay should be 
repeated to obtain a more accurate result. Interestingly the compounds containing the 
trypanosome P2 recognition motif (131 and 152) show no activity against the malaria 
parasite. 
3.7.4 Oligopeptidase B (OPB) 
OPB is a serine peptidase with a substrate specificity similar to trypsin, which is a major 
digestive enzyme. OPB hydrolyses peptide bonds in low molecular mass peptides on the 
carboxy side of basic residues (for example arginine and lysine).169 No crystal structure for 
OPB is available, however the structure of the closely related prolyl oligopeptidase has 
been determined. This revealed the presence of two domains; an N-terminal propeller 
domain, and a C-terminal hydrolase domain, which contains the substrate-binding and 
catalytic residues. 
N. Bland working for Prof. J. Mottram and Prof. G. Coombs (Universities of Glasgow and 
Strathclyde) used some of these macrocyclic polyamines to study the inhibition of OPB 
cloned from Leishmania major. Although the compounds are not exceedingly active (Table 
9), they do inhibit the enzyme no matter what substituent is present, which is surprising as 
polyamines have previously been shown to be mild stimulants of these types of 
enzymes.169 Therefore it is hypothesised that there is a non-substrate-like interaction 
occurring, for example at an allosteric site such as the pore of the propeller domain. The 
compounds may block access to the active site of the enzyme. 
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3.7.5 Fluorescence 
Drug analogues 72, 90 and 91, which displayed the greatest in vitro activity, also fluoresce 
at certain wavelengths. A number of experiments were carried out to determine where the 
compound accumulates within the parasite as it causes toxicity. Using a fluorescence 
microscope, tests were carried out using 72 and 91 on wild type T. brucei 427, mutant 
clone knockout T. brucei ∆Tbat1 (P2 purine transporter null), and Leishmania mexicana. 
The trypanosomes were viewed under normal light (DIC) and then excited at different 
wavelengths to view fluorescence. Figure 20 contains the absorption and fluorescence 
emission spectra of fluorescein-5-isothiocyanate-labelled goat anti-mouse IgG antibody in 
pH 8.0 buffer (FITC) (green), rhodamine phalloidin in pH 7.0 buffer (RHOD) (red) and 
DAPI bound to DNA (DAPI) (blue) which were the three regions used to observe 
fluorescence.170 
 
Figure 20 
3.7.5.1 Trypanosoma brucei 
Using both the wet slide technique and blood smears, the fluorescence of compounds 72 
and 91 was observed at various time points under normal light and then using different 
wavelengths. They were dispersed within the parasite cells within 30 minutes (Figure 21 
shows trypanosome after 30 minutes with compound 91 at x100 magnification). 
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Figure 21 
91 had also become accumulated in some of the parasite’s intracellular organelles after 60 
minutes (Figure 22 shows trypanosome after one hour with compound 91). It is impossible 
at this stage to determine into which organelle the drug is accumulating, and further 
experiments need to be carried out using known organelle stains. Conclusions about the 
mode of toxicity of these macrocycles may then be made. 
 
T. brucei x100 DIC T. brucei x100 DAPI 
T. brucei x100 RHOD T. brucei x100 FITC 
 
Figure 22 
Drug 91 was also given to mutant clone knockout T. brucei and the same procedure carried 
out. As before, the drug became cytosolic after around 30 minutes, and then after an hour 
had become more punctate in some areas. This suggests that these compounds do not enter 
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the trypanosomes via the P2 purine transporter, but probably enter by passive diffusion 
across the cell membrane. 
3.7.5.2 Leishmania mexicana 
Leishmaniasis is another parasitic disease spread by the bite of infected sand flies in 
tropical and subtropical countries. There are a number of different forms of this disease, 
but the most common are cutaneous leishmaniasis, which causes skin sores, and visceral 
leishmaniasis, which affects some of the internal organs of the body.171 Although these 
polyamines have not yet been tested for toxicity against leishmania, compounds 72 and 91 
were used to view drug uptake into L. mexicana. Using the wet slide technique, 72 and 91 
were found to become cytosolic after 30 minutes, and were concentrated in specific 
organelles after one hour, similar to the activity within trypanosomes. Alamar Blue assays 
are required to define any general toxicity. 
3.7.6 Polyamine Investigation 
An investigation was carried to establish how these novel polyamines kill the parasites. A 
number of Alamar Blue assays were carried out to determine if adding a concentration of 
some of the parasite’s natural polyamines affects the drug activity. This may indicate 
which biochemical pathway the compounds are interrupting. 
Six compounds (36, 66, 72, 90, 91, 84) were tested against T. brucei as before, by treating 
the parasite with serial concentrations of the drug, this time dissolved in a 0.1 M solution 
of the polyamine (putrescine 18, spermidine 19 or spermine 20) in HMI-9 medium. IC50 
values were calculated from the spectrophotometric data, and it was found that adding 
putrescine has no effect on the drug activity (Figure 23). However adding spermine or 
spermidine killed all the trypanosomes on the plate. Unfortunately 0.1 M of spermine and 
spermidine is toxic to the trypanosomes and so this experiment must be repeated at a lower 
polyamine concentration. 
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Figure 23 
3.8 Conclusion and Future Work 
A library of 21 tetraazamacrocyles was prepared and tested against T. brucei, P. 
falciparum, HEK cells and for activity as OPB inhibitors. A number of compounds showed 
potent toxicity against the parasites, in particular 91 which underwent in vivo testing. The 
library also contained two compounds bearing a P2 purine transporter recognition motif, 
which led to parasite specificity of these compounds. Fluorescence investigation and 
further Alamar Blue assays gave an insight into the mode of entry and action of these 
tetraazamacrocycles. 
Further fluorescence work should be carried out to determine the exact organelles in which 
the compounds are accumulating, and this may tell us more about which biological 
pathway the drugs are affecting. The ability of the macrocycle to coordinate with metals 
such as iron and copper should also be investigated as the cause of cell death in biological 
systems. 
Further analogues should be prepared bearing more than one substituent (for example 153), 
which may increase the log P value of the macrocycle and assist the uptake into the 
parasites. There is also the opportunity to have more than one benzamidine moiety on the 
macrocycle 154, creating an analogue of pentamidine 2, which may be more toxic in vitro. 
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NH HN
HNNH
R
154
R
R =
153
NH2
NH
 
A route towards substituted TETA analogues was attempted. N1,N2-Bis-(2-aminoethyl)-
butane-1,2-diamine 155 was prepared from 1,2-dibromobutane and 1,2-diaminoethane in a 
modest yield as a racemate (Scheme 47).172 A variety of dibromo compounds are 
commercially available and so a range of substituted compounds may be prepared in this 
way. Cyclisation using the iron-template method has not yet been carried out. 
H2N
H
N
N
H
NH2
155
Br
Br H2N
NH2
EtOH
36%
 
Scheme 47 
88 
4 Synthesis of Enantiomerically Enhanced 
Tetraazamacrocycles    
4.1 Introduction 
Over the past fifteen to twenty years drug chirality, and in particular the use of single 
enantiomers instead of racemic mixtures, has become an area of great interest. This has 
resulted in considerable advances in the synthesis, analysis and separation of chiral 
compounds, as well as an increased appreciation of the potential significance of the 
differential biological properties of the enantiomers of chiral drugs that are administered as 
racemates.173-176 
After scientific meetings in the late 1980s and early 1990s, the American FDA and 
European guidelines recognised the significance of chirality in pharmacology and 
therapeutics. This led with increasing frequency to the synthesis of new chiral chemical 
compounds as single enantiomers as opposed to racemic mixtures. In addition, many 
established drugs marketed as racemates were re-evaluated and re-marketed as single 
enantiomers. This development is known as “The Chiral Switch”.177 
4.2 Aims of this Work 
It has been demonstrated that a number of substituted tetraazamacrocycles have moderate 
to high in vitro activity against trypanosomes (Chapter 3). These compounds are currently 
synthesised as racemic mixtures, and so the aim was to develop a general strategy for the 
synthesis of single stereoisomers of each compound. This may result in the halving of the 
required dose of the active drugs. 
4.3 Synthesis of Enantiomerically Enhanced Substituted 
Tetraazamacrocycles 
4.3.1 Route I 
In Chapter 3.2.2 tosylated cyclen 43 was successfully synthesised in 79% yield from 
ditosylated ethylenediamine 45 and 44. Retrosynthesis of our target chiral compounds 156 
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and 157 therefore suggests that the synthesis could start from an amino acid, for example 
phenylglycine, which is commercially available in both the R and S forms (Scheme 48). 
NH HN
HNNH
Ph
+
R = 156
S = 157
N
H
H
N OHHO
R = 158
S = 159
H2N
NH2
Ph
H2N
OH
Ph
O
 
Scheme 48 
Ditosylated diamines 166 and 167 were synthesised over five steps from phenylglycine 
(Scheme 49).178,179,180 
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NH3 (l)
CHCl3
R = 162, 84%
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Scheme 49 
Using the (R)-isomer 166, cyclisation with N,N’,O,O’-tetra(p-toluenesulfonyl)-N,N’-bis(2-
hydroxyethyl)-ethylenediamine 44 was carried out under phase-transfer conditions using 
tetrabutylammonium bromide (Scheme 50).104 However, only starting material was present 
at the end of the reaction time. This step was also attempted using traditional Richman-
Atkins conditions with caesium carbonate and DMF,90 however no product was observed 
in the NMR spectra. Increasing the reaction time did not affect this result and it was 
concluded that the aryl group provides a steric clash, which interrupts the pseudo-Thorpe-
Ingold effect created by the tosyl groups. 
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NN
Ph
N
Ts
Ts
N OTsTsO
TsHN NHTs
Ph
166
44
a) Bu4NBr 25%
    LiOH (aq) 2.5%
    toluene
or
b) Cs2CO3
    DMF
168
Ts Ts
TsTs
 
Scheme 50 
4.3.2 Route II 
Stetter and Mayer in 1961 had successfully cyclised a di-acid chloride 169 with 1,2-
diamino ethane to form 1,4-ditosyl-6,11-dioxo-1,4,7,10-tetraazacyclododecane 170 
(Scheme 51).165 
N
Ts
Ts
N ClCl
O
O
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H2N
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O
Ts
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Scheme 51 
The target material was retrosynthesised to 169 and diamines 158 and 159, which had been 
prepared previously (Scheme 52). 
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Scheme 52 
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Starting material 169 was prepared over four steps from tosylated ethylenediamine 45 
(Scheme 53).119,165 
Na
MeOH
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MeO
AcOH
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Scheme 53 
The cyclisation step was then carried out under high dilution conditions in benzene, using 
triethylamine, 169 and 158; however the expected product 171 was not observed (Scheme 
54). 
N
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Scheme 54 
The reaction was repeated using racemic 1,2-diaminopropane 175 and 169, which gave 
compound 176 quantitatively (Scheme 55). Therefore in this method, the aromatic ring 
present in 158 is also affecting the cyclisation reaction. This route towards 
enantiomerically enhanced macrocycles was abandoned for two reasons: firstly the high 
dilution conditions in benzene are not advisable for safety reasons; and secondly, after 
cyclisation the macrocycle would require a further two steps to reduce the amide groups 
and remove the tosyl protecting groups. 
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Scheme 55 
4.3.3 Route III 
Retrosynthesis of our target material in a slightly different way from route I led to an 
alternative strategy, which resembles the route by Garrity.120 We can begin our synthesis 
with phenylglycine, or any other amino acid, and diethanolamine (Scheme 56). 
NH HN
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H2N
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H
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Scheme 56 
The tritosylated (R)-amine 182 was prepared over four steps from phenylglycine (Scheme 
57).113,180,181,182 
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Scheme 57 
Cyclisation was investigated under Lukyanenko’s phase transfer conditions, and then with 
the traditional caesium carbonate method; however cyclisation did not go to completion 
(Scheme 58). Varying the reaction times and conditions made no difference, and only 
starting material was recovered from the reaction mixture in each case. Again it seems that 
the proximity of the extra aryl group on starting material 182 is disturbing the pseudo-
Thorpe-Ingold effect. 
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Scheme 58 
4.3.4 Route IV 
A final attempt to synthesise an enantiomerically enhanced tetraazamacrocycles referred 
back to Garrity’s publication, where racemic compound 184 was synthesised under 
Richman-Atkins conditions (Scheme 59).120 
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Scheme 59 
It was proposed that the extra carbon between the polyamine and the phenyl group is 
necessary to prevent steric clashes. Therefore using a route described previously, (S)-
phenylalanine was converted into 189 over five steps (Scheme 60).113,180,181,182 
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Scheme 60 
189 was then successfully cyclised with 47 under Richman-Atkins conditions to give 190 
in an excellent yield (Scheme 61). 
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Scheme 61 
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This reaction was also attempted using phase-transfer conditions described earlier;104 
however the product was impure and obtained in a low yield. 
4.3.5 Removal of Tosyl Groups 
There are a number of reported methods for the removal of tosyl protecting groups, 
however many are highly inefficient (see Chapter 3.2.5). Garrity used lithium aluminium 
hydride to deprotect tosyl groups.120 However previous attempts within the Robins group 
using this method have failed. In a preparation reported by Parker et al. and adapted by S. 
Jones from the Robins group, 190 was deprotected using sulfuric acid in ethanol, and the 
tetrahydrobromide salt was formed using hydrobromic acid (Scheme 62).89,101 
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Scheme 62 
191 requires conversion into the free base and purification before full characterisation. 
Unfortunately due to time constraints this work was not completed. 
4.4 Conclusions and Future Work 
A strategy has been found for the synthesis of single enantiomers of substituted 
tetraazamacrocycles. The starting materials are commercially available amino acids and so 
a wide range of compounds may be prepared. Unfortunately this route is lengthy and 
requires an undesirable tosyl deprotection. 
The most biologically active substituted macrocycle is 91, which has a large aromatic 
moiety and this compound cannot be retrosynthesised to a commercially available amino 
acid. Also, it is thought that the large ring structure may impede the cyclisation process of 
our preferred route. Another way to prepare single enantiomers of this compound, and 
other related aromatic macrocycles, may be by utilising chiral HPLC apparatus to separate 
the enantiomers of a racemate. 
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5 Anti-Cancer Alkylating Agents 
5.1 Cancer 
Cancer is the name given to illness caused by the uncontrolled growth and division of cells. 
Cancer is found everywhere in the plant and animal kingdoms. The earliest reference to 
human cancer is from an Egyptian papyrus written between 3000 and 1500 BC describing 
tumours of the breast.183 Cancer is caused by numerous effects and can occur in any cell of 
the body. 
Our body’s cells undergo constant growth and multiplication under rigorous control within 
our tissues and organs. To divide, a cell first replicates its DNA to make an exact copy. 
The cell then splits to form two identical ‘daughter’ cells. If the strict control over this 
process is lost, it can lead to cells multiplying irregularly to form a lump or ‘tumour’ of 
abnormal cancerous tissue.183 
A tumour alone can cause discomfort, for example by blocking the digesting system, or in 
the case of leukaemia (cancer of white blood cells), normal blood function is lost. Tumours 
can also press against nerves and alter normal body functions by releasing hormones. If a 
tumour becomes malignant it can spread via metastasis. Cancerous cells break away from 
the tumour and start multiplying in another part of the body.183 
5.2 Cancer Statistics 
There are over 200 different types of cancer although lung, breast, large bowel (colorectal) 
and prostate cancer are the most common accounting for over half of all new cases. 
275,000 people are diagnosed with cancer every year and it causes 26% of all deaths 
annually in the United Kingdom.184 
5.3 Cancer Therapy 
Modern medicine offers us a number of ways to tackle cancer. The four main methods are 
as follows. 
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5.3.1 Surgery 
Although only 13% of cancers are cured by surgery, it is carried out in 90% of cancer 
patients. Tissue biopsies are critical for diagnosis, and it is also used as a preventive in 
certain cancers.183 
5.3.2 Radiation Therapy 
Electromagnetic radiation is used to disrupt the atoms within tumour cells. This stops cell 
proliferation and growth and causes cell death. Radiation has the greatest effect on rapidly 
dividing cancer cells; however it does also affect normal cells.183 
5.3.3 Biotherapy 
This therapy employs the body’s natural defence systems to control the cancer. Some 
examples are using interleukins to increase the activity of lymphocytes; interferons to 
increase the cell-killing activity of the immune system; and gene therapy, which involves 
inserting genes into tumour cells to change their proliferation activity.183 
5.3.4 Chemotherapy 
Chemotherapy uses cytotoxic drugs to control tumour growth, shrink tumours, remove 
metastatic cancer growths and relieve pain. There are a number of different types of anti-
cancer agents including antibiotics, antimitotics, hormones, antimetabolites, inorganic 
compounds and alkylating agents.183 
5.4 Alkylating Agents 
Scientists have compared alkylating agents to the ancient Roman god Janus, who had two 
faces on one head facing in opposite directions (Figure 24). These chemical compounds, 
like Janus, have a dual nature with the power to cause great damage as well as the ability to 
cure disease. The history of the use of the alkylating agent mustard gas demonstrates this 
analogy well.185 
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Figure 24 
5.4.1 Mustard Agents: Chemical Warfare to Chemotherapy 
Mustard gas is the common name of 1,1-thiobis(2-chloroethane) 192, which is also known 
as blister gas, sulfur mustard, Kampstoff Lost, and yperite. It was first synthesised in 1860 
by Frederick Guthrie who reacted SCl2 with ethylene (Scheme 63).186 Guthrie also noted 
the toxic effects of the product on his skin. 
S ClClSCl2+
192
 
Scheme 63 
Despite its name, this agent is not gaseous but a clear to pale yellow viscous oil with a 
melting point of 14 oC. Mustard gas is odourless, however when it is mixed with other 
chemicals and dispersed as an aerosol it has a distinctive odour that has been compared to 
mustard, garlic or horseradish.187 
Mustard gas was first used as a chemical warfare agent in July 1917 during World War I in 
Belgium. It is a deadly and debilitating poison, particularly dangerous due to its ability to 
penetrate all protective clothing and the masks that were available at the time.188 Exposure 
to the chemical of more than 50% of body surface area is usually fatal. It is a vesicant 
(blister-inducing agent) and despite no immediate symptoms, 4-24 h after exposure, skin 
will turn into deep, burning and itching blisters. The eyes become sore and the eyelids 
swollen, possibly leading to conjunctivitis and blindness. If the aerosol is inhaled, the 
mucous membranes of the respiratory system will bleed and blister leading to pulmonary 
oedema.188,189 Mustard gas was only fatal in 1% of cases and so its efficiency was mainly 
due to its incapacitation effect: a wounded soldier slows an army more than a dead 
soldier.189 
Since 1917 mustard gas has been used in a number of other conflicts: for example by the 
UK against Iraqi rebels (1920); by the Soviet Union in China (1930); by Italy against 
Ethiopia (1935-1940); and Iraq against Iran (1983-1988).189 
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A number of epidemiology studies quickly linked the exposure of mustard gas (whether 
through military or occupational contact) to an increased risk of lung and other respiratory 
tract cancer, and later with cancers of other tissues.187 Mustard gas was found to cause 
DNA damage and genetic mutations in all test systems including fungi, bacteria, in vitro 
rodent cells and in vivo mammalian experiments.187 
In 1943 during World War II an incident occurred in the Italian port of Bari where German 
bombers sank 16 ships, one of which contained 100 tonnes of mustard gas. Dr Cornelius 
Packard Rhoads made a startling discovery while treating survivors by noticing a large 
reduction in their white blood cell counts.185 He then proposed that the ingredient of the 
chemical agent could be used to treat cancer, in particular leukaemia (Hodgkin’s disease). 
Around the same time, two pharmacologists (Goodman and Gilman) at Yale University 
showed that nitrogen mustard analogues affected rapidly dividing cells.190 This research 
led to the development of mechlorethamine 193, a bifunctional nitrogen mustard analogue 
of mustard gas that is still used today in the treatment of leukaemia.183 
N
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5.4.2 Mechanism of Action 
The mechanism of action of these chemicals is via the formation of strong covalent bonds 
by alkylation of various nucleophilic moieties.191 Both cytotoxic and chemotherapeutic 
effects are due to the alkylation of DNA primarily at the N-7 position in guanine 194, 
although other DNA bases and protein residues (for example cysteine 195) can also be 
alkylated in this way.192,193 
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Mutagenesis and teratogenesis occur when one bond is made with a nucleophile; however, 
compounds containing two reactive chloroethyl side chains can act as bifunctional 
alkylating agents (Figure 25). If the agent reacts with two guanine residues on the same 
strand the result is ‘limpet attachment’ which does not prevent the separation of the DNA 
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stands, but does prevent vital processing enzymes from accessing the DNA resulting in 
apoptosis.192 
NR
Cl
Cl
 
Figure 25 
Bifunctional alkylating agents cross-link between two nucleic acid chains or between a 
protein and a nucleic acid. The cytotoxicity corresponds to the formation of inter-strand 
DNA cross-links via the formation of an aziridinium ion with subsequent alkylation within 
the DNA major groove (Scheme 64).192 
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Scheme 64 
The compound then alkylates again to form a cross-link that prevents the DNA unwinding 
and this prevents any further cell replication processes, ultimately resulting in cell death 
(Figure 26). 
 
Figure 26 
Alkylating agents are not cell-cycle-phase specific although they are found to have the 
greatest effect during DNA synthesis, as cells exposed to the drug in earlier stages, such as 
G1, have enough time to repair DNA damage (Figure 27).194 These drugs are also 
proliferation dependent, displaying highest potency in rapidly growing and diving cells. 
Nascent cells have a longer time to correct any DNA damage before mutagenesis occurs.194 
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Figure 27 
5.4.3 Nitrogen Mustard Anti-Cancer Agents  
Since the discovery of the first prototypic anti-cancer agent mechlorethamine 193 in the 
1940s, a number of analogues have been developed and used to treat a variety of tumours. 
Mechlorethamine (commonly known as Mustargen) was used to treat prostate cancer. 
Modifications of this nitrogen mustard were made to improve solubility, stability and 
membrane transport, and this led to the development of chlorambucil 196, which 
underwent clinical trials in the 1950s.195 
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Chlorambucil is an orally administered drug for the treatment of chronic lymphocytic 
leukaemia, ovarian cancers, trophoblastic neoplasms and Waldenström 
macroglobulinemia, as well as being used as an immunosuppressive drug.195 The main side 
effect of chlorambucil is bone marrow suppression. Another N-mustard analogue is 
melphalan 197, a phenylalanine derivative of mechlorethamine, which is used to treat 
multiple myeloma, malignant melanoma and ovarian cancer.195 
Despite the relative success of these N-mustard alkylating agents against cancer, they still 
had dangerous and severe side effects from the blistering of mucous membranes, reduced 
immunity and seizures, to the induction of further cancers.196,197 These undesirable and life 
threatening side effects encouraged the development of prodrugs to minimise side effects 
and increase the selectivity of the drugs to cancerous tissue. One of the first N-mustard 
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prodrugs was cyclophosphamide 198, which is used to treat a number of cancers including 
Hodgkin’s disease and solid tumours, as well as treating some autoimmune disorders.198 
Developed in 1958, cyclophosphamide was designed to be cleaved by phosphoramidase 
enzymes in vivo, liberating the active mustard moiety. However, in practice the drug is 
oxidised by enzymes in the liver to give the active metabolite 4-hydroxycyclophosphamide 
199, which exists in equilibrium with its tautomer aldophosphamide 200 (Scheme 65). 
Most of the aldophosphamide is oxidised by aldehyde dehydrogenase (ALDH) to form 
carboxyphosphamide and a small amount is converted into phosphoramide mustard 201 
that forms cross-links within DNA. Acrolein 202 is also produced which is toxic to the 
bladder epithelium leading to hemorrhagic cystitis.198 
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Scheme 65 
Despite these side effects, cyclophosphamide 198 is still the most common anti-cancer 
alkylating agent used today.183,198 
5.5 Development of N-Mustards within the Robins Group 
In the mid 1990s, during her PhD research, N. Henderson synthesised a range of 
bifunctional mustard compounds based on piperidine 203.199 The conformational 
restriction imposed by the piperidine ring was investigated to determine if it would affect 
the aziridinium ion formation. Compound 204 showed cytotoxicity against human colon 
carcinoma cell lines with an IC50 of 8.5 µM.200 Henderson then aimed to increase the 
selectivity of the alkylation at the guanine N-7 site. A number of bispiperidine derivatives 
205 were synthesised which were cytotoxic in three cisplatin resistant cell lines, and they 
showed increased guanine selectivity when compared to melphalan.201 However the IC50 
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values were not as low as melphalan despite effective cross-linking of DNA at lower 
concentrations. 
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At this point it was observed that there was a relationship between the chain length of the 
carbon-linker and the biological activity, indicating an optimum distance between the 
nitrogens. In 1999 F. Anderson investigated this area further in her PhD research, and 
produced a series of homochiral bispyrrolidine mustard derivatives 206, along with a 
number of alkyl linear and cyclic mustards (such as 207 and 208).112 It was found that 
compounds with 2-, 5-, and 6- carbon linkers gave the best alkylation data whereas 3- and 
4-carbon linkers gave no DNA cross-linking activity.202 
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This result contrasts with that of conventional mustard drugs. Unfortunately none of these 
novel compounds gave high cytotoxicity and so Dr S. Lacy began working on the use of 
macrocyclic polyamines as a framework to synthesise alkylating agents. Macrocyclic 
polyamines have been used widely as ligands for metal chelation.203-206 They also offer a 
route to compounds with a range of ring sizes, a vast variety of structures, and can have 
different substituents on the carbon and nitrogen atoms. Dr Lacy synthesised tetrakis-(2-
chloroethyl)-1,4,7,10-tetraazacyclododecane 209, an alkylating agent that is a derivative of 
commercially available cyclen 36. 209 was found to have exceptional DNA cross-linking 
activity, with 100% cross-linking at 0.1 µM, and in tests against a human colon carcinoma 
cell line, 209 showed a higher cytotoxicity (IC50 = 22 µM) than chlorambucil 196 (IC50 = 
45 µM).207 
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Following this discovery, a number of poly-2-chloroethylated macrocyclic polyamines 
were developed with varying ring sizes, numbers of nitrogens, substituents on carbons, and 
carbon chain lengths between the nitrogens. These compounds (209 – 213) were tested for 
biological activity with a number of promising results (see Table 10). 
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Compound DNA cross-linking at 0.1 µM (%) IC50 (µM) 
209 100 22 
210 64 10 
211 94 8 
212 100 9 
213 30 13 
Table 10 
Because of difficulties experienced in the synthesis of some target macrocycles, L. Parker 
aimed to develop a flexible, reliable method for the synthesis of azamacrocycles of 
variable sizes with different carbon chain lengths between the nitrogens.86,208 Parker also 
targeted the low selectivity of current chemotherapeutic agents against cancer by designing 
redox-active compounds as prodrugs.209 These Cu (II) complexes are electrochemically 
reduced in hypoxic (low oxygen) tissue to release the N-mustard cytotoxin. Mustard 
complexes 214 and 215 showed irreversible redox behaviour and low thermodynamic 
stability and so behaved as typical mustard drugs but had no hypoxia selectivity. Complex 
39 however displayed reversible redox behaviour and high thermodynamic stability under 
aqueous conditions exhibiting excellent hypoxia selectivity against a lung tumour cell 
line.209 
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5.6 Aim of this Work 
Further investigation has been carried out within the Robins group to discover if the size 
and shape of aza and oxoaza macrocycles affects their activity as alkylating agents. 216 
prepared by S. Jones was found to have an IC50 value of 4.0 µM which is the most toxic of 
these types of compound prepared so far.89 
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Cyclen-based alkylating agents therefore remain the most active compounds in vitro, and 
so all novel macrocycles were based on the lead compound (36). The aim of this project is 
to convert the novel substituted tetraazamacrocycles synthesised in Chapter 3 into anti-
cancer alkylating agents 217 (Scheme 66). These compounds bear aryl groups with 
different functional groups that vary the electronic demand on the macrocyclic ring system. 
This may affect the aziridinium ion formation and thus increase or decrease the rate of 
DNA alkylation. 
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Scheme 66 
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5.7 Progress Towards Substituted Tetraazamacrocyclic 
N-Mustard Derivatives 
In this section the progress towards the preparation of substituted tetrakis-(2-chloroethyl)-
1,4,7,10-tetraazacyclododecane derivatives will be discussed. The test reactions were 
carried out on non-substituted, commercially available cyclen 36 before applying them to 
the substituted compounds. 
5.7.1 N-Hydroxyethylation of Cyclen 
In her quest to optimise the synthesis of polyazamacrocyclic N-mustard derivatives, Parker 
tried a number of routes to reach the poly-N-(2-chloroethyl) compounds but was 
unsuccessful. These included chloroacetamides as intermediates and the use of reductive 
alkylation (Scheme 67).86,210,211,212 
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Scheme 67 
However, the most successful route involved first synthesising poly-N-(2-hydroxyethyl) 
derivatives using ethylene oxide, before converting the hydroxyl groups into chlorines. 
Parker used ethanol as the reaction solvent and added a large excess of ethylene oxide. 
However she produced a number of products with various degrees of alkylation (Scheme 
68). 
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Scheme 68 
Caroline M. Reid, 2006  Chapter 5, 108 
Although the various products could be separated by Kugelrohr distillation, we adapted a 
preparation by BuØen and co-workers to use water as the reaction solvent.213 Previously an 
uncalculated excess of ethylene oxide had been used, resulting in the formation of a 
clathrate. Therefore it is essential to use only a small excess (100 - 200%) of the 
stoichiometric amount of the macrocycle. Ethylene oxide is highly volatile and so 
controlling the temperature is advantageous. Once the reaction is complete the excess 
ethylene oxide is simply evaporated in vacuo. High temperatures, long reaction times, and 
large quantities of ethylene oxide can lead to by-products caused by side chain elongation. 
Ring-opened ethylene oxide (ethylene glycol) can also polymerise to form polyethylene 
glycols as by-products. Thus, the optimum conditions were achieved when the ethylene 
oxide was added to a small volume of water at 0 oC and this solution was dropped slowly 
into a cooled stirred solution of cyclen 36 in water. The reaction mixture was then stirred 
for two hours at this temperature before the excess ethylene oxide was removed by rotary 
evaporation to give the tetrapodand 220 as a yellow oil in 98% yield (Scheme 69). 
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Scheme 69 
Many attempts were made to extract and recrystallise 220 using a variety of solvent 
systems, and a very small amount of pure white crystalline material was collected after 
continual extraction with hexane. 
5.7.2 N-Mustard Derivatives 
The hydroxyethylated product can then be converted into the active N-mustard derivative 
by stirring and heating in an excess of thionyl chloride overnight (Scheme 70).214 Removal 
of any excess thionyl chloride is done in vacuo, to isolate the product without need for 
further purification; however the compound may be precipitated from methanol with 
diethyl ether if necessary. 
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Scheme 70 
5.7.3 N-Hydroxyethylation of Racemic 2-Phenyl-1,4,7,10-
Tetraazacyclododecane 66 
N-Hydroxyethylation of substituted tetraazamacrocycle 66 was attempted under the same 
conditions as before (Scheme 71). However, problems were quickly encountered at this 
stage. 
221
N N
NN
OH
OHHO
HO
NH HN
HNNH
O
10 eq
H2O, 0 oC
2 h
66
Ph Ph
 
Scheme 71 
Firstly 66 is a viscous oil which did not dissolve well in water, and so it was impossible to 
stir the reaction mixture smoothly. Despite using the same equivalents of reagents and 
reaction time, the result was a mixture of products. The hydroxyethyl C-H peaks appear in 
the same region as the ring C-H protons in the 1H NMR spectrum, making it very difficult 
to identify the integration of each peak. It was therefore difficult to determine whether the 
peaks represented the correct four-times hydroxyethylated product, mixtures of partially 
hydroxyethylated by-products or polyethylene glycol. Attempts were made to crystallise 
the desired material from a number of different solvent systems with no success. It was 
thought that the aryl group on the C-2 position may cause steric hindrance around the N-1 
site and so the main product may be the tri-hydroxyethylated compound. The computer-
generated image in Figure 28 that mimics the ring conformation suggests that the ring sits 
out of the way, however this is not conclusive evidence. 
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Figure 28 
Due to this setback, other methods were tried for the N-hydroxyethylation of phenyl-
substituted derivatives of cyclen. A number of reactions were investigated using 
commercially available cyclen as the starting material. Table 11 contains some of the 
methods, along with the reaction conditions and reagents. In many cases, the product 
contained a mixture of mono-, bi- and tri-alkylated side products. These mixtures are 
difficult to separate by any chromatographic method due to the polarity of the compounds, 
although recrystallisation was attempted in some cases. Routes V, VII and VIII were the 
most promising. 
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Route Starting 
Material 
Reagents and Reaction Conditions Target 
Material 
Result 
I 36 BrCH2CO2Et, DMF215 222 - 
II 36 BrCH2CO2Et, KI, DMF 222 - 
III 36 BrCH2CO2Et, Cs2CO3, DMF216 222 - 
IV 36 BrCH2CO2Et, DMF, ∆ 222 - 
V 36.4HCl ClCH2CO2Et, Na2CO3, CH3CN, ∆217 222 10% 
VI 36 ClCH2CO2Et, Cs2CO3, CH3CN, ∆ 222 - 
VII 36 ClCH2CO2H, NaOH, H2O, ∆218 223 23% 
VIII 36 ClCH2CH2OCH3, NaOH, aq EtOH, ∆219 224 93% 
Table 11 
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5.7.3.1 Route V 
The first promising route towards 220 involved preparing 222 from the tetrahydrochloride 
salt of cyclen in a low yield, using ethyl chloroacetate and sodium carbonate in 
acetonitrile.217 Initially, a brown viscous oil was produced, however recrystallisation was 
achieved from ethyl acetate. Deprotection and reduction of 222 was carried out 
successfully using eight equivalents of diisobutyl aluminium hydride to give 220 in 
quantitative yield (Scheme 72).220 
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Scheme 72 
This method was applied to the substituted macrocycle 66, however, despite many attempts 
the desired product 225 could not be isolated (Scheme 73). 
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Scheme 73 
5.7.3.2 Route VII 
The first attempt via route VII produced a white solid in 23% yield, and both the 1H and 
13C NMR spectra suggested that the correct product 223 (dota) had been formed.218 
However, an accurate mass measurement could not be obtained. The solid was taken onto 
the next step regardless, with the aim to reduce the carboxylic acid to the hydroxyl moiety. 
This was investigated using two methods; the first using lithium aluminium hydride221 in 
diethyl ether, and the second using borane.222 Unfortunately the poor solubility of 223 in 
the solvents was a problem and therefore no production of target material 220 was obtained 
(Scheme 74). 
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Scheme 74 
5.7.3.3 Route VIII 
The most successful reaction was route VIII using 2-chloroethyl methyl ether in basic 
aqueous conditions, yielding yellow-white crystals 224 in 93% yield.219 The next step is 
the removal of the methyl ether group to give the tetraol. Literature precedence and 
experience within the Robins group has shown that methoxy-group deprotection can be 
carried out using either trimethylsilyl iodide223 or boron tribromide.224 Unfortunately, 
neither of these methods was successful, returning only starting material despite varying 
the equivalents of reagents or increasing reaction times (Scheme 75). 
N N
NN
224
OMeMeO
MeO OMe
220
N N
NN
OH
OHHO
HO
a) TMSI, CHCl3, MeOH, Na2SO4
or
b) BBr3, CH2Cl2
 
Scheme 75 
It was thought that this route could be adapted by using an alternative protected 2-
chloroethanol derivative. Using tert-butyl-dimethylsilyl chloride (TBDMSCl) and 
imidazole in THF, 226 was prepared quantitatively (Scheme 76).225 The TBDMS 
protecting group in theory should be easier to remove in later steps.  
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Scheme 76 
Under the same conditions as before, 226 was reacted with cyclen to produce a yellow-
white solid. The 1H NMR spectrum of the crude product showed the absence of the 
TBDMS peaks, which were expected at around δ 0.8. It was postulated that the basic 
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conditions of the reaction had removed the protecting group. Recrystallisation from hexane 
gave a small amount of white crystals that had the correct mass for deprotected compound 
220, however the 1H and 13C NMR spectra were inconclusive (Scheme 77). 
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Scheme 77 
The methoxymethyl (MOM) group was also used to protect 2-chloroethanol using 
MOMBr and Hünig's base in dichloromethane (Scheme 78); however we were unable to 
isolate the target material.226 
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Scheme 78 
5.8 Conclusions and Future Work 
No substituted derivatives of cyclen were successfully converted into their corresponding 
alkylating agents. A number of problems occurred during this investigation, but these may 
be overcome in the future. The main point to be taken is the difference in properties 
between cyclen and its substituted derivatives. In future, the test reactions would be better 
employed on the substituted derivatives because a number of reactions that were successful 
on cyclen were not on the aromatic analogues. The solubility of the substituted starting 
material was problematic, making them difficult to dissolve and stir in a range of starting 
materials. One possibility would be to attempt the ethylene oxide method again, using 
ethanol or methanol instead of water. 
In the other routes attempted (V, VII, VIII), the recrystallisation step was key. In future, 
using different solvent systems and longer crystallisation times may increase the yield and 
quality of product. It would be useful to obtain crystal structures for the products of 
successful reactions to determine the conformation of the ring in order to confirm whether 
the substituted analogues with the bulky group could be alkylated at the N-1 position. The 
target material was not isolated from a number of reaction mixtures due to time constraints. 
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One of the main barriers in the characterisation of compounds was the complicated 1H and 
13C NMR spectra of the substituted analogues. Analysis heavily relied on mass spectral 
data in a number of cases, which often did not give conclusive evidence. 
The route presented in Chapter 5.7.3.3 provides an opportunity to investigate different 
protecting groups of 2-chloroethanol, and in this area of work the possibilities were not 
exhausted. Other possible protecting groups include substituted ethyl ethers, benzyl ethers 
and sulfonates. An attractive target material would contain a group such as tosylate, as this 
often leads to products that are easily crystallised. 
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6 Synthesis of Pyrazolidine-3,5-diones for the 
Treatment of Cancer 
6.1 Cancer-Causing Genes 
It is now understood that cancer is caused and driven by mutations and the abnormal 
expression of genes that alter cellular pathways, which normally regulate the life and death 
of healthy cells. These mutations can be the result of many stimuli; some well-documented 
ones are exposure to cigarette smoke and ultraviolet radiation.183 There are 291 known 
cancer-causing genes that are divided into four main groups. 227 
6.1.1 Oncogenes 
These are genes that stimulate cell growth rate. When mutated, oncogenes are switched on 
permanently.183 
6.1.2 Suicide Genes 
Apoptosis (cell suicide) is normal and highly important. Under stress, cells will induce 
apoptosis to prevent cancer development. If suicide genes are mutated a cell damaged by 
stress may undergo cell division where the daughter cells are also mutated.183 
6.1.3 DNA-Repair Genes 
DNA is constantly attacked and is often damaged. There are a number of genes that 
primarily code for DNA-repair proteins. If these genes are damaged, the cell's ability to 
repair itself is reduced and this results in the accumulation of gene errors leading to cancer 
formation.183 
6.1.4 Tumour Suppressor Genes 
Tumour suppressor genes perform the opposite role to oncogenes and are active when a 
cell is at ‘rest’, and they switch off cell division function. One of the most important 
tumour suppressor genes is called p53, which codes for a tetrameric tumour protein p53.183 
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6.2 p53: “Guardian of the Genome” 
An article in Science states that “it is possible that p53 is absolutely crucial for cancer - that 
it is always inactivated, directly or indirectly, during all human carcinogenesis”.228 
p53 was discovered in 1979 by David Lane, Arnold Levine and Lloyd Old, and was voted 
molecule of the year by Science Magazine in 1993.229 Once described as “the guardian of 
the genome” due to its role in preventing genomic mutation, p53 is central to a cell's 
anticancer function.230 p53 is a DNA binding transcription factor, named on account of its 
53 kilodalton (kDa) molecular mass. Its gene p53 was first cloned in 1983 by Moshe Oren 
and is located in human chromosome 17. 
p53 is 393 amino acids long with three domains, an N-terminal transcription-activator 
domain, a central DNA-binding core domain, and a C-terminal homo-oligomerisation 
domain. Mutations of p53 usually occur in the DNA-binding core domain, removing its 
ability to bind to its target DNA sequences.231 This results in the loss of the transcriptional 
activity of these genes. If the gene p53 is mutated, tumour suppression is greatly reduced. 
This can be inherited as a disease known as Li-Fraumein syndrome when people inherit 
only one functional copy of p53. People with this disease usually develop tumours in early 
adulthood.232 p53 is directly mutated in ∼50% of all human cancers, and in the other 50% 
of cases, wild type p53 is inactivated by a variety of other methods.233 
p53 is normally found in low concentrations in the cell bound to another protein called 
Human Double Minute-2 (HDM2) and together they form an autoregulatory feedback 
mechanism to prevent tumour formation. Figure 29 contains the negative feedback loop 
(however HDM2 is represented by MDM2 (Mouse Double Minute-2)). The presence of 
p53 stimulates the expression of HDM2 by its gene (HDM2), and in turn, HDM2 inhibits 
p53 activity by blocking its transcriptional activity that induces its degradation by acting as 
an ubiquitin ligase (E3). Ubiquitinated p53 is transported in the cytoplasm for degradation 
by cytoplasmic proteasomes. Stress signals, such as DNA damage or oncogene activity, 
induce p53 activation. This favours p53 phosphorylation, which prevents it binding to 
HDM2, in turn preventing p53 degradation. p53 can then go on to bind to p53-response 
elements, inducing the transcription of various genes which results in a number of cellular 
responses such as DNA repair, differentiation, senescence (cell deterioration), cell-cycle 
arrest, or apoptosis.233,234 
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Figure 29 
HMD2 requires a closer look; not only is it a p53 binding protein, but it also performs the 
catalytic function of an E3 ligase, facilitating the covalent attachment of ubiquitin proteins 
to p53. The ubiquitin-proteasome system is an important general regulatory pathway that 
controls the levels of key proteins, enzymes and receptors. Substrates that are intended for 
proteosome-mediated hydrolysis are labelled by the multiple-attachment of ubiquitin to 
form a poly-ubiquitinated protein.235 
Ubiquitylation occurs in a cascade of steps (Figure 30). Firstly ubiquitin is activated in two 
steps by an E1 ubiquitin-activating enzyme in an ATP driven process. The result is a 
thioester linkage from the E1 cysteine sulfhydryl group to the C-terminal carboxyl group 
of ubiquitin. The next stage is the transfer of ubiquitin from E1 to the active site of an 
ubiquitin-conjugating enzyme (E2). The final step of the process occurs when an E3 
ubiquitin-protein ligase (HDM2) recognises the E2 and its substrate, and transfers the 
substrate using the RING (or RING finger) domain. This process is repeated to poly-
ubiquitinate the substrate, which is now ready for degradation in the proteasome.236 
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Figure 30 
6.3 p53-HDM2 as a Drug Target 
The rescue of p53 function in malignant cells would be a desirable anticancer strategy. p53 
reactivation in tumour cells could trigger mass cellular suicide, and so there is an urgent 
need to find HDM2 inhibitors.237 How do we target E3 ligases with drugs? Protein-protein 
interactions are awkward targets as proteins usually have large, flat interacting surfaces 
that are not easily affected by small molecule drug targets. However, the p53-HDM2 
interaction site has been mapped to show that when the unstructured p53 protein docks 
onto HDM2, a conformational change occurs at the p53 transactivation domain to form an 
amphiphilic α-helix that projects three hydrophobic amino acid residues Phe19, Trp23, and 
Leu26 into a deep hydrophobic pocket on the HDM2 surface (Figure 31).238 
 
Figure 31 
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Novel peptides which bound to HDM2 with a higher affinity than p53 were found, 
allowing biophysical, combinational permutation and crystal structure studies. These, as 
well as the development of quantitative structure-activity relationship (QSAR) studies, 
allowed the identification of small molecule HDM2 antagonists.238 
6.3.1 Small Molecule HDM2 Antagonists 
The first small molecule HDM2 antagonists, which were reported in 1999, are derivatives 
of phenoxy-acetic acid and phenoxymethyl tetrazole, called the chalcones 229. They have 
shown IC50 values within the µM range by binding in the hydrophobic pocket of HDM2.239 
However, they also inhibit glutathione-S-transferase activity as an undesirable side effect. 
Non-peptidic polycyclic antagonists 230 were also prepared by Zhao and co workers, 
which show moderate affinity for HDM2 and the initiation of p53-moderated apoptosis in 
tumour cell lines.240 
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A fungal extract identified from a library screening identified the nonapeptide chlorofusin 
231 that inhibits the p53-HDM2 interaction. However due to its complex structure and 
high molecular mass, chlorofusin is an unsuitable drug candidate but is a lead structure for 
future drug design.241 
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The first potent and selective small molecule antagonists were identified by Vassilev and 
co-workers in 2004.  They are cis-imidazoline derivatives called the nutlins 232.242 Nutlins 
displace p53 from the hydrophobic pocket of HDM2 and bind tightly with IC50 values 
within the 100-300 nM range. These compounds project functional groups into the binding 
pocket and mimic the interaction of the three critical amino acids Phe19, Trp23, and Leu26. 
Nutlin activity is only observed in cells with wild-type p53, but not in mutant or deleted 
p53 as the antitumour effect is on the p53 pathway. 
In the same year, workers at the Karolinska Institute in Sweden reported a small molecule 
called Rita 233 (Reactivation of p53 and Induction of Tumour cell Apoptosis), which was 
identified in a library screen. Like the nutlins, this compound binds to p53 and induces its 
accumulation in tumour cells and prevents the p53-HDM2 interaction resulting in 
substantial cell suicide.237 Rita is 2,5-bis(5-hydroxymethyl-2-thienyl)furan (NSC652287) 
and may serve as a lead compound for the design of drugs against tumours of wild-type 
p53. 
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6.3.2 Small Molecule HDM2 Ubiquitin Ligase Inhibitors 
There are also a number of examples of specific targeting of the E3 ubiquitin ligase 
activity using small molecules. Lai and co workers used an enzyme assay to identify 
inhibitors by monitoring the HDM2 catalysed ubiquitin-transfer to p53.235 They reported 
three chemically distinct types of inhibitor, each with selective action in the µmol range 
(234 - 236). In this case, the compounds behaved as reversible, non-competitive inhibitors 
with respect to p53 - blocking catalysis by HDM2 via a mechanism other than acting in the 
p53 binding site. 
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More recently Prof. K. Vousden FRS, director at the Beatson Cancer Institute in Glasgow, 
in collaboration with Dr Allan Weissman from the National Cancer Institute and Igen 
Pharmaceuticals, has developed a screen to identify small molecule inhibitors of the E3 
activity of HDM2 function.243 A high throughput assay was carried out in tumours 
containing wild-type p53, and from a library of 10,000 compounds, 40 were found to 
inhibit HDM2 autoubiquitylation by more than 50%. Additional in vitro gel-based assays 
identified three compounds containing a 5-deazaflavin structural motif (237 - 239).244 
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These compounds show some specific inhibition of the E3 activity of HDM2 in vitro and 
in vivo, allowing the stabilisation of p53 and HDM2, leading to the activation of p53-
dependent transcription and apoptosis. Unfortunately p53-independent toxicity was 
observed. Following this publication, Prof. Robins' group in the University of Glasgow 
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synthesised a small library of 5-deazaflavin-containing compounds in order for Prof. 
Vousden to test their inhibitory effects on HDM2 ligase.245 
6.4 Aim of this Work 
In the high throughput assay carried out by Vousden and co-workers, another compound, 
4-(5-bromo-2-furfurylidene)-1-phenyl-pyrazolidine-3,5-dione 240, was identified as an 
HDM2 autoubiquitylation inhibitor.243 Our aim was to extend this work to develop an 
efficient synthesis of 240, and to synthesise a small library of analogues, varying the 
electronic character of the substituents in an attempt to study structure/activity 
relationships and to develop more potent inhibitors. 
N NH
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6.5 Synthesis and Evaluation of Pyrazolidine-3,5-diones 
240 can be synthesised over two steps by formation of 241 from phenylhydrazine followed 
by a Knoevenagel-type condensation with 5-bromo-2-furaldehyde to complete the 
synthesis (Scheme 79). This route provides a way of making different analogues of 240, by 
using differently substituted furfuraldehyde derivatives or phenylhydrazines to build up a 
library of compounds for investigation of potency, solubility and selectivity of analogues 
of the lead compound. 
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Scheme 79 
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6.5.1 Preparation of 1-phenylpyrazolidine-3,5-dione 241 
6.5.1.1 Route I 
The first route to 1-phenylpyrazolidine-3,5-dione 241 followed a preparation by Conrad et 
al. from 1906.246 Commercially available phenylhydrazine was reacted with diethyl 
malonate and sodium ethoxide to give 241 in 49% yield (Scheme 80). 
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49%
 
Scheme 80 
Conrad’s 64% yield could not be matched; however their higher yields were possibly due 
to a mixture of 241 and an inorganic by-product that we had managed to separate. Further 
purification by recrystallisation from water produced a pure yellow powder, which gave 
excellent NMR spectroscopic data, but resulted in lower yields. The crude material can be 
used in the next step of the synthesis. The reaction mechanism for this condensation is 
given in Scheme 81. 
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Scheme 81 
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6.5.1.2 Route II 
A second route was attempted using a method reported by Duffy and co-workers, which 
involved reacting phenylhydrazine with acetic anhydride to form 242 in 96% yield 
(Scheme 82).247 242 was then treated with malonic acid and phosphorus trichloride. TLC 
showed incomplete reaction with little product formed. Flash chromatography could be 
used to separate the product; however low yields were predicted and so this route was 
abandoned. 
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Scheme 82 
6.5.1.3 Route III 
A route following a preparation by J. Ferguson of the Robins group involved treating 
trimethylacetyl chloride with triethylamine and malonic acid, before adding DMAP and 
phenylhydrazine (Scheme 83).248 Unfortunately TLC of the reaction mixture showed that 
the reaction had not gone to completion, despite using longer reaction times. The stated 
work-up using flash chromatography may also have been problematic due to the polar 
nature of the target material, and so this route was also discarded. Route I was therefore the 
best method for the synthesis of 241. 
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Scheme 83 
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6.5.2 Preparation of 4-(5-Bromo-2-furfurylidene)-1-phenyl-
pyrazolidine-3,5-dione 240 
6.5.2.1 Route I 
To complete the synthesis of 240 requires only one step, and the first attempt used a 
method reported by Hassanein which requires heating 241 and 5-bromo-2-furaldehyde 
under reflux with piperidine (Scheme 84).249 Filtration of the brown precipitate gave pure 
compound 240; however the 10% yield was disappointing. 
240
N NH
O O
O
Br
N NH
O O
241
OBr O
H
0.1 eq piperidine
abs. EtOH
10%
 
Scheme 84 
6.5.2.2 Route II 
An aldol condensation using a method by Abass provided higher yields of 240.250 
Equimolar amounts of 241, 5-bromo-2-furaldehyde and sodium acetate were heated in 
glacial acetic acid under reflux. Following filtration and rinsing with ethyl acetate, the pure 
golden brown product was obtained in 65% yield (Scheme 85). 
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Scheme 85 
The mechanism of this condensation is shown in Scheme 86, and this route was used to 
provide analogues of 240. It must be noted that this reaction results in the production of 
two different geometric isomers, and the ratio of the isomers can be estimated from the 1H 
and 13C NMR spectra. 
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Scheme 86 
6.5.3 Preparation of 4-(5-Bromo-2-furfurylidene)-1-phenyl-
pyrazolidine-3,5-dione Analogues 
Seven analogues of 240 were prepared by condensing 241 with commercially available 
aldehydes. They included a range of different functional groups on the bottom 
heterocycles, varying heteroatoms within the five-membered ring, and a larger aromatic 
moiety (243 – 249). A further thirteen analogues were prepared (250 – 262) by fourth year 
project student N. Jobson using the same method and are included here for comparison 
purposes.251 Table 12 contains the structures with the yields, log P values and some UV 
analysis. 
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Compound R Yield (%) Est. log P λmax (nm) 
240 OBr
 
65 2.31 - 
243 O
 
77 1.42 - 
244 O
 
67 1.97 - 
245 OO2N
 
86 1.24 - 
246 O
HO
 
48 0.5 - 
247 HN
 
42 0.94 - 
248 SBr
 
82 2.76 - 
249 
 
65 2.05 - 
250 
MeO
MeO
 
34 1.69 394 
251 
O2N
 
22 1.87 326 
252 
F
 
22 2.25 328 
253 
Cl
 
26 2.69 331 
254 
Br
 
23 2.94 334 
255 
 
35 3.23 346 
256 
 
19 4.40 369 
257 
MeO
 
24 2.13 - 
258 
EtO
 
16 2.62 - 
259 
OH
 
22 1.57 - 
260 
Cl
 
14 2.69 - 
261 
Br
 
12 2.94  
262 SO2N
 
19 1.69 - 
Table 12 
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6.5.4 Biological Evaluation of Library 
Compounds 243 – 256 were tested at the Cancer Research UK Beatson Laboratories in 
Glasgow along with 240 for comparison. The cultured cells were exposed to the 
compounds and then SDS-PAGE was used to separate the proteins by size. After a 
Western Blot, the comparison of the intensity of the compound bands with a control band 
gave an indication of biological activity. A positive control was used to indicate the 
maximum amount of stabilisation. If the compound band is more intense than the control 
band, then stabilisation of p53 is taking place. The darker the band appears, the higher the 
potency of the drug candidate. 
1      2     3     4    5     6    7     8     9   10   11   12    13   14
 
Figure 32 
Figure 32 shows an example Western Blot containing a known HDM2 inhibitor (band 2) 
and a proteosome inhibitor adriamycin (band 14). Bands 3 – 13 are drug candidates. In 
general it was found that none of the compounds showed significant stabilisation of p53, 
and although compound 240 was theoretically the positive control, it also displayed little 
activity. 
6.6 Conclusion and Future Work 
Overall compounds 243, 244, 249, 250 and 252 displayed activity; however these results 
were weak and non-reproducible. From the results it is difficult to rank the compounds in 
order of potency, and no structure-activity relationships can be defined. 
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7 Experimental 
7.1 General Experimental Details 
All reactions were carried out under an inert atmosphere unless otherwise stated, using 
oven-dried or flame-dried glassware. Solutions were added via syringe unless otherwise 
stated. THF and Et2O were freshly distilled from Na-benzophenone; CH2Cl2, toluene, 
DMF and pyridine were distilled from CaH2 prior to use. Petroleum ethers refer to the 
fraction boiling at 40-60 oC. Reagents were obtained from Aldrich Chemical Company 
(Gillingham, Dorset, UK), Alfa Aesar Lancaster (Morecambe, Lancs, UK), or Alfa Aesar 
Avocado (Heysham, Lancs, UK) and used without further purification unless otherwise 
stated. Purification by column chromatography was carried out using Fischer Silica 60A 
silica gel (mesh size 35-70 µm) as the stationary phase. Melting points were measured 
using Gallenkamp apparatus and are uncorrected. IR spectra were recorded using Golden 
Gate, nujol or KBr on a JASCO FT/IR 410 spectrometer. NMR spectra were recorded 
using a Bruker AV400 or DPX/400 spectrometer. Chemical shifts are given in ppm relative 
to SiMe4. Chemical shifts in 13C NMR spectra are given in ppm relative to CDCl3 as 
internal standard (77.00 ppm). All NMR J values are given in Hz. Mass spectra were 
recorded on a JEOL JMS700 spectrometer. Optical rotations were determined as solutions 
irradiating with the sodium D line (λ = 589 nm) using an AA series Automatic polarimeter. 
[α]D values are given in units 10-1 degcm2g-1. 
7.2 Experimental to Chapter 3 
7.2.1 General Procedures (3A – 3D) 
A. Preparation of tosylated cyclen under phase transfer conditions:104 A solution of 
tosylated amine (1 eq) and tosylated diol (1 eq) dissolved in toluene (60 mL per mmol) was 
added to a mixture of tetrabutylammonium bromide (0.25 eq) and aq LiOH (2.5%) (10 mL 
per mmol) in toluene (20 mL per mmol) stirred and heated under reflux. The mixture was 
stirred vigorously at this t for 20 h – 7 d. After this time, the organic layer was separated 
and evapourated in vacuo to leave a solid. 
B. Formation of tosylated amines and diols:113 p-Toluenesulfonyl chloride (1 eq per 
tosylation site) was dissolved in dry pyridine (0.5 mL per mmol) and cooled to 0 oC. The 
amine or diol (1 eq) was added slowly and the solution stirred at this t for 4 h, and then 
Caroline M. Reid, 2006  Chapter 7, 130 
stirred over night at rt. The solution was then poured into an ice : H2O mixture and allowed 
to precipitate over night. After this time, the solid was filtered and washed with H2O, 
before recrystallising in EtOH. 
C. Synthesis of glyoxals and monohydrates from acetophenone derivatives:129 
Acetophenone (1 eq) was added to stirring solution of selenium (IV) oxide (1.1 eq) in 1,4-
dioxane : H2O mixture (0.75 mL per mmol : 0.1 mL per mmol). The reaction mixture was 
stirred and heated under reflux for 18 h -7 d followed by TLC. After this time, the solution 
was filtered through Celite to remove selenium residues. The liquid was then 
concentrated in vacuo to give the glyoxal. 
The glyoxals in some cases were converted to the monohydrate by dissolving in H2O (5 
mL per mmol) and stirring and heating at 100 oC for 2 h.252 After this time the aq solution 
was filtered, and left to stand to allow precipitation of the product, which was filtered and 
dried under reduced pressure. 
D. Iron template cyclisation to give substituted tetraazamacrocycles:128 A solution of 
triethylenetetramine (TETA) (1 eq), in MeOH (7 mL per mmol) was added dropwise over 
10 min to a solution of ferric chloride (1 eq) in MeOH (15 mL per mmol). The mixture was 
stirred at rt for 2 h. A solution of glyoxal (1 eq) in MeOH (17 mL per mmol) was added 
and the mixture was stirred for a further 4 h at this t. NaBH4 (10 eq) was added carefully 
with cooling, and the mixture was heated under reflux for 2-19 h. After this time, the 
solvent was removed in vacuo, and the resulting residue was dissolved in a minimum of 
H2O. The pH was adjusted to 1 using conc HCl and the aq layer was extracted with CH2Cl2 
(x 3). The aqueous layer was adjusted to pH 14 with NaOH pellets then extracted with 
CHCl3 (x 3). The organic layers were combined, dried over anhydrous K2CO3, and 
concentrated under reduced pressure to give the azamacrocycle. 
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7.2.2 Experimental Details 
1,4,7,10-Tetrakis-(toluene-4-sulfonyl)-1,4,7,10-tetraaza-cyclododecane
 (43) 
N N
NN
Ts
Ts Ts
Ts
 
Using general procedure 3A, 43 was synthesised from ditosylated ethylenediamine 45 (737 
mg, 2.0 mmol) and N,N’,O,O’-tetra(p-toluenesulfonyl)-N,N’-bis(2-hydroxyethyl)-
ethylenediamine 44 (1.53 g, 2.0 mmol) after stirring for 20 h under reflux, as a pale solid 
(1.25 g, 79%). mp: 276-279 oC (lit.90 278-280 oC); δH (400 MHz, CDCl3): 2.38 (12H, s, 4 x 
CH3), 3.36 (16H, s, 8 x ring CH2), 7.26 (8H, d, J 8.2 Hz, 8 x Ar-H), 7.62 (8H, d, J 8.2 Hz, 
8 x Ar-H); δC (100 MHz, CDCl3): 21.0 (4 x CH3), 51.3 (8 x CH2), 79.2 (4 x ArC), 127.0 (4 
x ArCH), 127.4 (4 x ArCH), 130.0 (4 x ArCH), 130.1 (ArCH), 144.0 (4 x ArC); LRMS 
(FAB): 789.5 ([M+H]+, 16%), 242.4 (100), 142.2 (16), 91.5 (19); HRMS calcd for 
C36H44N4O8S4 789.2120, found 789.2123. 
43 was also prepared using general procedure 3A by cyclising 46 (5.0 g, 8.8 mmol) and 47 
(5.02 g, 8.8 mmol) to give 43 as a white solid (6.83 g, 98%) after 7 d. 
1, 1’-Ethylenedi-2-imidazoline (48) 
N N
N N
 
To a stirred solution of TETA (100 mL, 669 mmol), was added N,N-dimethylformamide 
dimethyl acetal (178 mL, 1.34 mol). The solution was heated under reflux for 2 h before 
the reaction mixture was dried in vacuo to produce an off-white solid (111.12 g, 100%). 
mp: 106.5-108 oC (lit.105 107-109 oC); νmax (neat)/cm-1: 2935 (CH2), 2848 (NCH2, C-H 
stretch), 1649 (C=N); δH (400 MHz, CDCl3): 3.16 (4H, t, J 9.6 Hz, 2 x CH2), 3.20 (4H, s, 2 
x CH2), 3.78 (2H, t, J 9.6 Hz, CH2), 3.78 (2H, t, J 9.6 Hz, CH2), 6.74 (2H, s, 2 x CH); δC 
(100 MHz, CDCl3): 47.1 (2 x CH2), 49.1 (2 x CH2), 55.6 (2 x CH2), 157.8 (2 x CH); 
LRMS (EI+): 166.1 ([M]+, 55%), 165.1 (16), 124.1 (7), 84.1 (34), 83.1 (100), 56.1 (100).  
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2,3,4,5,6,7,8,8c-Octahydro-1H-4a,6a,8a-triaza-2a-azo-
niacyclopent[fg]acenaphthylene bromide (49) 
N N
NN
Br
 
To a solution of CH3CN (1.4 L) was added 48 (30.0 g, 180 mmol), dibromoethane (21.8 
mL, 252.0 mmol), and K2CO3 (19.9 g, 144.0 mmol). The mixture was stirred and heated 
under reflux for 3 h, before the solution was filtered to remove K2CO3, and dried in vacuo, 
to give 49 as a dark yellow viscous oil (50 g, 100%). νmax (neat)/cm-1: 2935 (CH2), 2817 
(N-CH) cm-1; NMR spectroscopy agreed with lit. values;105 δH (400 MHz, D2O): 2.47-2.93 
(6H, m, 3 x CH2), 3.4-3.6 (6H, m, 3 x CH2), 3.6-3.8 (4H, m, 2 x CH2), 4.7 (1H, s, CH); δC 
(100 MHz, CDCl3): 41.1 (2 x CH2), 41.7 (2 x CH2), 45.7 (2 x CH2), 48.5 (2 x CH2), 68.9 
(CH), 158.8 (C). 
1,4,7,10-Tetraazacyclododecane (cyclen) (36) 
NH HN
HNNH
 
49 (105 g, 384.0 mmol) was dissolved in H2O (420 mL), and the solution was added 
dropwise to a solution of KOH (172.5 g, 3.08 mol) heated under reflux in H2O (365 mL). 
The resulting solution was heated under reflux for a further 30 min. The solution was 
gravity filtered while hot and the filtrate concentrated in vacuo until crystallisation 
occurred. 36 was produced as pale yellow crystals. Cyclen was extracted into hot toluene 
and obtained by concentration (47.02 g, 71%); mp: 114-116 oC (lit.106 110-113 oC); νmax 
(neat)/cm-1: 2927 (CH2), 2898 (CH2), 2870 (CH2), 2812 (NCH2), 1502 (N-H); δH (400 
MHz, CDCl3): 1.77 (4H, br s, 4 x NH), 2.60 (16H, s, 8 x CH2); δC (100 MHz, CDCl3): 46.3 
(8 x CH2). 
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N,N’,O,O’-Tetra(p-toluenesulfonyl)-N,N’-bis(2-hydroxyethyl)-ethylenediamine
 (44) 
TsO
Ts
N N
Ts
OTs
 
Using p-toluenesulfonyl chloride (38.59 g, 202.4 mmol) and N,N’-bis(2-hydroxyethyl)-
ethylenediamine (5 g, 33.74 mmol), 44 was prepared as a bright yellow solid (17.96 g, 
70%) via general procedure 3B. mp: 127-129 oC (lit.253 144-146 oC); νmax (neat)/cm-1: 2959 
(Ar-CH3), 1173 (SO2-O), 1149 (SO2-O), 1038 (S=O); δH (400 MHz, CDCl3): 2.37 (12H, s, 
4 x CH3), 2.23 (4H, s, 2 x NCH2), 3.29 (4H, t, J 5.4 Hz, 2 x NCH2), 4.07 (4H, t, J 5.4 Hz, 2 
x OCH2), 7.27 (8H, d, J 8.3 Hz, 8 x Ar-H), 7.64 (4H, d, J 8.3 Hz, 4 x Ar-H), 7.7 (4H, d, J 
8.3 Hz, 4 x Ar-H); δC (100 MHz, CDCl3): 22.0 (4 x CH3), 50.0 (2 x NCH2), 50.3 (2 x 
OCH2), 69.4 (2 x NCH2), 127.8 (8 x ArCH), 130.4 (8 x ArCH), 132.8 (2 x ArC), 135.4 (2 x 
ArC), 144.4 (2 x ArC), 145.6 (2 x ArC); LRMS (FAB): 765.5 ([M+H]+, 84%), 593.5 (71), 
382.3 (71), 228.2 (37), 154.1 (78), 91.5 (100); HRMS calcd for C34H40O10N2S4 765.1644 , 
found 765.1647. 
Another route to prepare 44 involved adding sodium hydroxide pellets (1.34 g, 33.5 mmol) 
to a cooled stirred mixture of N,N’-bis(2-hydroxyethyl)-ethylenediamine (1.0 g, 6.7 mmol) 
in H2O (4 mL) at 0 oC. Et2O (4 mL) was then added with vigorous mixing before p-
toluenesulfonyl chloride (6.4 g, 33.5 mmol) was added. The solution was stirred at this t 
for 1 h before warming to rt and stirring for a further 3 h. The mixture was filtered and the 
precipitate was rinsed with Et2O (3 x 10 mL) before recrystallising from CHCl3. 44 was 
produced as white solid (562 mg, 11%). 
44 was also prepared by adding N,N’-bis(2-hydroxyethyl)-ethylenediamine (500 mg, 3.4 
mmol) in CH2Cl2 (5 mL) to a cooled stirred solution of p-toluenesulfonyl chloride (3.22 g, 
16.9 mmol) in CH2Cl2 (5 mL) at 0 oC. Triethylbenzylammonium chloride (TEBACl) (210 
mg, 0.92 mmol) and aq sodium hydroxide (0.68 g, 17.0 mmol in 4 mL H2O) were then 
added and the mixture was stirred at rt for 4 h. The solution was then poured into H2O (10 
mL), and the organic phase removed and washed with H2O (3 x 5 mL) before drying over 
MgSO4 and concentrating under vacuum. This method gave 44 as a white solid (2.07 g, 
80%) which contained some starting material. 
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N,N’,N’’-Tris(p-tolylsulfonyl)diethylenetriamine (46) 
Ts
N NHTsTsHN
 
Using general procedure 3B, 46 was prepared from diethylenetriamine (2.0 g, 19.4 mmol) 
and p-toluenesulfonyl chloride (11.1 g, 58.2 mmol) as a white solid (7.7 g, 70%); mp: 174-
176 oC (lit.254 174-176 oC); δH (400 MHz, DMSO-d6): 2.39 (3H, s, CH3), 2.40 (6H, s, 2 x 
CH3), 2.81 (4H, dt, J 7.7 Hz, 2 x CH2-N), 3.02 (4H, t, J 7.7 Hz, 2 x CH2-N), 7.38 (2H, d, J 
8.2 Hz, 2 x Ar-H), 7.40 (4H, d, J 8.2 Hz, 4 x Ar-H), 7.54 (2H, d, J 8.2 Hz, 2 x Ar-H), 7.66 
(4H, d, J 8.2 Hz, 4 x Ar-H); δC (100 MHz, DMSO-d6): 21.3 (3 x CH3), 48.7 (2 x CH2N), 
48.7 (2 x CH2N), 126.9 (4 x CH), 127.2 (2 x CH), 130.0 (2 x CH), 130.2 (4 x CH), 135.7 
(2 x C), 137.7 (2 x C), 143.1 (2 x C). 
N,O,O'-Tri(p-toluenesulfonyl)diethanolamine (47) 
Ts
N OTsTsO
 
N,O,O'-Tri(p-toluenesulfonyl)diethanolamine 47 was prepared as white needle-like 
crystals (31.9 g, 59%) from diethanolamine (10 g, 95.1 mmol) and p-toluenesulfonyl 
chloride (81.6 g, 428 mmol) using general procedure 3B. mp: 85-87 oC (lit.255 93-96 oC); 
δH (400 MHz, CDCl3): 2.45 (3H, s, CH3), 2.48 (6H, s, 2 x CH3), 3.40 (4H, t, J 6.2 Hz, 2 x 
CH2-N), 4.14 (4H, t, J 6.2 Hz, 2 x CH2-O), 7.31 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.38 (4H, d, J 
8.0 Hz, 4 x Ar-H), 7.64 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.78 (4H, d, J 8.0 Hz, 4 x Ar-H); δC 
(100 MHz, CDCl3): 21.6 (CH3), 21.7 (2 x CH3), 48.5 (2 x CH2-N), 68.3 (2 x CH2-O), 127.3 
(4 x CH), 128.0 (4 x CH), 130.0 (4 x CH), 132.5 (2 x C), 135.3 (C), 144.2 (2 x C), 145.3 
(C). 
1,4,7,10-Tetraazacyclododecane (36) 
NH HN
HNNH
 
43 (1.25 g, 1.58 mmol) and 98% H2SO4 (1.6 mL) were stirred and heated at 110 oC for 40 
h. The mixture was then poured into a conical flask and cooled in an ice bath. H2O (2 mL) 
was slowly added before KOH pellets were added with stirring to reach pH 14. EtOH (2 
mL) was added and the mixture was filtered under reduced pressure. The precipitate was 
washed with EtOH (4 x 5 mL) and the EtOH extracts combined and dried in vacuo. The 
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residue produced was dissolved in a minimum of 1M HCl and then extracted with CH2Cl2 
(3 x 5 mL). The aq phase was then basified to pH 14 with KOH pellets and extracted with 
CHCl3 (4 x 5 mL). The organic layers were combined, dried over K2CO3 and reduced in 
vacuo to give a pale oil. Recrystallisation from acetone gave cyclen 36 as a white solid 
(240 mg, 88%). δH (400 MHz, CDCl3): 1.77 (4H, br s, 4 x NH), 2.60 (16H, s, 8 x CH2). 
Tetrahydrobromide salt of cyclen (53) 
NH2H2N
H2NNH2
4Br
 
Conc H2SO4 (8 mL) was heated to 165 oC in a conical flask. 43 (3.0 g, 3.8 mmol) was 
added and solution stirred rapidly for 6 min. Transferring the solution to a second conical 
flask cooled in ice H2O cooled the reaction. The solution was then added dropwise to a 
stirring flask of EtOH (26 mL). Et2O (20 mL) was then added slowly and solution cooled 
to 0 oC. The solution was filtered and the solid dissolved in a minimum of hot H2O (3 mL) 
and then 48% HBr (3 mL) was added. The solution was then filtered to remove 
precipitated hydrobromide salt, and the filtrate concentrated in vacuo to give the 
tetrahydrobromide salt 53 as a white powder (798 mg, 42%). δH (400 MHz, D2O): 3.02 
(16H, s, 8 x CH2), 3.36 (4H, s, 4 x NH); δC (100 MHz, D2O): 43.7 (8 x CH2). 
1,4,7,10-Tetraazacyclododecane (36) 
NH HN
HNNH
 
53 (798 mg, 1.6 mmol) was combined with H2O (10 mL), toluene (3 mL), and NaOH (256 
mg, 6.4 mmol) in a round-bottomed flask fitted with Dean-Stark apparatus. The solution 
was stirred and heated under reflux for 24 h to remove all H2O, before the toluene solution 
was filtered and concentrated under vacuum to give cyclen 36 as a cream solid (196 mg, 
71%). δH (400 MHz, CDCl3): 1.77 (4H, br s, 4 x NH), 2.60 (16H, s, 8 x CH2). 
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Phenylglyoxal (59) 
O
H
O
 
Using acetophenone (700 µL, 5.99 mmol), 59 monohydrate was prepared as a white-green 
solid (790 mg, 100%) via general procedure 3C. mp: 77-78 oC (lit.256 76-78 oC); δH (400 
MHz, CDCl3): 4.14 (1.4H, br s, C(OH)2H), 5.91 (0.7H, s, C(OH)2H), 7.42-7.48 (2H, m, 2 x 
Ar-H), 7.57-7.63 (1H, m, Ar-H), 8.03-8.11(2H, m, 2 x Ar-H), 9.6 (0.3H, s, CHO). δC (100 
MHz, CDCl3): 89.0 (C(OH)2H), 129.3 (2 x Ar-H), 130.3 (2 x Ar-H), 132.6 (ArC), 135.1 
(Ar-H), 193.2 (C=O). 
4’-Methoxyphenylglyoxal (60) 
O
H
O
MeO
 
Using 4’-methoxyacetophenone (3.5 g, 23.3 mmol), 60 hydrate was prepared as a brown 
solid (3.82 g, 100%) by general procedure 3C. mp: 93-95 oC (lit.257 126-128 oC); νmax 
(neat)/cm-1: 3413 (OH), 2940 (CO-H), 2845 (OCH3), 1737 (C=O, aldehyde), 1679 (C=O, 
ketone); δH (400 MHz, CDCl3): 3.64 (3H, s, OCH3), 4.59 (2H, br s, C(OH)2H), 6.23 (0.9H, 
s, C(OH)2H), 6.81-6.93 (2H, m, 2 x Ar-H), 8.02-8.05 (2H, m, 2 x Ar-H), 9.57 (0.1H, s, 
CHO); δC (100 MHz, CDCl3): 56.0 (CH3), 89.0 (CH), 114.5 (2 x CH), 125.6 (C), 132.9 (2 
x CH), 165.1 (C), 191.6 (C); LRMS (CI+): 165.1 ([M+H]+, 100%), 135.09 (29); HRMS 
calcd for C9H10O4 165.0552, found 165.0553. 
3’,4’-Dimethoxyphenylglyoxal (61) 
O
H
OMeO
OMe
 
Using 3’,4’-dimethoxyacetophenone (4.19 g, 23.3 mmol), 61 was prepared as a dark 
yellow solid (4.5 g, 100%) using general procedure 3C. mp: 100-103 oC (hydrate lit.258 
199-200 oC); νmax (neat)/cm-1: 3415 (OH), 3114 (ArC-H), 2839 (OCH3), 1670 (C=O, 
aldehyde), 1583 (C=O, ketone); δH (400 MHz, CDCl3): 6.87 (1H, d, J 8.5 Hz, Ar-H), 7.61 
(1H, d, J 1.9 Hz, Ar-H), 7.91 (1H, dd, J 8.5, 1.9 Hz, Ar-H), 9.6 (1H, s, CHO); δC (100 
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MHz, CDCl3): 56.4 (CH3), 56.6 (CH3), 89.2 (ArCH), 110.8 (ArCH), 112.0 (ArCH), 125.4 
(ArC), 126.0 (CH), 149.5 (ArC), 155.1 (ArC), 190.6 (C=O); LRMS (CI+): 194.09 ([M]+, 
16%), 165.08 (100), 137.09 (16), 122.06 (13); HRMS calcd for C10H10O4 194.0579, found 
194.0581. 
4’-Fluorophenylglyoxal (62) 
O
H
O
F
 
Using general procedure 3C, 62 hydrate was prepared as a brown solid (3.5g, 100%) from 
4’-fluoroacetophenone (2.83 mL, 23.3 mmol). mp: 89-91 oC (lit.259 108-110 oC); νmax 
(neat)/cm-1: 3080 (Ar-H), 2949 (CO-H), 1748 (C=O, aldehyde), 1692 (C=O, ketone), 1101 
(C-F); δH (400 MHz, CDCl3): 4.95 (1.94H, br s, C(OH)2H ), 6.24 (0.97H, s, C(OH)2H), 
7.06-7.10 (2H, m, 2 x Ar-H), 8.08-8.11 (2H, m, 2 x Ar-H), 9.56 (0.03H, s, CHO); δC (100 
MHz, CDCl3): 88.8 (CH), 116.1 (ArCH), 116.3 (ArCH), 128.7 (ArC), 132.8 (ArCH), 132.9 
(ArCH), 165.4 (ArC), 191.2 (C=O); LRMS (CI+): 153.09 ([M+H]+, 100%), 123.08 (8); 
HRMS calcd for C8H5O2F 153.0352, found 153.0353. 
4’-(Trifluoromethyl)-phenylglyoxal (63) 
O
H
O
F3C
 
Using 4’-(trifluoromethyl)acetophenone (2.0 g, 10.6 mmol), 63 hydrate was prepared as a 
brown solid (2.15 g, 100%) via general procedure 3C. mp: 88-90 oC (lit.260 90-105 oC); 
νmax (neat)/cm-1: 3326 (OH), 3227 (OH), 2975 (Ar-H), 2895 (CH2), 1701 (C=O, aldehyde), 
1582 (C=O, ketone), 1323 (C-F); δH (400 MHz, CDCl3): 6.29 (1H, s, C(OH)2H), 7.69 (2H, 
d, J 8.3 Hz, 2 x Ar-H), 8.16 (2H, d, J 8.3 Hz, 2 x Ar-H); δC (100 MHz, CDCl3): 89.3 (CH), 
126.3 (2 x ArCH), 130.6 (2 x ArCH), 135.2 (ArC), 136.0 (ArC), 136.2 (CF3, q, J 33.0 Hz), 
192.4 (C=O); LRMS (CI+): 203.1 ([M+H]+, 100%), 173.1 (25); HRMS calcd for C9H5O2F3 
203.032, found 203.0318. 
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4’-Nitrophenylglyoxal (64) 
O
H
OO2N
 
Using 4’-nitroacetophenone (5.0 g, 30.2 mmol), 64 was prepared using general procedure 
3C as a yellow solid (4.34 g, 80%); mp: 67-72 oC (lit.257 131-132 oC); νmax (neat)/cm-1: 
3415 (OH), 3114 (Ar-H), 2857 (CO-H), 1705 (C=O, aldehyde), 1604 (C=O, ketone), 1518 
(NO2); δH (400 MHz, CDCl3): 7.19 (0.36H, s, C(OH)2H), 8.22-8.36 (4H, m, 4 x Ar-H), 
9.59 (0.64H, s, CHO); δC (100 MHz, CDCl3): 90.0 (CH), 123.5 (ArCH), 123.6 (ArCH), 
130.5 (ArCH), 130.8 (ArCH), 138.5 (ArC), 149.8 (ArC), 195.3 (C=O); LRMS (CI+): 180.1 
([M+H]+, 100%), 166.1 (5), 150.1 (22); HRMS calcd for C8H5O4N 180.0297, found 
180.0297. 
2-Fluorenylglyoxal (65) 
O
H
O
 
By general procedure 3C, 65 hydrate was prepared as a white solid  (892 mg, 42%) from 2-
acetylfluorene (2 g, 9.6 mmol). mp: 125-127 oC (lit.260 127-129 oC); νmax (neat)/cm-1: 3404 
(OH), 3352 (OH), 3051 (Ar-H), 2957 (CH2), 1685 (C=O, aldehyde), 1608 (C=O, ketone); 
δH (400 MHz, CDCl3): 3.9 (2H, s, CH2), 7.32-7.39 (2H, m, 2 x Ar-H), 7.53-7.55 (1H, m, 
Ar-H), 7.78-7.84 (2H, m, 2 x Ar-H), 8.19 (1H, dd, J 8, 0.8 Hz, Ar-H), 8.33 (1H, d, J 0.8 
Hz, Ar-H), 9.66 (1H, s, CHO); δC (100 MHz, CDCl3): 36.4 (CH2), 89.2 (CH), 119.8 
(ArCH), 121.1 (ArCH), 125.4 (ArCH), 126.2 (ArCH), 127.0 (ArCH), 128.1 (ArCH), 128.6 
(ArCH), 132.0 (ArC), 140.0 (ArC), 142.9 (ArC), 144.5 (ArC), 145.8 (ArC), 195.9 (C=O); 
LRMS (EI+): 222.1 ([M]+, 5%), 210 (33), 193.1 (73), 165.1 (100); HRMS calcd for 
C15H10O2 222.0681, found 222.0682. 
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2-(Phenyl)-1,4,7,10-tetraazacyclododecane  (66) 
NH HN
HNNH
HA
HB'
HB
 
Using phenylglyoxal (3.0 g, 19.2 mmol) 66 was afforded as a viscous brown oil (4.12 g, 
84%) via general procedure 3D; νmax (neat)/cm-1: 3273 (NH), 3055 (Ar-H), 2936 (CH2), 
2804 (NCH2); NMR spectroscopy agreed with lit. values;128 δH (400 MHz, CDCl3): 1.65 
(4H, s, 4 x NH), 1.97 (1H, t, J 10.4 Hz, HB’), 2.11 (1H, dt, J 11.2, 3.2 Hz, CH), 2.46 (2H, t, 
J 6.0 Hz, CH2), 2.62 (2H, t, J 6.4 Hz, 2 x CH) 2.66 (2H, t, J 6.4 Hz, 2 x CH), 2.74 (2H, t, J 
6.0 Hz, 2 x CH), 2.81 (2H, br t, J 10.8 Hz, CH, CHB), 2.96 (1H, dt, J 10.8, 2.4 Hz, CH), 
3.0 (1H, dt, J 11.6, 2.4 Hz, CH), 3.79 (1H, dd, J 10.0, 2.4 Hz, CHA), 7.21 (1H, t, J 7.2 Hz, 
Ar-H), 7.25 (2H, t, J 7.2 Hz, 2 x Ar-H), 7.31 (2H, t, J 6.8 Hz, 2 x Ar-H); δC (100 MHz, 
CDCl3): 41.8 (CH2), 46.3 (CH2), 46.3 (CH2), 52.8 (CH2), 53.4 (CH2), 58.3 (CH2), 60.4 
(CH), 61.7 (CH2), 127.0 (2 x ArCH), 127.5 (ArCH), 128.4 (ArCH), 142.6 (ArC); LRMS 
(CI+): 249.3 ([M+H]+, 100%), 243.2 (8), 206.2 (6), 163.2 (9); HRMS calcd for C14H24N4 
249.2079, found 249.2077. 
2-(4’-Methoxyphenyl)-1,4,7,10-tetraazacyclododecane (67) 
NH HN
HNNH
OMe
 
Using 60 (372 mg, 2.73 mmol) 67 was produced as a dark brown solid (634 mg, 83%) via 
general procedure 3D; νmax (neat)/cm-1: 3249 (NH), 2936 (CH2), 2804 (NCH2, OCH3); δH 
(400 MHz, CDCl3): 1.42 (4H, s, 4 x NH), 1.95 (1H, t, J 10.8 Hz, CHB’), 2.09 (1H, dt, J 
11.2, 3.6 Hz, CH), 2.45 (2H, t, J 6.4 Hz, 2 x CH), 2.61 (2H, t, J 5.6 Hz, 2 x CH), 2.66 (2H, 
t, J 6.4 Hz, 2 x CH), 2.74 (2H, t, J 6.4 Hz, 2 x CH), 2.77-2.79 (2H, m, CHB, CH), 2.97 (1H, 
dt, J 11.2, 2.4 Hz, CH), 3.0 (1H, br t, J 10.8 Hz, CH), 3.72 (3H, s, OCH3), 3.74 (1H, br d, J 
2.4 Hz, CHA), 6.80 (2H, d, J 8.4 Hz, 2 x Ar-H), 7.23 (2H, d, J 8.4 Hz, 2 x Ar-H); δC (100 
MHz, CDCl3): 40.8 (CH2), 45.3 (2 x CH2), 51.8 (CH2), 52.4 (CH2), 54.2 (CH3), 57.3 
(CH2), 58.8 (CH), 60.7 (CH2), 112.7 (2 x ArCH), 127.0 (ArCH), 128.4 (ArCH), 133.9 
(ArC), 157.9 (ArC); LRMS (CI+): 267.3 ([M+H]+, 100%), 261.2 (12), 224.2 (4); HRMS 
calcd for C14H23FN4 267.1985, found 267.1989. 
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2-(3’,4’-Dimethoxyphenyl)-1,4,7,10-tetraazacyclododecane  (68) 
NH HN
HNNH
OMe
OMe
 
Using 61 (1.59 g, 8.19 mmol) 68 was synthesised as a brown oil (2.04 g, 81%) by general 
procedure 3D; νmax (neat)/cm-1: 3304 (NH), 2939 (CH2), 2834 (NCH2, OMe); δH (400 
MHz, CDCl3): 1.89 (4H, br s, 4 x NH), 1.97 (1H, t, J 10.4 Hz, CHB’), 2.10 (1H, dt, J 11.2, 
2.8 Hz, CH), 2.46 (2H, t, J 6.4 Hz, 2 x CH), 2.63 (2H, t, J 5.6 Hz, 2 x CH), 2.67 (2H, t, J 
6.0 Hz, 2 x CH), 2.74-2.81 (4H, m, CHB, 3 x CH), 2.96 (1H, dt, J 11.2, 2.4 Hz, CH), 3.01 
(1H, br t, J 11.2 Hz, CH), 3.73 (1H, dd, J 10.0, 2.0 Hz, CHA), 3.79 (3H, s, OCH3), 3.82 
(3H, s, OCH3), 6.75 (1H, d, J 8.0 Hz, Ar-H), 6.84 (1H, dd, J 8.0, 2.0 Hz, Ar-H), 6.89 (1H, 
s, Ar-H); δC (100 MHz, CDCl3): 41.8 (CH2), 46.5 (CH2), 46.5 (CH2), 52.7 (CH2), 54.0 
(CH2), 56.3 (2 x CH3), 58.5 (CH2), 60.5 (CH), 62.1 (CH2), 110.5 (ArCH), 111.3 (ArCH), 
119.4 (ArCH), 135.6 (ArC), 148.7 (ArC), 149.2 (ArC); LRMS (CI+): 309.3 ([M+H]+, 
100%), 266.2 (23), 223.2 (10), 181.1 (12); HRMS calcd for C16H28O2N4 309.2291, found 
309.2289. 
2-(4’-Fluorophenyl)-1,4,7,10-tetraazacyclododecane (69) 
NH HN
HNNH
F
 
Using 62 (831 mg, 5.46 mmol) gave 69 as a dark brown solid (1.17 g, 80%) via general 
procedure 3D; νmax (neat)/cm-1: 3262 (NH), 3006 (Ar-H), 2939 (CH2), 2809 (NCH2), 1219 
(C-F); δH (400 MHz, CDCl3): 1.55 (4H, br s, 4 x NH), 1.93 (1H, t, J 10.4 Hz, CHB’), 2.08 
(1H, dt, J 10.8, 3.2 Hz, CH), 2.45 (2H, t, J 6.4 Hz, 2 x CH), 2.61 (2H, t, J 6.0 Hz, 2 x CH), 
2.65 (2H, t, J 6.0 Hz, 2 x CH), 2.72-2.79 (4H, m, CHB, 3 x CH), 2.95 (1H, dt, J 11.2, 2.4 
Hz, CH), 3.0 (1H, br t, J 11.2 Hz, CH), 3.76 (1H, dd, J 10.4, 2.4Hz, CHA), 6.93 (2H, t, J 
8.8 Hz, 2 x Ar-H), 7.26-7.30 (2H, m, 2 x Ar-H); δC (100 MHz, CDCl3): 42.2 (CH2), 46.6 
(CH2), 46.6 (CH2), 53.1 (CH2), 53.6 (CH2), 58.6 (CH2), 60.1 (CH), 62.1 (CH2), 115.4 
(ArCH), 115.6 (ArCH), 128.8 (ArCH), 128.9 (ArCH), 138.8 (ArC), 157.9 (ArC-F, d, J 
243.5 Hz); LRMS (EI+): 278.3 ([M+H]+, 12%), 205.2 (100), 193.2 (8), 162.1 (15), 121.1 
(48); HRMS calcd for C15H26ON4 278.2107, found 278.2108. 
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2-(4’-Trifluoromethylphenyl)-1,4,7,10-tetraazacyclododecane  (70) 
NH HN
HNNH
CF3
 
Using 63 (205 mg, 1.01 mmol) 70 was made as a yellow-brown oil (203 mg, 64%) using 
general procedure 3D; νmax (neat)/cm-1: 3305 (NH), 2925 (CH2), 2815 (NCH2), 1161 (C-F) 
cm-1; δH (400 MHz, CDCl3): 1.67 (4H, br s, 4 x NH), 1.96 (1H, t, J 10.0 Hz, CHB’), 2.15 
(1H, m, CH), 2.46 (2H, t, J 6.4 Hz, 2 x CH), 2.62 (2H, t, J 6.0 Hz, 2 x CH), 2.66 (2H, t, J 
6.8 Hz, 2 x CH), 2.73 (2H, t, J 6.0 Hz, 2 x CH), 2.81 (2H, m, CHB, CH), 2.90-2.93 (1H, m, 
CH), 2.98-3.06 (1H, m, CH), 3.87 (1H, br d, J 10.0 Hz, CHA), 7.45 (2H, d, J 8.0 Hz, 2 x 
Ar-H), 7.51 (2H, d, J 8.0 Hz, 2 x Ar-H); HCl salt δC (100 MHz, D2O): 35.9 (CH2), 43.8 
(CH2), 44.5 (CH2), 48.9 (CH2), 51.6 (CH2), 53.7 (CH2), 55.2 (CH2), 58.2 (CH), 123.2 
(ArC), 126.2 (2 x ArCH), 128.0 (2 x ArCH), 138.5 (ArC), 145.5 (CF3, m); LRMS (CI+): 
317.2 ([M+H]+, 100%), 274.2 (51), 254.2 (20), 231.2 (32), 173.2 (42), 79.1 (69); HRMS 
calcd for C15H24N4F3 317.1953, found 317.1952. 
2-(4’-Nitrophenyl)-1,4,7,10-tetraazacyclododecane  (71) 
NH HN
HNNH
NO2
 
Using 64 (978 mg, 5.46 mmol) 71 was yielded as a brown oil (1.08 g, 67%) using general 
procedure 3D; νmax (neat)/cm-1: 3285 (NH), 2936 (CH2), 2815 (NCH2), 1513 (NO2); NMR 
spectroscopy agreed with lit. values;128 δH (400 MHz, CDCl3): 1.86 (4H, br s, 4 x NH), 
1.95 (1H, br t, J 10 Hz, CHB’), 2.12 (1H, dt, J 11.2, 3.2 Hz, CH), 2.48 (2H, t, J 6.0 Hz, 
CH), 2.63-2.67 (4H, m, 4 x CH), 2.76-2.83 (4H, m, CHB, 3 x CH), 2.98 (1H, dt, J 11.6, 2.8 
Hz, CH), 3.04 (1H, br t, J 11.6 Hz, CH), 3.92 (1H, dd, J 10.0, 2.4 Hz, CHA), 7.51 (2H, d, J 
8.8 Hz, 2 x Ar-H), 8.11 (2H, d, J 8.8 Hz, 2 x Ar-H); δC (100 MHz, CDCl3): 41.9 (CH2), 
46.3 (CH2), 46.4 (CH2), 52.6 (CH2), 53.2 (CH2), 58.3 (CH2), 60.1 (CH), 61.6 (CH2), 123.7 
(ArCH), 124.0 (ArCH), 128.3 (2 x ArCH), 147.7 (ArC), 150.4 (ArC); LRMS (EI+): 293.41 
([M+H]+, 5%), 276.2 (19), 220.1 (100); HRMS calcd for C14H23O2N5 293.1852, found 
293.1854. 
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2-(Fluorenyl)-1,4,7,10-tetraazacyclododecane  (72) 
NH HN
HNNH
 
Using 65 (892 mg, 4.0 mmol) 72 was produced as a brown oil (1.35 g, 100%) via general 
procedure 3D; νmax (neat)/cm-1: 2796 (NCH2, CH2), 1645 (ArC=C), 1298 (C-N); δH (400 
MHz, CDCl3): 1.8 (4H, br s, 4 x NH), 2.04 (1H, t, J 10.8 Hz, CHB’), 2.14 (1H, br t, J 10.8 
Hz, CH), 2.48 (2H, t, J 6.0 Hz, 2 x CH), 2.63 (2H, t, J 6.0 Hz, 2 x CH), 2.67 (2H, t, J 6.0 
Hz, 2 x CH), 2.74 (1H, t, J 10.8 Hz, CHB), 2.75 (2H, t, J 5.6 Hz, 2 x CH), 2.85 (1H, t, 10.8 
Hz, CH), 3.00 (1H, br t, J 11.6 Hz, CH), 3.04 (1H, br t, J 10.8 Hz, CH), 3.8 (2H, s, CH2), 
3.86 (1H, br d, J 7.6 Hz, CHA), 7.22 (1H, d, J 7.2 Hz, Ar-H), 7.29 (2H, m, 2 x Ar-H), 7.46 
(1H, d, J 7.2 Hz, Ar-H), 7.52 (1H, s, Ar-H), 7.64-7.70 (2H, m, 2 x Ar-H); δC (100 MHz, 
CDCl3): 37.2 (CH2), 43.2 (CH2) 46.6 (2 x CH2), 52.9 (CH2), 53.8 (CH2), 58.6 (CH2), 61.0 
(CH), 62.1 (CH2), 120.1 (ArCH), 120.2 (ArCH), 124.0 (ArCH), 125.4 (ArCH), 126.2 
(ArCH), 127.0 (ARCH), 127.1 (ArCH), 138.5 (ArC), 141.6 (2 x ArC), 143.7 (ArC), 143.9 
(ArC); LRMS (CI+): 337.3 ([M+H]+, 14%), 294.2 (100), 251.2 (22); HRMS calcd for 
C21H28N4 337.2392, found 337.2393. 
3,5-Bis-trifluoromethyl-phenyl-oxo-acetaldehyde 75 
H
O
O
F3C
CF3
 
Using 3’,5’-bis(trifluoromethyl)acetophenone (1.8 mL, 10 mmol), hydrate 75 was prepared 
as a green oil (3.2 g, 100%) via general procedure 3C; νmax (neat)/cm-1: 3417 (O-H), 1703 
(C(O)H), 1617 (Ar-H), 1278 (C-F); δH (400 MHz, DMSO-d6): 8.00 (1H, s, Ar-H), 8.31 
(2H, s, 2 x Ar-H), 9.59 (1H, s, C(O)H); δC (100 MHz, DMSO-d6): 120.5 (ArC), 123.2 
(ArC), 125.4 (ArCH), 127.3 (2 x ArCH), 131.4 (2 x CF3, q, J 33.8 Hz), 137.4 (ArC), 187.2 
(C(O)H), 194.1 (C=O); LRMS (FAB+): 271.1 ([M+H]+, 98%), 241.1 (100), 155.0 (84), 
137.2 (49), 90.9 (31); HRMS calcd for C10H5O2F6 271.0194, found 271.0199. 
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4’-Bromophenylglyoxal (76) 
O
H
OBr
 
76 was synthesised via general procedure 3C from 4’-bromoacetophenone (10 g, 50 mmol) 
as a yellow solid (10.65 g, 100%) and then converted to the monohydrate to give a pale 
brown solid. mp: 51-53 oC (lit.261 51-52 oC); δH (400 MHz, CDCl3): 3.98 (2H, s, 
C(OH)2H), 5.84 (1H, s, C(OH)2H), 7.60 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.93 (2H, d, J 8.8 Hz, 
2 x Ar-H); δC (100 MHz, CDCl3): 128.3 (CH), 129.9 (2 x ArCH), 131.3 (ArC), 131.9 (2 x 
ArCH), 135.8 (ArC), 197.1 (C=O); LRMS (CI+): 215.0 ([M+H]+, 100%), 213.0 (97), 199.0 
(13), 185.0 (9), 135.1 (24), 121.1 (5), 85.1 (15); HRMS calcd for C8H6O279Br 212.9551, 
found 212.9556. 
4’-Chlorophenylglyoxal (77) 
O
H
OCl
 
77 was synthesised via general procedure 3C from 4’-chloroacetophenone (26 mL, 200 
mmol) to give the glyoxal as a green-orange solid (33.7 g, 100%) and then converted to the 
monohydrate to give a white-pink solid. mp: 40-41 oC (lit.261 40-42 oC); δH (400 MHz, 
CDCl3) 4.94 (1H, s, C(OH)2H), 5.85 (2H, s, C(OH)2H), 7.44 (2H, dd, J 8.8, 1.0 Hz, 2 x Ar-
H), 8.02 (2H, d, J 8.8 Hz, 2 x Ar-H), 9.57 (0.5H, s, C(O)H); δC (100 MHz, CDCl3): 88.7 
(C(OH)2H), 129.3 (2 x ArCH), 130.48 (ArC), 131.3 (2 x ArCH), 141.5 (ArC), 191.7 
(C(O)H), 197.0 (C=O); LRMS (CI+): 169.06 ([M+H]+, 100%), 155.08 (5), 139.05 (8), 
135.10 (4), 113.19 (3), 73.08 (12); HRMS calcd for C8H6O235Cl 169.0056, found 
169.0057. 
4-Oxoacetyl-benzonitrile (78) 
O
H
O
N
 
Using general procedure 3C, 78 was synthesised from 4’-acetyl benzonitrile (2.0 g, 14 
mmol). The resulting residue was then separated on a silica column eluted with 1 : 1 
hexane : EtOAc to give a green oil (2.2 g, 100%). Rf = 0.13 (hexane : EtOAc 1 : 1) ; νmax 
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(KBr)/cm-1: 3034 (ArC-H), 2238 (C≡N), 1697 (C=O), 1657 (C=O), 1609 (ArC=C); δH 
(400 MHz, Acetone-d6): 5.82 (2H, s, C(OH)2H), 7.84 (2H, d, J 8.8 Hz, 2 x Ar-H), 8.20 
(2H, d, J 8.8 Hz, 2 x Ar-H), 9.5 (trace 1H, s, C(O)H); δC (100 MHz, Acetone-d6): 89.7 
(CH), 118.3 (CN), 130.7 (2 x ArCH), 132.9 (2 x ArCH), 137.5 (ArC), 161.9 (ArC), 189.3 
(C=O); LRMS (CI+): 160.1 ([M+H]+, 100%), 103.1 (60); HRMS calcd for C9H5NO2 
160.0399, found 160.0397. 
Furan-2-yl-oxo-acetaldehyde (79) 
H
O
O
O
 
Using general procedure 3C, hydrate 79 was prepared as a dark brown oil (7.5 g, 100%) 
from 2-acetylfuran (5.0 g, 45 mmol). Kugelröhr distillation afforded the product as a 
yellow-white solid (4.2 g, 75%); mp: 64-66 oC (lit.262 68-69 oC); νmax (neat)/cm-1: 3414 (O-
H), 3346 (O-H), 3134 (C-H), 1665 (C=O); δH (400 MHz, DMSO-d6): 5.49 (1H, s, C(O)H), 
6.73-6.74 (1H, m, Ar-H), 7.53 (1H, d, J 3.2, Ar-H), 8.04 (1H, s, Ar-H); δC (100 MHz, 
DMSO-d6): 88.6 (C(O)H), 112.4 (ArCH), 120.8 (ArCH), 148.1 (ArCH), 149.4 (ArC), 
185.3 (C=O); LRMS (CI+): 139.01 (36%), 125.07 ([M+H]+, 100%), 95.06 (39), 81.09 (3); 
HRMS calcd for C6H4O3 125.0239, found 125.0240. 
Thiophen-2-yl-oxo-acetaldehyde (80) 
H
O
O
S
 
Using 2-acetylthiophene (4.9 mL, 45 mmol), hydrate 80 was prepared as a brown oil (6.31 
g, 100%) via general procedure 3C. Kugelröhr distillation afforded the product as a cream 
solid (6 g, 95%). mp: 89-92 oC (lit.263 88-89 oC); νmax (neat)/cm-1: 3444 (O-H), 3093 (C-H), 
1646 (C=O); δH (400 MHz, DMSO-d6): 5.87 (1H, s, OH), 5.89 (1H, s, OH), 7.27 (1H, dd, 
J 5.2, 4.0 Hz, Ar-H), 7.55 (1H, d, J 9.2 Hz, Ar-H), 8.07-8.09 (1H, m, Ar-H); δC (100 MHz, 
DMSO-d6): 91.1 (C(OH)2H), 128.8 (ArCH), 135.5 (ArCH), 135.9 (ArCH), 139.6 (ArC), 
187.2 (C=O); LRMS (CI+): 141.1 ([M + H]+, 100%), 111.1 (12), 85.2 (5); HRMS calcd for 
C6H4O2S 141.0010, found 141.0011. 
Caroline M. Reid, 2006  Chapter 7, 145 
Naphthalen-2-yl-oxo-acetaldehyde (81) 
H
O
O
 
Using 2-acetylnaphthalene (5 g, 29 mmol), 81 was prepared as pale yellow crystals (4.5 g, 
83%) via general procedure 3C. mp: 108-111 oC (lit.264 108 oC); νmax (neat)/cm-1: 3446 (O-
H), 3430 (O-H), 3099 (C-H), 2896 (C=O), 1682 (C=O); δH (400 MHz, DMSO-d6): 5.87 
(1H, s, C(OH)2H), 6.87 (1H, s, OH), 6.88 (1H, s, OH), 7.65 (2H, ddt, J 24, 6.8, 1.2 Hz, 2 x 
Ar-H), 7.98-8.12 (4H, m, 4 x Ar-H), 8.80 (1H, s, Ar-H); δC (100 MHz, DMSO-d6): 89.2 
(C(OH)2H), 124.7 (ArCH), 126.9(ArCH), 127.7 (ArCH), 128.0 (ArCH), 128.7 (ArCH), 
129.6 (ArCH), 130.9 (ArC), 131.4 (ArCH), 132.0 (ArC), 135.1 (ArC), 196.2 (C=O); 
LRMS (EI+): 184.03 (M, 12%), 155.03 (100), 127.05 (88), 101.03 (7), 82.94 (12), 77.04 
(10); HRMS calcd for C12H8O2 184.0524, found 184.0523. 
Phenanthren-2-yl-oxo-acetaldehyde (82) 
H
O
O
 
Via general procedure 3C, 82 hydrate was prepared as a white solid (525 mg, 99%) from 2-
acetylphenanthrene (0.5 g, 2.3 mmol). Trituration with benzene gave the product as a pale 
yellow powder (0.23 g, 43%); mp 130-133 oC (lit.260 136-138 oC); νmax (neat)/cm-1: 3307 
(O-H), 3048 (C-H), 1694 (C=O); δH (400 MHz, DMSO-d6): 6.28 (1H, d, J 9.6 Hz, 
C(OH)2H), 7.21 (1H, dt, J 35.2, 7.2 Hz, OH), 7.71 (1H, s, OH), 7.72-7.76 (2H, m, 2 x Ar-
H), 7.84 (2H, q, J 12.4, 9.2 Hz, 2 x Ar-H), 8.0-8.04 (1H, m, Ar-H), 8.29 (1H, dd, J 8.8, 2.0 
Hz, Ar-H), 8.77 (1H, d, J 1.6 Hz, Ar-H), 8.83-8.85 (1H, m, Ar-H), 8.90 (1H, d, J 9.2 Hz, 
Ar-H); δC (100 MHz, DMSO-d6): 91.2 (C(OH)2H), 123.3 (ArCH), 123.7 (ArCH), 126.1 
(ArCH), 127.3 (2 x ArCH), 127.6 (ArCH), 128.1 (ArCH), 128.6 (ArCH), 129.0 (ArC), 
130.8 (ArC), 131.2 (ArCH), 131.3 (ArC), 132.6 (ArC), 133.0 (ArC), 193.6 (C=O); LRMS 
(EI+): 234 (M, 30%), 205 (100), 177 (85), 176 (62), 151 (25), 150 (14), 88 (25), 84 (43), 66 
(46); HRMS calcd for C16H10O2 234.0681, found 234.0682. 
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3,3-Dimethyl-2-oxo-butyraldehyde (83) 
O
O
H
 
Using general procedure 3C, hydrate 83 was produced from pinacolone (2 mL, 14.5 mmol) 
as a pale green oil (1.16 g, 100%) which turned into a white solid after a few hours. mp: 
90-91 oC (lit.265 91-92 oC); νmax (neat)/cm-1: 3382 (O-H), 2973 (CH3); δH (400 MHz, 
CDCl3): 1.21 (9H, s, 3 x CH3), 9.26 (1H, s, C(O)H); δC (100 MHz, CDCl3): 24.5 (3 x CH3), 
25.3 (C(O)H), 40.9 (C), 187.9 (C). 
2-(3,5-Bis-trifluoromethyl-phenyl)-1,4,7,10-tetraazacyclododecane (84) 
NH HN
HNNH
CF3
CF3
 
Using 75 (0.88 g, 5.4 mmol), 84 was produced as a brown oil (1.3 g, 54%) via general 
procedure 3D; νmax (NaCl)/cm-1: 3303 (N-H), 2933 (ArC-H), 1624 (ArC=C), 1339 (C-N), 
1177 (C-F), 1140 (C-F); δH (400 MHz, CDCl3): 1.92-1.99 (1H, m, CHB’), 2.10-2.9 (1H, m, 
CH), 2.35-2.37 (2H, m, 2 x CH), 2.44-2.46 (2H, m, 2 x CH), 2.61-2.88 (6H, m, 6 x CH), 
2.96 (1H, br t, J 11.6 Hz, CHB), 3.01 (1H, br t, J 11.2 Hz, CH), 3.92 (1H, br d, J 10.0 Hz, 
CHA), 7.69 (1H, s, Ar-H), 7.80 (2H, s, 2 x Ar-H); δC (100 MHz, CDCl3): 38.3 (CH2), 45.7 
(CH2),45.8 (CH2), 53.3 (CH2), 57.7 (CH2), 59.5 (CH), 60.5 (CH2), 61.2 (CH2), 119.3 
(ArC), 120.9 (ArCH), 122.0 (ArC), 124.7 (ArC), 125.6 (ArCH), 127.4 (ArCH), 131.5 (2 x 
CF3, q, J 33.0 Hz); LRMS (CI+): 385.3 ([M+H]+, 100%), 381.2 (69), 338.2 (15), 241.2 
(41), 173.3 (55); HRMS calcd for C16H23N4F6 385.1827, found 385.1825. 
2-(4’-Bromophenyl)-1,4,7,10-tetraazacyclododecane (85) 
NH HN
HNNH
Br
 
Using 4’-bromophenyl glyoxal monohydrate 76 (2.70 g, 11.7 mmol) the substituted 
azamacrocycle 85 was synthesised via general procedure 3D as a brown oil (2.70 g, 71%). 
νmax (NaCl)/cm-1: 2943 (Ar), 2895 (Ar), 1460 (-NH-), 822 (C-Br); δH (400 MHz, CDCl3): 
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1.05-3.00 (18H, m, 14 x CH, 4 x NH), 3.75 (1H, d, J 8.4 Hz, CHA), 7.20 (2H, d, J 8.0 Hz, 
2 x Ar-H), 7.37 (2H, d, J 8.0 Hz, 2 x Ar-H); δC (100 MHz, CDCl3): 38.8 (CH2), 41.6 
(CH2), 46.1 (CH2), 52.5 (CH2), 53.2 (CH2), 58.1 (CH2), 59.8 (CH), 61.5 (CH2) 121.2 
(ArC), 128.8 (2 x ArCH), 131.4 (2 x ArCH), 141.6 (ArC); LRMS (CI+): 327.2 ([M+H]+, 
58%), 284.1 (72), 241.1 (57), 173.3 (100), 130.2 (31); HRMS calcd for C14H24N479Br 
327.1184, found 327.1180. 
2-(4’-Chlorophenyl)-1,4,7,10-tetraazacyclododecane (86) 
NH HN
HNNH
Cl
 
86 was synthesised using 4’-chlorophenylglyoxal monohydrate 77 (855 mg, 4.6 mmol) via 
general procedure 3D as an orange oil (1.02 g, 78%). νmax (NaCl)/cm-1: 3283 (N-H), 2938 
(ArC-H), 1658 (ArC=C), 1315 (C-N), 755 (C-Cl); δH (400 MHz, CDCl3): 1.92 (2H, t, J 
10.4 Hz, 2 x CH), 2.08 (2H, t, J 10.4 Hz, 2 x CH), 2.34-3.08 (10H, m, 10 x CH), 3.76 (1H, 
d, J 9.6 Hz, CHA), 7.20-7.24 (4H, m, 4 x Ar-H); δC (100 MHz, CDCl3): 41.7 (CH2), 46.1 
(CH2), 46.2 (CH2), 52.6 (CH2), 53.2 (CH2), 58.2 (CH2), 59.7 (CH), 61.6 (CH2), 128.4 (2 x 
ArCH), 128.5 (2 x ArCH), 133.1 (ArC), 141.1 (ArC); LRMS (CI+): 283.3 ([M+H]+, 
100%), 240.2 (29), 197.2 (18), 173.3 (49); HRMS calcd for C14H24N435Cl 283.1689, found 
283.1687. 
2-(Benzonitrile)-1,4,7,10-tetraazacyclododecane (87) 
NH HN
HNNH
N
 
87 was synthesised from 4-oxoacetyl-benzonitrile (2.16 g, 13.6 mmol) using general 
procedure 3D as a brown solid (2.66 g, 72%). mp: 51-55 oC; νmax (NaCl)/cm-1: 3260 (N-
H), 2226 (C≡N), 1652 (N-H), 1608 (ArC=C), 1311 (C-N), 1133 (C-N); δH (400 MHz, 
CDCl3): 1.73 (4H, br s, 4 x NH), 1.97 (1H, t, J 10.8 Hz, CHB’), 2.14 (1H, dt, J 10.8, 3.2 Hz, 
CH), 2.38 (2H, t, J 6.0 Hz, 2 x CH), 2.49 (2H, t, J 6.4 Hz, 2 x CH), 2.64-2.86 (7H, m, 7 x 
CH), 3.00 (1H, dt, J 6.4, 2.4 Hz, CH), 3.90 (1H, dd, J 10.0, 2.4 Hz, CHA), 7.48 (2H, d, J 
8.2 Hz, 2 x Ar-H), 7.58 (2H, d, J 8.2 Hz, 2 x Ar-H); δC (100 MHz, CDCl3): 38.8 (CH2), 
41.7 (CH2), 46.1 (CH2), 51.3 (CH2), 53.3 (CH2), 58.2 (CH2), 60.0 (CH), 61.3 (CH2), 111.2 
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(CN), 118.8 (ArC), 127.8 (2 x ArCH), 132.2 (2 x ArCH), 148.0 (ArC); LRMS (FAB): 
274.2 ([M+H]+, 95%), 214.5 (35), 200.6 (60), 173.9 (100), 169.9 (77), 143.2 (32), 114.6 
(27), 98.8 (59), 87.0 (35); HRMS calcd for C15H24N5 274.2032, found 274.2027. 
2-(Furan-2-yl)-1,4,7,10-tetraazacyclododecane (88) 
NH HN
HNNH
O
 
Using 79 (0.6 g, 4.8 mmol) 88 was produced as a dark brown oil (0.62 g, 54%) via general 
procedure 3D; νmax (neat)/cm-1: 3289 (N-H), 2942 (C-H), 2815 (-CH2-), 1650 (C=C); δH 
(400 MHz, CDCl3): 1.87 (4H, br s, 4 x NH), 2.11 (1H, dt, J 10.8, 3.3 Hz, CHB’), 2.15 (1H, 
br t, J 11.0 Hz, CH), 2.35 (2H, t, J 6.4 Hz, 2 x CH), 2.47 (2H, t, J 5.2 Hz, 2 x CH), 2.62 
(2H, t, J 5.6 Hz, 2 x CH), 2.66 (2H, t, J 6.0 Hz, 2 x CH), 2.79-2.83 (2H, m, CH, CHB), 
2.88-3.00 (2H, m, 2 x CH), 3.91 (1H, dd, J 9.6, 2.8 Hz, CHA), 6.12 (1H, d, J 3.2 Hz, Ar-
H), 6.23-6.25 (1H, m, Ar-H), 7.27 (1H, s, Ar-H); δC (100 MHz, CDCl3): 41.7 (CH2), 46.1 
(CH2), 46.1 (CH2), 52.6 (CH2), 53.4 (CH2), 53.7 (CH), 58.2 (CH2), 61.1 (CH2), 104.2 
(ArCH), 109.0 (ArCH), 140.5 (ArCH), 154.4 (ArC); LRMS (CI+): 239.2 ([M+H]+, 100%), 
233.2 (62), 196.2 (18), 173.2 (23), 153.1 (14); HRMS calcd for C12H22N4O 239.1872, 
found 239.1870. 
2-(Thiophene-2-yl)-1,4,7,10-tetraazacyclododecane (89) 
NH HN
HNNH
S
 
Using 80 (0.73 g, 5.2 mmol) 89 was produced as a viscous dark brown oil (1.04 g, 79%) 
via general procedure 3D; νmax (neat)/cm-1: 3402 (N-H), 3231 (ArC-H), 2807 (-CH2-), 1639 
(C=C); δH (400 MHz, CDCl3): 2.09 (1H, t, J 10.0 Hz, CHB’), 2.34-2.42 (1H, m, CH), 2.47 
(2H, t, J 6.0 Hz, 2 x CH), 2.58-2.82 (8H, m, 8 x CH), 2.91 (1H, br t, J 11.6 Hz, CHB), 3.00 
(1H, br t, J 11.6 Hz, CH), 4.13 (1H, dd, J 10.0, 3.2 Hz, CHA), 6.88-6.90 (2H, m, 2 x Ar-H), 
7.14 (1H, dd, J 4.8, 0.8, Ar-H); δC (100 MHz, CDCl3): 41.5 (CH2), 46.0 (2 x CH2), 52.2 
(CH2), 53.3 (CH2), 55.6 (CH), 57.9 (CH2), 61.9 (CH2), 123.7 (ArCH), 124.1 (ArCH), 126.4 
(ArCH), 146.2 (ArC); LRMS (CI+): 255.2 ([M+H]+, 100%), 249.1 (46), 212.1 (29), 169.1 
(42), 144.1 (9), 126.1 (23), 71.1 (43); HRMS calcd for C12H22N4S 255.1643, found 
255.1641. 
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2-(Naphthalen-2-yl)-1,4,7,10-tetraazacyclododecane (90) 
NH HN
HNNH
 
Using 81 (1.01 g, 5.5 mmol), 90 was produced as a viscous dark brown oil (1.26 g, 77%) 
via general procedure 3D; νmax (neat)/cm-1: 3426 (N-H), 2944 (C-H), 2830 (-CH2-), 1653 
(C=C); δH (400 MHz, CDCl3): 1.97 (4H, br s, 4 x NH), 2.06 (1H, t, J 10.4 Hz, CHB’), 2.15 
(1H, dt, J 10.8, 3.2 Hz, CH), 2.48 (2H, t, J 6.0 Hz, 2 x CH), 2.59-2.63 (4H, m, 4 x CH), 
2.67 (2H, t, J 6.0 Hz, 2 x CH), 2.76 (1H, m, CH), 2.82 (1H, br t, J 10.4 Hz, CHB), 2.89 
(1H, m, CH), 3.02 (1H, br t, J 10.8 Hz, CH), 3.95 (1H, br d, J 8.0 Hz, CHA), 7.35-7.39 
(2H, m, 2 x Ar-H), 7.72-7.75 (4H, m, 4 x Ar-H), 7.78 (1H, s, Ar-H); δC (100 MHz, 
CDCl3): 41.6 (CH2), 46.2 (CH2), 46.3 (CH2), 52.4 (CH2), 53.4 (CH2), 58.1 (CH2), 60.4 
(CH), 61.6 (CH2), 125.4 (ArCH), 125.5 (ArCH), 125.8 (ArCH), 126.1 (ArCH), 127.6 
(ArCH), 127.9 (ArCH), 128.0 (ArCH), 133.0 (ArC), 133.4 (ArC), 140.0 (ArC); LRMS 
(CI+): 299.2 ([M+H]+, 17%), 256.2 (100), 213.1 (63), 188.1 (27), 170.1 (31), 161.1 (19), 
143.1 (19), 81.1 (33); HRMS calcd for C18H27N4 299.2236, found 299.2234. 
2-(Phenanthrene-3-yl)-1,4,7,10-tetraazacyclododecane (91) 
NH HN
HNNH
 
Using 82 (0.18 g, 0.77 mmol), 91 was produced as a viscous brown oil (1.04 g, 79%) via 
general procedure 3D; νmax (neat)/cm-1: 3257 (N-H), 2940 (C-H), 2860 (-CH2-), 1633 
(C=C); δH (400 MHz, CDCl3): 2.10 (1H, t, J 10.4 Hz, CHB’), 2.13 (1H, br t, J 9.2 Hz, CH), 
2.34 (2H, t, J 6.4 Hz, 2 x CH), 2.49 (2H, t, J 6.0 Hz, 2 x CH), 2.64 (2H, t, J 5.6 Hz, 2 x 
CH), 2.67-2.96 (5H, m, 4 x CH, CHB), 3.09 (1H, br t, J 11.6 Hz, CH), 4.02 (1H, br d, J 
10.0 Hz, CHA), 7.50-7.61 (6H, m, 6 x Ar-H), 7.65 (1H, s, Ar-H), 7.80-7.84 (1H, m, Ar-H), 
8.55-8.60 (1H, m, Ar-H); δC (100 MHz, CDCl3): 37.7 (CH2), 40.6 (CH2), 45.2 (CH2), 52.2 
(CH2), 57.1 (CH2), 59.2 (CH), 60.0 (CH2), 60.6 (CH2), 121.6 (ArCH), 121.9 (ArCH), 124.8 
(ArCH), 125.3 (ArCH), 125.5 (ArCH), 125.6 (ArCH), 125.9 (ArCH), 126.1 (ArCH), 127.5 
(ArCH), 128.6 (ArC), 129.1 (ArC), 130.9 (ArC), 131.0 (ArC), 139.8 (ArC); LRMS (FAB): 
349.3 ([M+H]+, 27%), 306.2 (11), 205.4 (10), 154.9 (100), 137.1 (72), 75.1 (31); HRMS 
calcd for C22H29N4 349.2392, found 349.2399. 
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2-(tert-Butyl)-1,4,7,10-tetraazacyclododecane (92) 
NH HN
HNNH
 
Using general method 3D azamacrocycle 92 was synthesised as a brown oil (1.15 g, 63%). 
νmax (NaCl)/cm-1: 3281 (N-H), 2810 (C-H), 1666 (N-H), 1315 (C-N); δH (400 MHz, 
CDCl3): 0.85 (9H, s, 3 x CH3), 1.52 (4H, br s, 4 x NH), 1.69 (1H, t, J 10.5 Hz, CH), 1.87 
(1H, dt, J 10.5, 3.5 Hz, CHB’), 2.33-2.47 (4H, m, 4 x CH), 2.59-2.68 (4H, m, 4 x CH), 
2.70-2.81 (4H, m, 4 x CH), 3.59 (1H, br t, J 9.6 Hz, CHA); δC (100 MHz, CDCl3): 38.8 
(CH2), 43.2 (CH2), 46.1 (CH2), 47.3 (C), 48.5 (CH2), 51.2 (CH2), 53.3 (CH2), 61.2 (CH2), 
65.9 (CH), 79.8 (3 x CH3); LRMS (FAB): 229.4 ([M+H]+, 100%), 186.7 (27), 144.1 (26), 
129.3 (19), 100.7 (14); HRMS calcd for C12H28N4, 229.2392 found 229.2396. 
Oxo-pyrene-2-yl-acetaldehyde (103) 
O
H
O
 
103 was synthesised from 1-acetylpyrene (1.5 g, 6 mmol) using general procedure 3C. The 
resulting residue was then separated on a silica column eluted with 1 : 1 hexane : EtOAc to 
give a yellow powder (1.59 g, 100%). Rf = 0.23 (hexane : EtOAc 1 : 1); mp: 107-111 oC;  
νmax (NaCl)/cm-1: 3041 (ArC-H), 1671 (C=O), 1594 (ArC=C), 1508 (ArC=C); δH (400 
MHz, CDCl3: 7.68-8.17 (9H, m, 9 x Ar-H), 9.81 (1H, s, C(O)H); δC (100 MHz, CDCl3): 
123 8 (ArCH), 124.2 (ArCH), 124.7 (ArCH), 126.4 (ArCH), 126.7 (ArCH), 127.0 (ArCH), 
127.3 (ArCH), 129.3 (ArC), 129.6 (ArC), 130.4 (ArCH), 130.5 (ArC), 131.1 (ArCH), 
131.9 (ArC), 134.0 (ArC), 135.4 (ArC),  135.7 (ArC), 190.5 (C=O); LRMS (EI+): 258.1 
(M, 15%), 229.1 (96), 201.1 (78), 100.0 (17), 82.9 (100), 47.0 (21); HRMS calcd for 
C18H10O2 258.0681, found 258.0680. 
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(4-Hydroxy-phenyl)-oxo-acetaldehyde (105) 
O
H
OHO
 
105 was prepared from 4’-hydroxyacetophenone (3 g, 22 mmol) using general procedure 
3C. The resulting liquid was separated on a silica column eluted with 1 : 1 hexane : EtOAc 
to give a pale yellow foam (2.54 g, 77%). Rf = 0.12 (hexane : EtOAc 1 : 1); mp: 85-86 oC 
(lit.257 86.5-87.5 oC); δH (400 MHz, Acetone-d6): 6.3 (1H, s, OH), 6.93 (2H, d, J 10.0 Hz, 2 
x Ar-H), 8.09 (2H, d, J 10.0 Hz, 2 x Ar-H), 9.64 (1H, s, C(O)H); δC (100 MHz, Acetone-
d6): 90.0 (C(OH)2H), 116.5 (2 x ArCH), 126.1 (ArC), 133.3 (2 x ArCH), 163.7 (ArC), 
192.2 (C=O); LRMS (EI+): 150.0 (M, 16%), 121.0 (100), 93.0 (100), 65 (100), 46 (100); 
HRMS calcd for C8H6O3 150.0317, found 150.0315. 
1-[4-(4,6-Diamino-[1,3,5]-triazin-2-ylamino)-phenyl]-ethanone (109) 
H
N
O N N
N NH2
NH2
 
A mixture of 4’-aminoacetophenone (1 g, 7.4 mmol) in H2O (26 mL) was heated under 
reflux. A solution of aq NaOH (7.4 mM) was then added dropwise over 1 h. Heating and 
stirring was continued for a further 3 h and then the mixture was cooled to rt. The solid 
was filtered and washed with H2O (10 mL) before drying under vacuum to 109 as a white 
solid (1.31 g, 72%). mp: >250 oC (lit.266 >300 oC); νmax (KBr)/cm-1: 3488 (N-H), 3344 (N-
H), 3120 (ArC-H), 1683 (C=O), 1637 (C=N), 1566 (ArC=C), 1527 (ArC=C); δH (400 
MHz, DMSO-d6): 2.52 (3H, s, CH3), 6.92 (1H, br s, NH), 7.15 (2H, br s, NH2), 7.23 (2H, 
br s, NH2), 7.89 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.98 (2H, d, J 8.8 Hz, 2 x Ar-H); LRMS (EI+): 
243.1 (M, 2%), 145.0 (100), 110.0 (44), 84.0 (78), 66.0 (90); HRMS calcd for C11H12N6O, 
244.0994, found 244.0991. 
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1-[4-(Trityl-amino)-phenyl]-ethanone (110) 
O
TrHN
 
Triphenylmethyl chloride (1.06 g, 3.8 mmol) was added to a solution of 4’-
aminoacetophenone (460 mg, 3.4 mmol) in dry pyridine (12 mL). The solution was stirred 
at rt for 4 d before the reaction mixture was diluted with EtOAc (25 mL) and then washed 
with aq CuSO4 solution (0.5 M, 50 mL) and brine (3 x 20 mL). The organic layers were 
dried over MgSO4, and concentrated in vacuo to give a white solid (938 mg, 73%). Rf = 
0.74 (20% THF in CH2Cl2); mp: 154-157 oC; νmax (KBr)/cm-1: 3055 (ArC-H), 1658 (C=O), 
1594 (ArC=C), 1281 (C-N); δH (400 MHz, CDCl3): 2.19 (3H, s, CH3), 5.60 (1H, s, NH), 
6.22 (2H, d, J 8.4 Hz, 2 x Ar-H), 6.98-7.18 (15H, m, 15 x Ar-H), 7.40 (2H, d, J 8.4 Hz, 2 x 
Ar-H); δC (100 MHz, CDCl3): 26.0 (CH3), 71.4 (C), 127.3 (2 x ArCH), 128.1 (2 x ArCH), 
128.3 (6 x ArCH), 129.2 (6 x ArCH), 129.8 (3 x ArCH), 144.7 (3 x ArC), 150.9 (2 x ArC), 
196.5 (C); LRMS (EI+): 377.0 (M, 16%), 300.1 (19), 244 (100), 215 (32), 165 (100), 106.1 
(28), 77 (73), 43 (46); HRMS calcd for C27H23NO 377.1780, found 377.1779. 
4-[(1,1-Dimethylethoxy)carbonylamino]acetophenone (111) 
O
BocHN
 
Di-tert-butyl dicarbonate (4.8 g, 22 mmol) was added to a solution of 4’-
aminoacetophenone (3 g, 22 mmol) in dry THF (130 mL). The mixture was stirred and 
heated at reflux for 5 d, before pouring onto H2O (50 mL), and extracting with EtOAc (100 
mL). The organic layer was then washed with H2O (50 mL) and brine (50 mL), dried over 
Na2SO4, and then dried under rotary evaporation to give a yellow solid. This was separated 
on a silica column eluted with 1 : 1 hexane : EtOAc to yield 111 as a white solid (3.53 g, 
75%). Rf = 0.44 (hexane : EtOAc 1 : 1); mp: 134-136 oC; NMR spectroscopy agreed with 
lit. values;267 δH (400 MHz, CDCl3): 1.45 (9H, s, 3 x CH3), 2.49 (3H, s, CH3), 6.81 (1H, br 
s, NH), 7.40 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.83 (2H, d, J 8.8 Hz, 2 x Ar-H); δC (100 MHz, 
CDCl3): 26.4 (CH3) 28.3 (3 x CH3) 81.2 (C), 117.4 (2 x ArCH), 129.9 (2 x ArCH), 131.7 
(ArC), 143.1 (ArC), 152.3 (C=O), 197.1 (C=O); LRMS (EI+): 235.1 (M, 37%), 179.1 (78), 
164.0 (65), 120.0 (76), 57.1 (100); HRMS calcd for C13H17NO3 235.1208, found 235.1210. 
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 (4-Acetyl-phenyl)-carbamic acid benzyl ester (112) 
O
CbzHN
 
Benzylchloroformate (1.14 mL, 8 mmol) was added dropwise to a solution of 4’-
aminoacetophenone (1.08 g, 8 mmol) and NaOH (320 mg, 8 mmol) in 1,4-dioxane : H2O 
mixture (8mL : 3 mL) cooled to 0 oC. The reaction mixture was then stirred at this 
temperature for 30 min, and then for a further 13 h at rt. The solvent was then removed 
under reduced pressure, and resulting solid dissolved into a EtOAc : H2O mixture (40 mL : 
40 mL). The organic layer was separated and concentrated in vacuo to give a bright yellow 
solid (2.15 g, 100%). Rf = 0.43 (hexane : EtOAc 1 : 1); mp: 112-115 oC (lit.268 118-119 
oC); δH (400 MHz, CDCl3): 2.48 (3H, s, CH3), 5.13 (2H, s, CH2), 7.08 (1H, br s, NH), 
7.26-7.32 (5H, m, 5 x Ar-H), 7.42 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.84 (2H, d, J 8.8 Hz, 2 x 
Ar-H); δC (100 MHz, CDCl3): 26.4 (CH3), 67.4 (CH2), 117.7 (ArCH), 128.4 (2 x ArCH), 
128.6 (2 x ArCH), 128.7 (2 x ArCH), 129.9 (2 x ArCH), 132.2 (ArC), 135.7 (ArC), 142.4 
(ArC), 152.9 (C=O), 197.1 (C=O); LRMS (EI+): 269.1 (M, 15%), 225.1 (7), 210.1 (6), 
167.0 (6), 149.0 (14), 107.0 (18), 91.0 (100), 69.1 (41); HRMS calcd for C16H15NO3 
269.1052, found 269.1049. 
p-(N-p-Tolylsulfonylamino)acetophenone (113) 
O
TsHN
 
A solution of 4’-aminoacetophenone (2.0 g, 15 mmol) in pyridine (35 mL) was added 
dropwise to a stirring solution of p-toluenesulfonyl chloride (3.39 g, 18 mmol) in pyridine 
(100 mL) cooled to 0 oC. The mixture was then stirred at rt for 24 h before pouring onto an 
ice : H2O mixture (300 mL). The solution was left to stand for 4 h to allow product to 
precipitate, which was then filtered and dried in vacuo yielding 113 as white fluffy crystals 
(3.32 g, 78%). mp: 202-204 oC (lit.269 204-205 oC); δH (400 MHz, CDCl3): 2.32 (3H, s, 
CH3), 2.47 (3H, s, CH3), 6.69 (1H, s, NH), 7.08 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.19 (2H, d, J 
8.0 Hz, 2 x Ar-H), 7.66 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.78 (2H, d, J 8.8 Hz, 2 x Ar-H); δC 
(100 MHz, CDCl3): 21.6 (CH3), 26.4 (CH3), 119.0 (2 x ArCH), 127.3 (2 x ArCH), 129.9 (2 
x ArCH), 130.0 (2 x ArCH), 141.1 (2 x ArC), 144.5 (2 x ArC), 196.8 (C=O). 
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 (4-Acetyl-phenyl)-carbamic acid 9H-fluoren-9-yl ester (114) 
O
FmocHN
 
4’-Aminoacetophenone (523 mg, 4 mmol) was added to a stirring solution of 9-
fluorenylmethylchloroformate (1.0 g, 4 mmol) in Et2O (35 mL) cooled to 0 oC. The 
mixture was stirred for 20 min at this temperature, and then at rt for 1 h. After this time, 
H2O (250 µL) was added and solution stirred for 10 min before filtering to give 114 as a 
white powder (731 mg, 53%). mp: 140-145 oC; νmax (KBr)/cm-1: 3350 (N-H), 3057 (Ar), 
2891 (C-H), 1608 (ArC=C), 1693 (NCO), 1520 (Ar), 1244 (COO); δH (400 MHz, CDCl3): 
2.49 (3H, s, CH3), 4.20 (1H, t, J 6.4 Hz, CH), 4.51 (2H, d, J 6.4 Hz, CH2), 6.89 (1H, s, 
NH), 7.25 (2H, dt, J 7.6, 1.2 Hz, 2 x Ar-H), 7.35 (2H, t, J 7.6 Hz, 2 x Ar-H), 7.54 (2H, d, J 
7.4 Hz, 2 x Ar-H), 7.71 (2H, d, J 7.4 Hz, 2 x Ar-H), 7.84 (2H, d, J 8.4 Hz, 2 x Ar-H); δC 
(100 MHz, CDCl3): 26.4 (CH3), 47.1 (CH), 67.1 (CH2), 117.7 (2 x ArCH), 120.2 (2 x 
ArCH), 124.9 (2 x ArCH), 127.2 (2 x ArCH), 127.9 (2 x ArCH), 129.9 (2 x ArCH), 132.3 
(ArC), 141.4 (2 x ArC), 142.2 (ArC), 143.6 (2 x ArC), 152.9 (C=O), 196.9 (C=O). 
[4-(2-Oxo-acetyl)-phenyl]-carbamic acid tert-butyl ester (116) 
O
H
OBocHN
 
Using general procedure 3C, 116 was synthesised from 111 (801 mg, 3.4 mmol). The 
resulting residue was separated on a silica column eluted with 1 : 1 hexane : EtOAc to give 
a yellow foamy solid (847 mg, 100%). Rf = 0.25 (hexane : EtOAc 1 : 1); νmax (KBr)/cm-1: 
3344 (N-H), 2978 (ArC-H), 1708 (C=O), 1602 (ArC=C), 1154 (C-O); δH (400 MHz, 
CDCl3): 1.45 (9H, s, 3 x CH3) 5.06 (1H, br s, C(OH)2H), 6.23 (1H, br s, OH), 6.97 (1H, br 
s, OH), 7.39 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.99 (2H, d, J 8.8 Hz, 2 x Ar-H), 9.57 (trace 1H, 
s, C(O)H); δC (100 MHz, CDCl3): 28.2 (3 x CH3), 81.6 (C), 88.6 (C(OH)2H), 117.6 
(ArCH), 117.6 (ArCH), 126.6 (ArC), 131.6 (ArCH), 132.3 (ArCH), 144.5 (ArC), 190.2 
(C=O), 191.3 (C=O); LRMS (EI+): 249.2 (M, 5%), 220.1 (76), 164.1 (98), 120.1 (47), 85.0 
(100), 47.0 (100); HRMS calcd for C13H15NO4 249.1001, found 249.1004. 
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4-Methyl-N-[4-(2-oxo-acetyl)-phenyl]-benzenesulfonamide (118) 
O
H
O
TsHN
 
118 was prepared using general procedure 3C from 113 (1.0 g, 3.46 mmol). The crude 
residue was then chromatographed on a silica column eluted with hexane : EtOAc (1 : 1) to 
give a green oil (36 mg, 3%). Rf = 0.1 (hexane : EtOAc 1 : 1); δH (400 MHz, CDCl3): 2.28 
(3H, s, CH3), 5.01 (1H, s, C(OH)2H), 7.11 (2H, d, J 8.8 Hz, 2 x Ar-H), 7.16 (2H, d, J 8.4 
Hz, 2 x Ar-H), 7.69 (2H, d, J 8.6 Hz, 2 x Ar-H), 7.75 (2H, d, J 8.6 Hz, 2 x Ar-H), 8.11 
(1H, s, NH); δC (100 MHz, CDCl3): 20.6 (CH3), 87.6 (C(OH)2H), 117.2 (2 x ArCH), 117.3 
(2 x ArCH), 126.2 (ArCH), 126.3 (ArCH), 129.0 (2 x ArCH), 134.6 (ArC), 141.8 (ArC), 
143.7 (ArC), 188.8 (ArC), 190.4 (C=O); LRMS (FAB): 304.0 ([M+H]+, 89%), 274.0 
(100), 84.9 (75), 75.1 (24); HRMS calcd for C15H14NO4S 304.0644, found 304.0649. 
N-Tritylaniline (120) 
NHTr
 
Triphenylmethyl chloride (3.35 g, 12 mmol) was added to a solution of aniline (1 mL, 11 
mmol) in dry pyridine (45 mL). The solution was stirred at rt for 4 d. The reaction mixture 
was then diluted with EtOAc (100 mL) and then washed with aq CuSO4 solution (0.5 M) 
(150 mL) and brine (3 x 50 mL). The organic layers were dried over MgSO4, and 
concentrated in vacuo to give a pale yellow solid (3.51 g, 95%). mp: 150-152 oC (lit.270 
151-152 oC); δH (400 MHz, CDCl3): 4.82 (1H, s, NH), 6.26 (2H, d, J 8.0 Hz, 2 x Ar-H), 
6.44 (1H, t, J 14.2 Hz, Ar-H), 6.61 (2H, dd, J 14.2, 8.0 Hz, 2 x Ar-H), 7.09-7.29 (15H, m, 
15 x Ar-H); δC (100 MHz, CDCl3): 71.5 (C), 116.2 (2 x ArCH), 117.4 (ArCH), 126.9 (3 x 
ArCH), 128.0 (6 x ArCH), 228.3 (2 x ArCH), 129.3 (6 x ArCH), 145.5 (3 x ArC) 146.3 
(ArC); LRMS (EI+): 335.2 (M, 10%), 243.1 (100), 228.1 (18), 183.1 (13), 165.1 (96), 84.0 
(40), 77.1 (35); HRMS calcd for C25H21N 335.1674, found 335.1672. 
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2-(4’-Benzylamine)-1,4,7,10-tetraazacyclododecane (124) 
NH HN
HNNH
NH2
 
A solution of BH3.THF (1M) (10 mL) was added slowly to a flask of stirring 87 (600 mg) 
under Ar. The solution was then stirred at rt for a further 19 h before the excess borane was 
quenched with MeOH (3 mL). The solvent was removed under vacuum and the residue 
was treated with boiling HCl (6M) (20 mL) for 2 h. After removal of the solvents in vacuo, 
the residue was basified to pH 12 using KOH (7M, 10 mL), and the aq solution extracted 
with CH2Cl2 (3 x 20 mL) which was then dried under reduced pressure to give 124 as a 
white viscous oil (391 mg, 64%). νmax (NaCl)/cm-1: 3466 (N-H), 2971 (ArC-H), 1615 
(ArC=C), 1072 (C-N); δH (400 MHz, CDCl3): 1.91 (2H, t, J 10.0 Hz, CHB’), 2.07-2.97 
(15H, m, 14 x CH, CH2, CHA), 7.17 (2H, d, J 7.0 Hz, 2 x Ar-H), 7.27 (2H, d, J 7.0 Hz, 2 x 
Ar-H); δC (100 MHz, CDCl3): 38.5 (CH2), 41.4 (CH2), 45.8 (CH2), 52.5 (CH2), 53.1 (CH2), 
58.1 (CH2), 59.8 (CH), 61.0 (CH2), 61.5 (CH2), 126.7 (2 x ArCH), 126.9 (2 x ArCH), 
141.0 (ArC), 142.4 (ArC); LRMS (CI+):  277.2 (M, 9%), 260.2 (12), 204.1 (100), 187.1 
(74), 132.1 (21), 99.1 (37), 58.1 (62); HRMS calcd for C15H27N5 277.2266, found 
277.2264. 
Benzamidine (129) 
NH
NH2
.HCl
 
129 was prepared as the hydrochloride salt under Pinner conditions:153 Benzonitrile (4.08 
mL, 40 mmol) was dissolved in dry CH2Cl2 (88 mL) and abs. EtOH (4.7 mL) added and 
cooled to -8 oC in a NaCl ice bath. The solution was saturated with dry HCl at this t for 20 
min, and then stirred at rt under an atmosphere of HCl for 18 h. The solvent was then 
removed under vacuum and Et2O (100 mL) was added. The precipitate was filtered, 
dissolved in ice cold H2O (30 mL) and 10% aq K2CO3 (75 mL) was added. The mixture 
was stirred at rt for 5 min before it was extracted with EtOAc (150 mL). The organic phase 
was dried over Na2SO4 and concentrated under reduced pressure to give a clear oil. This oil 
was combined with NH4Cl (2.35 g, 44 mmol) and MeOH : H2O (70 mL : 9 mL) and stirred 
and heated under reflux for 6 h. The solvent was then removed under vacuum and acetone 
(75 mL) was added. The precipitate was collected by filtration to achieve 129 as a white 
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solid (4.78 g, 76%). mp: 176-178 oC (lit.271 174-179 oC); δH (400 MHz, DMSO-d6): 7.55 
(2H, t, J 6.8 Hz, 2 x Ar-H), 7.63 (1H, t, J 7.4 Hz, Ar-H), 7.85 (2H, d, J 7.4 Hz, 2 x Ar-H); 
δC (100 MHz, DMSO-d6): 127.8 (2 x ArCH), 129.1 (2 x ArCH), 131.9 (ArCH), 135.2 
(ArC), 165.6 (CNH2). 
Benzamidine 129 was also prepared using lithium hexamethyl disilazane (LiHMDS): 
Benzonitrile (0.1 mL, 1 mmol) was dissolved in dry THF (4 mL) and cooled to -78oC. 
LiHMDS. THF (2 mL, 2 mmol) was added dropwise, and mixture stirred at this t for 2 h. 
The reaction mixture was then stirred for a further 2 h while warming to 0 oC. H2O (2 mL) 
was then added carefully, and solution extracted with CH2Cl2 (30 mL). The organic layer 
was then washed with brine (10 mL) and dried over MgSO4 before filtering and 
concentrating in vacuo to give a green oil (77 mg, 64%). LRMS (CI+): 121.2 ([M+H]+, 
100%), 85.1 (73); HRMS calcd for C7H8N2 121.0766, 121.0765. 
4-Acetyl-benzamidine (132) 
NH2
NH2
O
 
4’-Acetylbenzonitrile (0.5 g, 3.4 mmol) was dissolved in dry THF (14 mL) and cooled to -
78oC. LiHMDS.THF (7 mL, 7 mmol) was added dropwise, and mixture stirred at this 
temperature for 2 h. The reaction mixture was then stirred for a further 2 h while warming 
to 0 oC. H2O (15 mL) was then added carefully, and solution extracted with CH2Cl2 (50 
mL). The aq layer was acidified with conc HCl and extracted with EtOAc (25 mL), and 
then basified with NaOH and extracted with EtOAc (25mL). The organic layers were all 
combined and washed with brine (40 mL) before drying over MgSO4. Filtration and 
concentrating in vacuo gave 132 as a white solid (360 mg, 65%). mp: 54-55 oC; νmax 
(KBr)/cm-1: 3354 (N-H), 3096 (ArC-H), 1695 (C=N), 1685 (C=O), 1604 (ArC=C); δH (400 
MHz, DMSO-d6): 2.69 (3H, s, CH3), 3.44 (4H, br s, 4 x NH), 8.09-8.10 (4H, m, 4 x Ar-H); 
δC (100 MHz, DMSO-d6): 27.0 (CH3), 128.3 (2 x ArCH), 129.5 (2 x ArCH), 134.5 (ArC), 
139.8 (ArC) 166.6 (CNH2), 197.7 (C=O); LRMS (EI+): 164.0 ([M+H]+, 6%), 149.0 (22), 
121.0 (6), 84.0 (100), 66.0 (99), 46.0 (37); HRMS calcd for C9H12N2O 164.0950, found 
164.0944. 
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2-(Benzamidine)-1,4,7,10-tetraazacyclododecane.pentahydrochloride (131) 
NH HN
HNNH
NH2
NH
.5HCl
 
87 (637 mg, 2.3 mmol) was dissolved in THF (9 mL) under Ar and cooled to -78 oC. 
LiHMDS.THF (11.7 mL, 11.7 mmol) was then added dropwise with stirring. The mixture 
was stirred and warmed to rt and stirred at this t for 24 h. The solution was then cooled to 0 
oC and HCl.Et2O (10 mL) added. The brown precipitate was filtered and recrystallised 
from EtOH and Et2O, and the hygroscopic solid filtered and washed quickly with cold 
EtOH and Et2O a number of times to leave a fine pale brown powder (1.04g, 95%). νmax 
(KBr)/cm-1: 3150 (N-H), 1679 (C=N), 1546 (ArC=C), 1377 (C-N); δH (400 MHz, DMSO-
d6): 2.60-3.40 (21H, m, 14 x CH, 7 x NH), 3.85-3.88 (1H, m, CHA), 7.89-8.00 (4H, m, 4 x 
Ar-H); δC (100 MHz, DMSO-d6): 35.3 (CH2), 42.5 (CH2), 43.4 (CH2), 48.2 (CH2), 48.7 
(CH2), 53.8 (CH2), 55.0 (CH2), 57.6 (CH), 126.1 (2 x ArCH), 126.5 (2 x ArCH), 139.5 
(ArC), 163.3 (C=N). 
Methyl 3-phenylaminobenzoate (134) 
H
N CO2MePh
 
A screw-cap Schlenk tube equipped with a stirrer bar was charged with Pd2(dba)3 (9.2 mg, 
0.01 mmol), 2-dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl (XPhos) (24 mg, 0.05 
mmol) and sodium t-butoxide (135 mg, 1.4 mmol). The tube was evacuated and refilled 
with argon before methyl 3-chlorobenzoate (170 mg, 1.0 mmol), aniline (109 µL, 1.2 
mmol) and t-BuOH (1 mL) were added. The tube was then capped and reaction mixture 
heated and stirred at 100 oC for 30 min. After this time, the mixture was cooled to rt, 
diluted with EtOAc (5 mL) and suction filtered. The filtrate was reduced under vacuum, 
and residue separated by flash chromatography (1 : 1 hexane : Et2O) to give 134 as a 
yellow solid (57 mg, 25%). mp: 110-112 oC (lit.159 111-112.5 oC); δH (400 MHz, CDCl3): 
3.81 (3H, s, OCH3), 5.79 (1H, s, NH), 6.89 ( 1H, t, J 7.6 Hz, Ar-H), 7.00 (2H, dd, J 8.4, 0.8 
Hz, 2 x Ar-H), 7.14-7.24 (4H, m, 4 x Ar-H), 7.48 ( 1H, dt, J 7.6, 1.4 Hz, Ar-H), 7.63 (1H, 
t, J 1.4 Hz, Ar-H); δC (100 MHz, CDCl3): 52.2 (CH3), 118.2 (ArCH), 118.4 (ArCH), 121.5 
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(ArCH), 121.8 (ArCH), 129.2 (ArCH), 129.4 (2 x ArCH), 129.5 (2 x ArCH), 131.3 (ArC), 
142.4 (ArC), 143.6 (ArC), 167.2 (C=O). 
4-Amino-1-(2-tertbutoxycarbonyl)-benzamidine (137) 
NHBoc
NH
H2N
 
Di-tert-butyl dicarbonate (524 mg, 2.4 mmol) was added slowly to a stirring solution of 4-
aminobenzamidine dihydrochloride (500 mg, 2.4 mmol), aq NaOH (1M) (4.8 mL), THF 
(2.4 mL) and H2O (2.4 mL). The mixture was stirred at rt for 3 d before extraction with 
EtOAc (30 mL). The organic layer was dried over Na2SO4 and dried under reduced 
pressure. The residue was then separated on a silica column eluted with 1 : 1 hexane : 
EtOAc to give a white solid (370 mg, 66%). Rf = 0.07 (hexane : EtOAc 1 : 1); mp: 
decomposition >220 oC (lit.161 no characterisation); νmax (KBr)/cm-1: 3386 (-NH-), 1711 
(COO), 1610 (Ar), 1496 (NCO); δH (400 MHz, DMSO-d6): 1.42 (9H, s, 3 x CH3), 5.79 
(2H, s, NH2), 6.54 (2H, d, J 8.8 Hz, Ar-H), 7.71 (2H, d, J 8.8 Hz, 2 x Ar-H); δC (100 MHz, 
DMSO-d6): 28.0 (3 x CH3), 77.1 (C(CH3)3), 112.5 (2 x ArCH), 120.3 (ArC), 129.2 (2 x 
ArCH), 152.5 (ArC), 163.9 (C=N), 166.2 (C=O); LRMS (EI+): 235.1 ([M]+, 45%), 180.1 
(83), 162.0 (65), 135.1 (82), 119.0 (100), 92.0 (23), 57.1 (95), 41.1 (33); HRMS calcd for 
C12H17N3O2 235.1321, found 235.1322. 
4-Amino-1-(2-di-tertbutoxycarbonyl)-benzamidine (138) 
N(Boc)2
NH
H2N
 
Di-tert-butyl dicarbonate (26 g, 119 mmol) was added slowly to a stirring solution of 4-
aminobenzamidine dihydrochloride (10 g, 48 mmol), aq NaOH (1 M) (96 mL), THF (48 
mL) and H2O (48 mL). The mixture was stirred at rt for 7 d before extraction with EtOAc 
(300 mL). The organic layer was dried over Na2SO4 and dried under reduced pressure. The 
residue was then separated on a silica column eluted with 1 : 1 hexane : EtOAc to give a 
white solid (10.4 g, 65%). Rf = 0.33 (hexane : EtOAc 1 : 1); mp: 175-177 oC; νmax 
(KBr)/cm-1: 3386 (-NH-), 1711 (COO), 1610 (Ar), 1496 (NCO); δH (400 MHz, CD3OD): 
1.51 (9H, s, 3 x CH3), 1.52 (9H, s, 3 x CH3), 4.92 (2H, s, NH2), 7.51 (2H, d, J 8.8 Hz, 2 x 
Ar-H), 7.75 (2H, d, J 8.8 Hz, 2 x Ar-H); δC (100 MHz, CD3OD): 28.6 (3 x CH3), 28.7 (3 x 
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CH3), 80.3 (C(CH3)3), 81.3 (C(CH3)3), 118.8 (2 x ArCH), 129.5 (ArC), 129.7 (2 x ArCH), 
144.6 (ArC), 164.8 (C=N), 169.7 (2 x C=O); LRMS (EI+): 335.1 ([M]+, 8%), 280.1 (18), 
206.0 (14), 179.1 (31), 135.1 (16), 57.1 (100); HRMS calcd for C17H25N3O4 335.1845, 
found 335.1847. 
Benzanilide (143) 
N
H
O
 
Benzoyl chloride (1.0 g, 7 mmol) was added to a stirring solution of aniline (532 µL, 5.8 
mmol), 4-(dimethylamino)pyridine (992 mg, 8.12 mmol) and pyridine (695 µL, 8.58 
mmol) in CH2Cl2 (70 mL). The mixture was stirred at rt for 19 h before it was diluted with 
CH2Cl2 (50 mL) and washed with saturated aq Na2CO3 solution. The organic phase was 
then reduced in vacuo. The residue was then separated on a silica column eluted with 1 : 1 
hexane : EtOAc to give an off white solid (1.04 g, 90%). Rf = 0.5 (hexane : EtOAc 1 : 1); 
mp: 161-163 oC (lit.272 163 oC); δH (400 MHz, CDCl3): 7.09 (1H, tt, J 7.2, 1.4 Hz, Ar-H), 
7.31 (2H, t, J 8.4 Hz, 2 x Ar-H), 7.42 (2H, tt, J 6.8, 1.6 Hz, 2 x Ar-H), 7.49 (1H, tt, J 7.2, 
1.4 Hz, Ar-H), 7.58 (2H, d, J 7.4 Hz, 2 x Ar-H), 7.75 (1H, s, NH), 7.81 (2H, d, J 7.4 Hz, 2 
x Ar-H); δC (100 MHz, CDCl3): 120.2 (2 x ArCH), 124.6 (ArCH), 127.0 (2 x ArCH), 
128.9 (2 x ArCH), 129.2 (2 x ArCH), 131.9 (ArCH), 135.0 (ArC), 137.9 (ArC), 170.5 
(C=O). 
Benzoic acid (144) 
OH
O
 
To a solution of benzonitrile (2 mL, 19.6 mmol) in EtOH (20 mL) and H2O (20 mL) was 
added KOH (40 g, 713 mmol). The mixture was heated and stirred under reflux for 24 h 
before Et2O (15 mL) was added and the aq layer separated. The organic phase was washed 
with H2O (2 x 20 mL) and the aq layers combined and acidified with conc HCl to pH1. 
The aq phase was then extracted with Et2O (50 mL), which was washed with H2O (10 mL), 
dried over MgSO4 and the solvent removed in vacuo. 114 was achieved as white needle-
like crystals (1.85 g, 77%). mp: 121-122 oC (lit.273 123-124 oC); δC (100 MHz, CDCl3): 
128.5 (2 x ArCH), 129.4 (ArC), 130.3 (2 x ArCH), 133.9 (ArCH), 172.8 (C=O). 
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2-(Benzoic acid)-1,4,7,10-tetraazacyclododecane (142) 
NH HN
HNNH
OH
O
 
KOH pellets (10.0 g, 183 mmol) were slowly added to a stirring solution of 87 (1.0 g, 3.7 
mmol), EtOH (4 mL) and H2O (4 mL). The mixture was then stirred and heated under 
reflux for 3 d before Et2O (3 mL) was added, and the organic layer separated and washed 
with H2O (2 x 5 mL). The aq layers were combined and acidified with conc HCl before 
extraction with Et2O (75 mL). The organic phase was separated, washed with H2O (20 
mL), dried over MgSO4 and reduced in vacuo to give 142 as a pale brown solid (953 mg, 
88%). The mp is unavailable as compound is hygroscopic; νmax (KBr)/cm-1: 3632 (-NH-), 
3255 (COO-H), 1669 (Ar), 1558.0 (Ar); δH (400 MHz, CD3OD): 3.17-4.09 (15H, m, 14 x 
CH, CHA), 7.77 (2H, d, J 8.2 Hz, 2 x Ar-H), 8.13 (2H, d, J 8.2 Hz, 2 x Ar-H); δC (100 
MHz, CD3OD): 37.1 (CH2), 44.41 (CH2), 44.9 (CH2), 46.0 (CH2), 50.1 (CH2), 54.0 (CH2), 
55.5 (CH2), 59.1 (CH), 129.2 (2 x ArCH), 131.7 (2 x ArCH), 133.7 (ArC), 138.9 (ArC), 
168.7 (C=O); LRMS (FAB): 293.2 ([M+H]+, 22%), 192.5 (100), 176.7 (45), 131.4 (5); 
HRMS calcd for C15H25O2N4 293.1978, found 293.1980. 
2-(Benzoyl chloride)-1,4,7,10-tetraazacyclododecane (145) 
NH HN
HNNH
Cl
O
 
142 (50 mg, 0.17 mmol) and SOCl2 (0.5 mL, 5.95 mmol) were stirred and heated at 70 oC 
for 2 h until HCl production stopped. The excess SOCl2 was removed in vacuo to give 145 
as a yellow solid (53 mg, 100%). 145 was taken onto next step without further purification 
or characterisation. 
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4-Acetyl-benzoic acid benzyl ester (146) 
O
BnO
O
 
Benzyl bromide (362 µL, 3 mmol) was added to a stirring solution of 4’-acetyl benzoic 
acid (500 mg, 3 mmol) and triethylamine (425 µL, 3 mmol) in THF (6 mL). The solution 
was stirred at rt for 48 h after which the solvent was removed under reduced pressure. The 
residue was then extracted with Et2O (75 mL) and H2O (30 mL). The organic layer was 
separated, washed with brine and dried over MgSO4 before reducing in vacuo to give a 
white solid (562 mg, 72%). mp: 32-36 oC (lit.166 no characterisation); νmax (KBr)/cm-1: 
1214 (COO), 1710 (C=O ketone), 3034 (Ar), 2962 (CH2), 1499 (Ar); δH (400 MHz, 
CDCl3): 2.57 (3H, s, CH3), 5.32 (2H, s, CH2), 7.29-7.40 (5H, m, 5 x Ar-H), 7.93 (2H, d, J 
8.6 Hz, 2 x Ar-H), 8.09 (2H, d, J 8.6 Hz, 2 x Ar-H); δC (100 MHz, CDCl3): 26.9 (CH3), 
67.2 (CH2), 128.2 (2 x ArCH), 128.3 (ArCH), 128.5 (2 x ArCH), 128.7 (2 x ArCH), 130.0 
(2 x ArCH), 133.9 (2 x ArC), 140.3 (ArC), 165.6 (C=O), 197.5 (C=O); LRMS (EI+): 254.0 
([M]+, 73%), 239.0 (19), 147.0 (100), 91.0 (93); HRMS calcd for C16H14O3 254.0943, 
found 254.0947. 
4-(1-Chloromethyl-1-formylamino)-1-(2-tertbutoxycarbonyl)-benzamidine
 (150) 
NHBoc
NH
N
H
Cl
O
 
To a solution of 4-amino-1-(2-tertbutoxycarbonyl)-benzamidine (220 mg, 0.94 mmol), and 
triethylamine (195 µL, 1.4 mmol) in CH2Cl2 (2.4 mL) was added dropwise a solution of 
chloroacetyl chloride (85 µL, 0.98 mmol) in CH2Cl2 (1 mL). The reaction mixture was 
stirred at rt for 19 h before washing with aq HCl (1M) (3 mL) and H2O (2 x 3 mL). The 
organic layer was then dried over Na2SO4 and reduced in vacuo. The residue was then 
separated on a silica column eluted with 1 : 1 hexane : EtOAc to give 150 as a green oil 
(293 mg, 59%). Rf = 0.1 (hexane : EtOAc 1 : 1); (lit.161 no characterisation); δH (400 MHz, 
CDCl3): 1.45 (9H, s, 3 x CH3), 4.13 (2H, s, CH2), 7.52 (1H, d, J 8.8 Hz, Ar-H), 7.62 (1H, 
d, J 8.8 Hz, Ar-H), 7.75 (2H, dd, J 8.8, 3.2 Hz, 2 x Ar-H), 8.19 (NH), 8.64 (NH), 8.70 
(NH); δC (100 MHz, CDCl3): 28.1 (3 x CH3), 43.0 (CH2), 82.9 (C), 119.6 (2 x ArCH), 
Caroline M. Reid, 2006  Chapter 7, 163 
129.0 (2 x ArCH), 129.3 (ArC), 141.1 (ArC), 149.8 (C=N), 164.5 (C=O), 164.5 (C=O); 
LRMS (EI+): 312.0 ([M]+, 4%), 238.0 (15), 212.0 (28), 196.0 (23), 162.0 (9), 120.0 (23), 
59.0 (95), 41.1 (100); HRMS calcd for C14H19N3O335Cl 312.1115, found 312.1113. 
N-[4-(1,4,7,10-Tetraazacyclododec-2-yl)-benzyl]-N-(tert-butoxycarbonyl)-N-
bis(tert-butoxycarbonyl)-carboxamidine (151) 
NH HN
HNNH
N
H
N(Boc)2
NBoc
 
124 (305 mg, 1.1 mmol) was dissolved in abs MeOH (17 mL) under Ar at rt. N,N’-Di-Boc-
1H-pyrazole-1-carboxamidine (170 mg, 0.55 mmol) and then N,N-diisopropylethylamine 
(96 µL, 0.55 mmol) were added and the mixture stirred for 24 h at rt. The reaction mixture 
was then concentrated in vacuo to give a yellow oil (488 mg, 100%), which was then taken 
onto the Boc-deprotection step without further purification. 
2-(N-Benzylguanidine)-1,4,7,10-tetraazacyclododecane.hexahydrochloride
 (152) 
NH HN
HNNH
N
H
NH2
NH
.6HCl
 
151 (488 mg, 1.1 mmol) was stirred in aq HCl (6M) (10 mL) for 5 h at rt. The solution was 
concentrated under reduced pressure, and the yellow residue recrystallised from EtOH and 
Et2O to give the hexahydrochloride salt 152 as a white solid (1.4 g, 99%). νmax (KBr)/cm-1: 
3397 (N-H), 2900 (ArC-H), 2957 (ArC-H), 1670 (C=N), 1446 (C-N); δH (400 MHz, 
CD3OD): 3.26-3.87 (16H, m, 14 x CH, CH2), 4.48 (1H, d, J 6.4 Hz, CHA), 6.80 (3H, br s, 3 
x NH), 7.45 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.58 (2H, br s, 2 x NH), 7.73 (2H, d, J 8.0 Hz, 2 x 
Ar-H); δC (100 MHz, CD3OD): 35.6 (CH2), 39.7 (CH2), 40.7 (CH2), 43.35 (CH2), 47.4 (2 x 
CH2), 51.2 (CH2), 53.2 (CH), 56.0 (CH2), 127.7 (ArCH), 128.4 (ArCH), 131.7 (ArC), 
133.3 (2 x ArCH), 139.3 (ArC), 157.2 (C=NH, rotomer), 158.7 (C=NH, rotomer). 
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N1,N2-Bis-(2-aminoethyl)-butane-1,2-diamine (155) 
H2N NH HN NH2
HA
 
1,2-Dibromobutane (1.81 mL, 15 mmol) was added over 5 min to a stirring solution of 1,2-
diaminoethane (2 mL, 30 mmol) in EtOH (10 mL). The mixture was heated under reflux 
for 18 h. KOH (4.2 g, 8.6 mol) was added and solution stirred at rt for 10 min. The solution 
was reduced by rotary evaporation until most of the solvent had been removed, before 
filtering through sintered glass, and rinsing with aq KOH solution (50%, 10 mL). The 
filtrate was recovered and another volume of aq KOH solution added (10 mL) before 
filtering again. The yellow organic layer was separated from the aq phase, and dried over 
KOH pellets. Filtering the solution and removal of solvent in vacuo gave the tetraamine 
155 as a racemic yellow solid (1.9 g, 36%). νmax (neat)/cm-1: 1599 (-NH-), 1560 (-NH2); δH 
(400 MHz, CDCl3): 0.69 (3H, t, J 7.6 Hz, CH3-CH2), 1.28 (2H, m, CH3-CH2), 2.40-2.53 
(10H, m, 5 x CH2), 2.87 (1H, t, J 6.4 Hz, HA); δC (100 MHz, CDCl3): 10.0 (CH3), 25.2 
(CH2), 41.5 (CH2), 42.0 (CH2), 49.5 (CH2), 52.4 (CH2), 52.5 (CH2), 60.1 (CH); LRMS 
(CI+) 175.2 ([M+H]+, 100%), 160.2 (5), 142.2 (26), 132.2 (16); HRMS calcd for C8H22N4 
175.1923, found 175.1920. 
7.2.3 Biological Materials and Methods for Chapter 3 
7.2.3.1 Trypanosome Cell Line 
Trypanosoma brucei brucei 427 
T. b. brucei strain EATRO (East African Trypanosomiasis Research Organisation) 427 was 
used routinely for uptake assays. These stocks were supplied by Dr M. P. Barrett, 
University of Glasgow. 
T. b. brucei 427 ∆Tbat1 Mutant Clone 
The ∆Tbat1 (P2) null mutant clone was constructed by sequential replacement of TbAT1 
with the neomycin and puromycin resistance markers in T. b. brucei 427. This knockout 
cell line was four-fold less sensitive to melarsoprol and melarsen oxide. These stocks were 
originally supplied by E. Matovu and are held at the University of Glasgow. 
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7.2.3.2 Growth and Maintenance of Bloodstream-Form Trypanosome Stocks 
In vitro
 culture 
Cultures were incubated in sterile culture flasks at 37 oC and 5% CO2 in HMI-9 medium 
containing 20% heat-inactivated foetal calf serum. 5 mL cultures were seeded with 200 µL 
of culture at 2 x 106 cells/mL. Cells were allowed to grow for 3 d after which they had 
reached maximum density (approximately 2 x 106 cells/mL) and were passaged again in 
the same way. 
In vivo
 culture 
Trypanosomes were stored in capillary tubes, in liquid nitrogen storage facilities, in blood 
containing 10.5% DMSO. Wistar rats or ICR mice (depending on the number of 
trypanosomes required) were infected by intraperitoneal injection of the parasite stabilates. 
Parasitaemias were checked daily by examination of a tail blood smear under phase 
contrast. Parasitaemia was scored using the rapid matching method. When the parasitaemia 
reached 1 x 109 cells/mL the animal was sacrificed using CO2 and the blood collected by 
cardiac puncture in a syringe containing 100 U/mL heparin in CBSS. 
7.2.3.3 Trypanotoxicity 
In vitro Toxicity Assay (Alamar Blue Assay) 
The Alamar Blue assay was used to assess toxicity in vitro.274 Doubling serial dilutions of 
test compound were set out in a 96 well plate in duplicate, in a volume of 100 µL HMI-9 
medium.275 100 µL of trypanosomes at 2 x 105 cells/mL were added to each well. After 48 
h incubation at 37 oC and 5% CO2, 10% Alamar Blue (20 µL) was added to each well and 
the plates incubated for a further 24 h. Unspecified enzymes in the live cells reduce the 
Alamar Blue to the colourless form. The concomitant change in absorption at 600 nm can 
be measured spectrophotometrically, or fluorometric measurements can be taken at 530 nm 
excitation and 590 nm emission as the amount of fluorescence detectable at these 
wavelengths increases in the reduced dye. All measurements were taken fluorometrically. 
The IC50 value was calculated by analysing the data with the IC50 value algorithm of the 
Grafit 4.0 (Erithracus Software) or using Prism 3.0 (GraphPad, San Diego, CA, USA). 
Values were checked for accuracy by visually examining cell viability and motility. Each 
experiment was performed in duplicate and replicated at least once. 
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In the investigation of polyamine effect on toxicity, the drug compound was dissolved in a 
0.1 M solution of putrescine, spermidine or spermine in HMI-9 before serial dilutions were 
made. 
In vivo
 Toxicity Assay 
Female NMRI mice weighting 22-25 g were infected with cryopreserved stabilates of T. b. 
brucei STIB 795 (derivate of strain 427). Each mouse was infected intraperitoneally with 
(2-4) x 104 bloodstream forms. Melarsoprol (arsobal; Aventis) acted as standard drug and 
was diluted with sterile distilled water to an appropriate concentration. Groups of four mice 
were treated on days three, four, five and six intraperitoneally with 20 mg/kg of 91. A 
control group remained untreated. The parasitaemia of all animals were checked on day 
seven post-infection and every second day until visible, at which point, mice were 
euthanased. 
7.2.3.4 Human Embryonic Kidney Cells 
Human Embryonic Kidney Cells (HEK), strain 293T, were used as the mammalian cell 
line for comparative analyses. HEK cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (Sigma) with penicillin/streptomycin (10 mg/mL), L-Glutamax (200 nM), and 
10% newborn calf serum in vented culture flasks at 37 oC in 5-10% CO2 atmosphere, 
passaging when cells on the monolayer are 80-85% confluent. The Alamar Blue assay 
protocol was modified from the one used for live trypanosomes; 100 µL of a 3 x 105 
cells/mL suspension was added to each well of a 96 well plate and incubated at 37 oC for 3 
h to allow cells to adhere to the bottom of the wells. Preparation of drug stocks in doubling 
dilution was added after the incubation period, incubated for a further 12-16 h before the 
addition of 10% Alamar Blue (20 µL). After 24 h the plates were read fluorometrically and 
visually as above. 
7.2.3.5 Fluorescence Assays 
Wet Slides 
A culture of the cells in HMI-9 medium was centrifuged and the excess medium poured 
off. 5.0 mL of CBSS solution was used to re-suspend the cells before centrifuging and 
pouring off excess CBSS. This process was repeated twice to wash the cells and remove 
soluble blood components. 2.0 µL of 10.0 mM fluorescent drug compounds was added to 
0.5 mL cells in CBSS solution in a 0.5 mL vial. After five min the vial was centrifuged, the 
excess solution removed, and 0. 2 µL solution removed to a glass slide and a cover slip 
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added. This was viewed directly through the Zeiss Axioscope FL fluorescence microscope 
using a Zeiss 02 filter at an excitation wavelength of 330 nm and an emission wavelength 
of 400 nm. Images were obtained by the same method but using an Axiovert 200M 
Fluorescence microscope. This technique was repeated to cover a 5-90 min time period 
Blood Smear 
Blood was collected as previously described from ICR mice presenting peak parasitaemias. 
0.5 µL of 10.0 mM fluorescent drug compounds was added to 500 µL of whole blood at rt 
to give a starting concentration of 10.0 µM. This was thoroughly mixed and approximately 
2.0 µL removed to a glass slide and covered to produce a wet blood smear that was viewed 
over a 5-90 min time period. This was viewed, and images obtained directly as before. 
7.2.3.6 Malarial Assays 
The parasitaemia of a Plasmodium falciparum (3D7 strain) culture was determined by 
counting Giemsa stained blood smears and diluted to 1% parasitaemia in 2% haematocrit. 
The compounds tested were diluted to 400 µM in medium and filter sterilised. 96 well 
plates were prepared by pipetting 100 µL medium (RPMI 1640) into each well. To the first 
well 100 µL of drug was added and doubling dilutions were carried out across the plate. As 
a control no drug was added to the last well. Into each well, 100 µL culture was added. The 
plates were incubated at 37 oC in a sealed culture chamber gassed with 5% CO2, 1% O2 
and 94% N2. After 24 h, 100 µL media was removed and 100 µL fresh medium containing 
0.5 µCi/well [3H]-labelled hypoxanthine (Amersham, 37 MBq/mL (1mCi/mL) radioactive 
concentration, 925 GBq/mmol (25 Ci/mmol) specific activity) was added. The plates were 
incubated as before 24 h. Afterwards the plates were frozen at -20 oC until harvested. 
After thawing at rt, the cells were harvested onto a filter mat (Wallac) using a Tomec cell 
harvester. The filter mats were dried and sealed in sample bags with Wallac Betaplate 
Scint scintillation liquid (Perkin Ellmer). The mats were counted using a Wallac Trilux 
1450 microbeta liquid scintillation and luminescence counter. 
7.2.3.7 Enzyme Assays 
Recombitant Leishmania major oligopeptidase B (5.0 ng) was incubated in 100 mM Tris 
(pH 8) with varying concentrations of polyamines (72, 88, 90, 91 and 131) for 10 mins 
prior to the addition of the substrate, z-RR-amc (Bachem, Nottingham, UK), at a saturating 
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concentration (10 µM). Activity was determined by the change in fluorescence (λex = 355 
nm, λex = 460 nm) at 21 oC using an EnVision 2102 plate reader (Perkin Elmer, Bucks, 
UK). The relative activity was calculated from the ratio of initial velocity in the presence 
of inhibitor to that of uninhibited controls and IC50 values were calculated using FigP 
(Fig.P Software Corporation, Hamilton, Canada). 
7.3 Experimental to Chapter 4 
7.3.1 Experimental Details 
Methyl (R)-phenylglycinatehydrochloride (160) 
H3N
OMe
O
Cl
 
The hydrochloride salt was obtained by forming a suspension of (R)-phenylglycine (9.6 g, 
64 mmol) in dry MeOH (50 mL), and conc HCl (116 mmol, 10 mL) was added. The 
mixture was then stirred and heated at reflux for 8 h. The solution was concentrated in 
vacuo to leave a white powder (12.8 g, 100%); mp: 228-230 oC (lit.180 202 oC); δH (400 
MHz, CDCl3): 3.74 (3H, s, OCH3), 5.22 (1H, s, CH), 7.38-7.48 (5H, m, 5 x Ar-H); δC (100 
MHz, CDCl3): 54.3 (CH3), 56.7 (CH), 128.4 (2 x ArCH), 130.1 (2 x ArCH), 130.82 
(ArCH), 139.1 (ArC), 170.0 (C=O); LRMS (CI+): 349.3 ([M+H]+, 100%), 347.3 (7), 287.3 
(44), 271.2 (8), 243.2 (6), 216.2 (10); HRMS calcd for C16H36O4N4 349.2815, found 
349.2815. 
Methyl (S)-phenylglycinatehydrochloride (161) 
H3N
OMe
O
Cl
 
The hydrochloride salt was obtained by forming a suspension of (S)-phenylglycine (10 g, 
66 mmol) in dry MeOH (50 mL), and conc HCl (166 mmol, 10 mL) was added. The 
mixture was then stirred and heated at reflux for 8 h. The solution was concentrated in 
vacuo to leave a white powder (10.3 g, 100%); mp: 214-216 oC (lit.180 202 oC); δH (400 
MHz, CDCl3): 3.76 (3H, s, OCH3), 5.22 (1H, s, CH), 7.39-7.47 (5H, m, 5 x Ar-H); δC (100 
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MHz, CDCl3): 54.3 (CH3), 56.7 (CH), 128.4 (2 x ArCH), 130.1 (2 x ArCH), 130.82 
(ArCH), 139.7 (ArC), 170.0 (C=O). 
Methyl (R)-phenylglycinate (162) 
H2N
OMe
O
 
Liquid NH3 was bubbled through a suspension of hydrochloride 160 (12.90 g, 64 mmol), 
in CHCl3 (55 mL) for 10 min. The precipitated ammonium chloride was filtered off, and 
washed with CHCl3 (10 mL). The organic solution was concentrated in vacuo to give 162 
as a pale yellow oil (8.84 g, 84%).[α]D21 -23.2 (c 1.0, CHCl3) (lit.178 [α]D -180 (c 2.0, 
C6H6); νmax (neat)/cm-1: 3028 (Ar-H), 1604 (NH2), 1221 (COO), 1168 (COO) cm-1; δH 
(400 MHz, CDCl3): 1.94 (3H, s, OCH3), 4.61 (1H, s, CH), 7.27-7.39 (5H, m, 5 x Ar-H); δC 
(100 MHz, CDCl3): 52.8 (CH3), 59.1 (CH), 127.2 (2 x ArCH), 128.4 (ArCH), 129.4 (2 x 
ArCH), 140.7 (ArC), 174.9 (C=O); LRMS (CI+): 166.1 ([M+H]+, 100%), 149.1 (5), 106.1 
(6); HRMS calcd for C9H11O2N 166.0868, found 166.0867. 
Methyl (S)-phenylglycinate (163) 
H2N
OMe
O
 
Liquid NH3 was bubbled through a suspension of hydrochloride 161 (10.28 g, 51 mmol), 
in CHCl3 (40 mL) for 10 min. The precipitated NH4Cl was filtered off, and washed with 
CHCl3 (10 mL). The organic solution was concentrated in vacuo to give 163 as a pale 
yellow oil (7.94 g, 94%). [α]D21 23.4 (c 1.0, CHCl3) (lit.178 [α]D 170 (c 2.0, C6H6); νmax 
(neat)/cm-1: 3031 (Ar-H), 1599 (NH2), 1220 (COO), 1168 (COO) cm-1; δH (400 MHz, 
CDCl3): 1.94 (3H, s, OCH3), 4.62 (1H, s, CH), 7.29-7.40 (5H, m, 5 x Ar-H); δC (100 MHz, 
CDCl3): 52.8 (CH3), 59.2 (CH), 127.2 (2 x ArCH), 128.4 (ArCH), 129.2 (2 x ArCH), 140.7 
(ArC), 174.9 (C=O); LRMS (CI+): 166.1 ([M+H]+, 100%), 149.1 (5), 106.1 (7); HRMS 
calcd for C9H11O2N 166.0868, found 166.0865. 
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(R)-Phenylglycinamide (164) 
H2N
NH2
O
 
A solution of 162 (8.843 g, 54 mmol) in conc aq NH3 (7 mL, 35%) was stirred at rt for 2 d, 
before evaporating to dryness to give 164 as a pale yellow solid (7.49 g, 92%). mp: 119-
123 oC (lit.178 130-136 oC); νmax (neat)/cm-1: 3370 (CONH2), 3338 (CONH2), 3054 (Ar-H), 
1604 (NH2); δH (400 MHz, CDCl3): 4.47 (1H, s, CH), 5.57 (br s, NH2), 6.77 (br s, NH2), 
7.22-7.36 (5H, m, 5 x Ar-H); δC (100 MHz, CDCl3): 60.3 (CH), 127.3 (2 x ArCH), 128.6 
(ArCH), 129.3 (2 x ArCH), 141.2 (ArC), 176.2 (C=O); LRMS (CI+): 151.1 ([M+H]+, 
100%), 134.12 (4), 106.13 (11); HRMS calcd for C8H10ON2 151.0871, found 151.0872. 
(S)-Phenylglycinamide (165) 
H2N
NH2
O
 
A solution of 163 (7.94 g, 48 mmol) in conc aq NH3 (7.94 mL, 35%) was stirred at rt for 2 
d, before evaporating to dryness to give 165 as a pale yellow solid (5.85 g, 81%). mp: 111-
114 oC (lit.178 130-136 oC); νmax (neat)/cm-1: 3370 (CONH2), 3339 (CONH2), 3053 (Ar-H), 
1604 (NH2) cm-1; δH (400 MHz, CDCl3): 4.46 (1H, s, CH), 5.71 (br s, NH2), 6.83 (br s, 
NH2), 7.22-7.36 (5H, m, 5 x Ar-H); δC (100 MHz, CDCl3): 60.3 (CH), 127.3 (2 x ArCH), 
128.6 (ArCH), 129.3 (2 x ArCH), 141.1 (ArC), 176.3 (C=O); LRMS (CI+): 151.1 ([M+H]+, 
100%), 134.1 (3), 106.1 (11); HRMS calcd for C8H10ON2 151.0871, found 151.0871. 
(R)-1-Phenyl-ethylenediamine (158) 
H2N
NH2
 
To a suspension of LiAlH4 (18.94 g, 499 mmol) in THF (300 mL), was added 164 (7.49 g, 
49.9 mmol) portionwise with stirring and cooling with ice. The mixture was then stirred 
and heated at reflux for 5 d. With ice cooling, sodium sulfate decahydrate and Et2O (300 
mL) were added, and the solution was filtered through Celite and rinsed with Et2O (100 
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mL). Organics were combined and dried over MgSO4, then concentrated in vacuo to give 
158 as a yellow oil (2.11 g, 35%); [α]D24 -3.1 (c 1.0, CHCl3) (lit.178 [α]D -29.7); δH (400 
MHz, CDCl3): 2.72 (1H, dd, J 12.8, 6.8 Hz, CH), 2.81 (1H, dd, J 12.8, 5.2 Hz, CH), 3.79-
3.82 (1H, m, CH), 7.16-7.28 (5H, m, 5 x Ar-H); δC (100 MHz, CDCl3): 48.9 (NCH2), 57.3 
(NCH), 125.5 (2 x ArCH), 126.2 (2 x ArCH), 127.5 (ArCH), 142.0 (ArC). 
(S)-1-Phenyl-ethylenediamine (159) 
H2N
NH2
 
159 was prepared in the same way as (R)-isomer 158 starting with 165 (4.76 g, 31.7 mmol) 
to give a yellow oil (389 mg, 9%). [α]D24 11.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3): 2.75 
(1H, dd, J 12.8, 6.8 Hz, CH), 2.85 (1H, dd, J 12.8, 5.2 Hz, CH), 3.82-3.85 (1H, m, CH), 
7.12-7.30 (5H, m, Ar-H); δC (100 MHz, CDCl3): 49.1 (NCH2), 57.5 (NCH), 125.7 (2 x 
ArCH), 126.4 (2 x ArCH) 127.7 (ArCH), 142.2 (ArC). 
1,2-Bis(toluol-4-sulfonylamino)-phenyl-ethamine (R) (166)  
TsHN NHTs
 
NaOH (1.24 g, 31.0 mmol), was added slowly to an ice-cooled solution of 158 (2.11 g, 
15.5 mmol), in H2O (10 mL). Et2O (10 mL), then p-toluenesulfonyl chloride (5.9 g, 31.0 
mmol) were added and reaction mixture stirred vigorously for 1 h at this temp. The solid 
formed was filtered and rinsed with Et2O, then dried in vacuo. 166 was obtained as white 
crystals (4.18 g, 61%). mp: 138-142 oC (lit.276 160-161 oC); [α]D21 -21.2 (c 0.5, CH2Cl2); 
δH (400 MHz, CDCl3): 2.30 (3H, s, CH3), 2.34 (3H, s, CH3), 3.04-3.16 (2H, m, CH2), 4.25 
(1H, br d, J 5.0 Hz, CH), 4.92 (1H, br s, NH), 5.49 (1H, br d, J 5.5 Hz, NH), 6.89-6.91 
(2H, m, 2 x Ar-H), 7.06-7.11 (5H, m, 5 x Ar-H), 7.20 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.50 
(2H, d, J 8.0 Hz, 2 x Ar-H), 7.60 (2H, d, J 8.2 Hz, 2 x Ar-H); δC (100 MHz, CDCl3): 21.9 
(CH3), 21.9 (CH3), 48.6 (CH2), 57.7 (CH), 127.0 (2 x ArCH), 127.5 (2 x ArCH), 127.6 (2 x 
ArCH), 128.6 (ArCH), 129.2 (2 x ArCH), 130.0 (2 x ArCH), 130.2 (2 x ArCH), 136.9 
(ArC), 137.18 (ArC), 137.9 (ArC), 143.9 (ArC), 144.1 (ArC); LRMS (CI+): 445.1 
([M+H]+, 100%), 274.1 (69), 260.1 (35), 157.1 (39), 106.1 (27); HRMS calcd for 
C22H24O4N2S2 445.1256, found 445.1258. 
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1,2-Bis(toluol-4-sulfonylamino)-phenyl-ethamine (S) (167) 
TsHN NHTs
 
NaOH (237 mg, 5.92 mmol), was added slowly to an ice-cooled solution of 159 (403 mg, 
2.96 mmol), in H2O (1.85 mL). Et2O (1.85 mL), then p-toluenesulfonyl chloride (1.13 g, 
5.92 mmol) were added and reaction mixture stirred vigorously for 1 h at this temp. The 
solid formed was filtered and rinsed with Et2O, then dried in vacuo. 167 was obtained as 
white crystals (461 mg, 35%). mp: 138-142 oC (lit.276 160-161 oC); [α]D21 19.0 (c 0.5, 
CH2Cl2); δH (400 MHz, CDCl3): 2.31 (3H, s, CH3), 2.35 (3H, s, CH3), 3.06-3.12 (2H, m, 
CH2), 4.24 (1H, br d, J 5.0 Hz, CH), 4.81 (1H, br s, NH), 5.37 (1H, br d, J 5.5 Hz, NH), 
6.89-6.91 (2H, m, 2 x Ar-H), 7.09-7.11 (5H, m, 5 x Ar-H), 7.21 (2H, d, J 8.0 Hz, 2 x Ar-
H), 7.51 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.61 (2H, d, J 8.4 Hz, 2 x Ar-H); δC (100 MHz, 
CDCl3): 21.9 (CH3), 21.9 (CH3), 48.6 (CH2), 57.6 (CH), 127.0 (2 x ArCH), 127.5 (2 x 
ArCH), 127.6 (2 x ArCH), 128.6 (ArCH), 129.2 (2 x ArCH), 129.2 (2 x ArCH), 130.2 (2 x 
ArCH), 136.9 (ArC), 137.2 (ArC), 137.9 (ArC), 143.99 (ArC), 144.19 (ArC). 
N,N’-Ditosyl-ethylenediamine-N,N’-diacetic acid-dimethyl ester (173) 
N
Ts
Ts
N OMe
O
MeO
O
 
In a 3-necked flask was dissolved Na (250.6 mg, 10.9 mmol) in MeOH (14 mL) and N,N'-
ditosyl-ethylenediamine 45 added (2.0 g, 5.4 mmol). The mixture was then stirred and 
heated at reflux for 2 h. The MeOH was then distilled, and the remaining residue dried in 
vacuo. The powder was then added portionwise over 30 min to a stirring, ice-cooled flask 
of methylbromoacetate (4.11 mL, 43.4 mmol). After stirring at rt for 30 min, the excess 
methylbromoacetate was removed in vacuo. A mixture of H2O (10 mL) and CHCl3 (10 
mL) was added to the residue. The CHCl3 layer was washed with H2O (2 x 5 mL) before 
drying over CaCl2. The solution was then filtered and reduced in vacuo. The product was 
then crystallised from MeOH (1.14 g, 41%). mp: 108-112 oC (lit.165 124.3-126.8 oC); δH 
(400 MHz, CDCl3): 2.36 (6H, s, 2 x CH3), 3.14 (4H, s, 2 x CH2), 3.56 (6H, s, 2 x OCH3), 
4.01 (4H, s, 2 x CH2), 7.24 (4H, d, J 8.0 Hz, 4 x Ar-H), 7.63 (4H, d, J 8.0 Hz, 4 x Ar-H); 
δC (100 MHz, CDCl3): 21.6 (2 x CH3), 48.6 (2 x CH2), 50.1 (2 x CH2), 52.2 (CH3), 127.5 
(4 x ARCH), 129.7 (4 x ArCH), 135.7 (2 x ArC), 143.9 (2 x ArC), 169.3 (2 x C=O). 
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N,N’-Ditosyl-ethylenediamine-N,N’-diacetic acid (174) 
N
Ts
Ts
N OH
O
HO
O
 
A mixture of 173 (1.1g, 2.15 mmol), AcOH (5.16 mL) and conc HCl (1.29 mL) was stirred 
and heated under reflux for 12 h. The resulting white crystals were filtered and rinsed with 
acetic acid (2 x 2 mL) before drying in vacuo (574 mg, 55%). mp: 206-208 oC (lit.165 
228.9-229.8 oC); δH (400 MHz, DMSO-d6): 2.42 (6H, s, 2 x CH3), 3.27 (4H, s, 2 x CH2), 
3.98 (4H, s, 2 x CH2), 7.41 (4H, d, J 8.2 Hz, 4 x Ar-H), 7.66 (4H, d, J 8.2 Hz, 4 x Ar-H); 
δC (100 MHz, DMSO-d6): 21.0 (2 x CH3), 47.0 (2 x CH2), 49.3 (2 x CH2), 126.9 (4 x 
ArCH), 129.7 (4 x ArCH), 136.3 (2 x ArC), 143.3 (2 x ArC), 170.4 (2 x C=O). 
N,N’-Bis-(toluene-4-sulfonyl)-N,N’-ethanediyl-bis-glycyl chloride (169) 
N
Ts
Ts
N Cl
O
Cl
O
 
174 (531 mg, 1.1 mmol) and SOCl2 (5.6 mL, 76.8 mmol) were stirred and heated under 
reflux for 5 h, heating no higher than 80 oC. After HCl production had ceased, excess 
thionyl chloride was removed in vacuo. The pale brown solid 169 was crystallised from 
benzene (536.3 mg, 94%); mp: 134-136 oC (lit.165 223-224 oC); νmax (neat)/cm-1: 1799 
(COCl), 1345 (SO2N), 1159 (SO2N); δH (400 MHz, DMSO-d6): 2.47 (6H, s, 2 x CH3), 3.31 
(4H, s, 2 x CH2), 4.04 (4H, s, 2 x CH2), 7.46 (4H, d, J 8.4 Hz, 4 x Ar-H), 7.72 (4H, d, J 8.4 
Hz, 4 x Ar-H); δC (100 MHz, DMSO-d6): 21.0 (2 x CH3), 49.3 (2 x CH2), 126.9 (4 x 
ArCH), 129.7 (4 x ArCH), 136.3 (2 x ArC), 143.3 (2 x ArC), 170.4 (2 x C=O). 
11-Methyl-4,7-bis-(toluene-4-sulfonyl)-1,4,7,10-tetraazacyclododecane-2,9-
dione (176) 
N HN
HNN
Ts
Ts
O
O
 
In a dry flask was added dry CH2Cl2 (27 mL) and NEt3 (0.053 mL, 0.38 mmol). To this 
was added simultaneously via two separate syringe pumps, 169 (100 mg, 0.19 mmol) in 
CH2Cl2 (7 mL), and 1,2-diaminopropane (0.016 mL, 0.19 mmol) in CH2Cl2 (7 mL), over 7 
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h while stirring at rt. After a further 30 min stirring at rt, the mixture was reduced under 
pressure to yield 176 as a white solid (163.0 mg, 100%); νmax (neat)/cm-1: 3256 (C(O)N), 
1346 (SO2N), 1160 (SO2N);LRMS (CI+): 523.1 ([M+H]+, 3%), 157.1 (45), 85.1 (100); 
HRMS calc for C23H31O6N4S2, 523.1685, found 523.1682. 
2-Amino-N-(2-aminoethyl)-2-phenyl acetamide (179) 
H2N
H
N
O
NH2
HB
HA HA'
HB'
HX
 
160 (12.9 g, 64 mmol) was dissolved in neat ethylenediamine (30 mL) at 0-5 oC, and 
reaction mixture stirred at rt for 4 d. After this time the excess ethylenediamine was 
removed in vacuo. The residue was taken up in CHCl3 (250 mL) and precipitate filtered 
off. The organic solution was concentrated under reduced pressure to give a dark brown 
viscous oil (10.43 g, 84%); [α]D21 -47.4 (c 0.5, CH2Cl2); νmax (neat)/cm-1: 3286 (NH), 3028 
(NH), 2925 (NH), 2862 (NH), 1519 (CO-N); NMR spectroscopy agreed with lit. values;277 
δH (400 MHz, D2O): 2.53 (1H, d, J 6.4 Hz, CHA), 2.55 (1H, d, J 6.4 Hz, CHA’), 3.10 (1H, 
d, J 6.4 Hz, CHB), 3.12 (1H, d, J 6.4 Hz, CHB’), 4.40 (1H, s, CHX), 7.23-7.32 (5H, m, 5 x 
Ar-H); δC (100 MHz, D2O): 39.7 (CH2), 41.7 (CH2), 58.8 (CH), 126.6 (2 x ArCH), 128.2 
(ArCH), 129.6 (2 x ArCH), 140.1 (ArC), 176.0 (C=O); LRMS (CI+): 194.1 ([M+H]+, 
100%), 176.1 (25), 106.1 (17); HRMS calcd for C10H15N3O 194.1293, found 194.1295. 
2-Phenyl-2-(toluene-4-sulfonylamino)-N-[2-(toluene-4-sulfonylamino)-ethyl]-
acetamide (180) 
TsHN
H
N
O
NHTs
HB
HA HA'
HB'
HX
 
To a solution of p-toluenesulfonyl chloride (670 mg, 3.5 mmol) in dry pyridine (11 mL) at 
0 oC, was added drop-wise a solution of 179 in dry pyridine (2 mL). The solution was then 
stirred at 0 oC for 3 h, then at rt for 3 d. Solution added to ice and H2O, and left overnight 
to allow precipitation of product as a yellow solid (645 mg, 96%). mp: 138-139 oC; [α]D20 -
3.4 (c 1.0, CH2Cl2); νmax (neat)/cm-1: 2359 (NH), 2341 (NH), 1541 (CO-N), 1353 (SO2-N), 
1160 (SO2-N); δH (400 MHz, CDCl3): 2.31 (3H, s, CH3), 2.35 (3H, s, CH3), 2.93-2.96 (2H, 
m, CH2), 3.19-3.31 (2H, m, CH2), 4.71 (1H, d, J 6.0 Hz, NH), 5.51-5.52 (1H, m, NH), 6.10 
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(1H, dd, J 8.8, 6.0 Hz, NH), 7.01 (2H, m, 2 x Ar-H), 7.08-7.16 (5H, m, 5 x Ar-H), 7.19-
7.22 (2H, m, 2 x Ar-H), 7.56 (2H, d, J 7.2 Hz, 2 x Ar-H), 7.63 (2H, d, J 8.4 Hz, 2 x Ar-H); 
δC (100 MHz, CDCl3): 20.5 (2 x CH3), 38.8 (CH2), 41.4 (CH2), 60.0 (CH), 126.0 (2 x 
ArCH), 126.3 (2 x ArCH), 126.5 (2 x ArCH), 127.6 (ArCH), 127.9 (2 x ArCH), 128.6 (2 x 
ArCH), 128.8 (2 x ArCH), 134.9 (ArC), 135.0 (ArC), 135.7 (ArC), 142.5 (ArC), 142.8 
(ArC), 169.2 (C=O); LRMS (FAB+): 502.2 ([M+H]+, 94%), 369.2 (18), 331.2 (37), 303.2 
(33), 260.1 (47), 215.1 (18), 147.1 (22), 106.3 (41), 73.7 (100); HRMS calcd for 
C24H27N3O5S2 502.1470, found 502.1474. 
(2R)-2-Phenyl-2-(toluenesulfonylamino)-N-[2-(toluenesulfonylamino)ethyl]-
aminoethane (181) 
TsHN
H
N NHTs
HB
HA HA'
HB'
HX
 
To a cooled solution of 180 (5.16 g, 10.3 mmol) suspended in THF (20 mL), was added 
BH3.THF (1M) (50 mL, 52.0 mmol) slowly. The mixture was then stirred and heated at 
reflux for 7 d. The excess borane was quenched by careful addition of MeOH (20 mL). The 
reaction mixture was then concentrated under reduced pressure. Dry EtOH (40 mL) was 
then added, and solution saturated with HCl gas at 0 oC. The mixture was then heated at 
reflux overnight, after which the solution was cooled in an ice bath. The resulting yellow 
solid was filtered, washed with Et2O (100 mL) and dried in vacuo (2.41 g, 48%). νmax 
(neat)/cm-1 3059 (ArH), 2361 (NH), 2337 (NH), 1323 (SO2-N), 1156 (SO2-N); δH (400 
MHz, CD3OD): 2.34 (3H, s, CH3), 2.46 (3H, s, CH3), 3.20-3.22 (2H, m, 2 x CH), 3.33-3.42 
(4H, m, 4 x CH), 4.68-4.71 (1H, m, HX), 7.02 (2H, d, J 8.2 Hz, 2 x Ar-H), 7.14-7.21 (5H, 
m, 5 x Ar-H), 7.44 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.54 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.80 (2H, 
d, J 8.0 Hz, 2 x Ar-H); δC (100 MHz, CD3OD): 21.4 (CH3), 21.5 (CH3), 39.9 (CH2), 49.2 
(CH2), 52.9 (CH2), 56.2 (CH), 128.0 (4 x ArCH), 128.3 (4 x ArCH), 129.6 (ArCH), 129.9 
(2 x ArCH), 130.0 (2 x ArCH), 131.0 (2 x ArCH), 137.2 (ArC), 137.5 (ArC), 138.7 (ArC), 
144.9 (ArC), 145.4 (ArC); LRMS (FAB): 488.1 ([M+H]+, 90%),  317.2 (7), 227.3 (9), 75.1 
(100); HRMS calcd for C24H30O4N3S2 488.1678, found 488.1674. 
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(2R)-N-[2-[(Toluenesulfonylamino)ethyl]-N-[2-(toluenesulfonyl)amino]-2-
phenyl-ethyl-toluenesulfonamide (182) 
TsHN
Ts
N NHTs
HB
HA HA'
HB'
HX
 
To a solution of p-toluenesulfonyl chloride (1.13 g, 5.9 mmol), in dry pyridine (10 mL), at 
0 oC, was added a solution of 181 (2.41 g, 4.9 mmol) in dry pyridine (20 mL) dropwise. 
The solution was then stirred at this temp for 3 h, then at rt for 2 d. The resulting yellow 
solution was added to a mixture of ice and H2O, and left for 48 h to allow precipitation of a 
yellow product. Filtration followed by drying in vacuo yielded 182 as pale yellow fluffy 
crystals (2.83 g, 90%). mp: 70-73 oC; [α]D24 -5.3 (c 1.0, CHCl3); νmax (neat)/cm-1: 3461 (N-
H), 3022 (C-H), 2724 (N-CH2), 1153 (N-SO2); δH (400 MHz, CD3OD): 2.34 (3H, s, CH3), 
2.42 (3H, s, CH3), 2.43 (3H, s, CH3), 2.46-2.51 (1H, m, CH), 2.60-2.67 (1H, m, CH), 2.85-
3.00 (2H, m, 2 x CH), 3.10 (1H, dd, J 14.8, 7.6 Hz, CHB), 4.51 (1H, t, J 7.6 Hz, CHA), 
7.02-7.05 (2H, m, 2 x Ar-H), 7.11-7.12 (3H, m, 3 x Ar-H), 7.17 (2H, d, J 8.0 Hz, 2 x Ar-
H), 7.33 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.37 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.57 (4H, d, J 8.0 
Hz, 4 x Ar-H), 7.66 (2 H, d, J 8.0 Hz, 2 x Ar-H); δC (100 MHz, CD3OD): 21.4 (CH3), 21.5 
(CH3), 21.6 (CH3), 42.2 (CH2), 50.8 (CH2), 55.9 (CH2), 58.2 (CH) 124.0 (ArCH), 127.0 
(ArCH), 127.1 (ArCH), 127.3 (ArCH), 127.4 (ArCH), 127.6 (ArCH), 127.8 (ArCH), 128.6 
(ArCH), 129.1 (ArCH), 129.2 (ArCH), 129.4 (ArCH), 129.8 (ArCH), 130.0 (ArCH), 134.9 
(ArC), 136.4 (ArCH), 136.8 (ArC), 137.0 (ArC), 138.1 (ArC), 143.2 (ArC), 143.5 (ArC), 
144.1 (ArC), 149.5 (ArCH), 2 missing; LRMS (FAB): 642.3 ([M+H]+, 75%), 471.3 (51), 
381.2 (41), 316.2 (100), 260.1 (20), 227.1 (25), 154.1 (48); HRMS calcd for C31H36O6N3S3 
642.1766, found 642.1765. 
L-Phenylalanine methyl ester hydrochloride (185) 
OMe
O
NH3 Cl
Ph
 
Conc HCl (5 mL) was added to a solution of L-phenyl alanine (5 g, 30 mmol) in MeOH 
(25 mL) and mixture stirred at rt for 19 h. Excess reagents and solvent were then removed 
under vacuum to give 185 as a pure white solid (6.07 g, 93%). mp: 213-216 oC; [α]D24 12.5 
(c 1.0, H2O); NMR spectroscopy agreed with lit. values;278 δH (400 MHz, D2O): 3.06 (1H, 
dd, J 14.8, 7.6 Hz, CH), 3.20 (1H, dd, J 14.8, 5.6 Hz, CH), 3.69 (3H, s, CH3), 4.18 (1H, dd, 
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J 7.6, 5.6 Hz, C(NH3)H), 7.13-7.30 (5H, m, 5 x ArH); δC (100 MHz, D2O): 35.6 (CH2), 
53.4 (CH), 54.2 (CH3), 128.0 (ArCH), 129.2 (2 x ArCH), 129.4 (2 x ArCH), 134.0 (ArC), 
171.5 (C=O); LRMS (CI+): 180.23 (M, 71%), 166.18 (100), 120.16 (20), 71.1 (37); HRMS 
calcd for C10H14NO2 180.1025, found 180.1026. 
N’-(2-Aminoethyl)-L-phenylalaninamide (186) 
H
N
O
NH2
NH2
Ph
 
185 (6.0 g, 28 mmol) was dissolved in neat 1,2-diaminoethane (10 mL) at 0 oC. The 
mixture was then stirred at rt for 4 d. Excess 1,2-diaminoethane was then removed under 
reduced pressure. The resultant solid was dissolved in CHCl3 (200 mL) and filtered. The 
filtrate was concentrated in vacuo to give a dark yellow oil (1.58 g, 27%). [α]D24 21.9 (c 
1.0, H2O); NMR spectroscopy agreed with lit. values;279 δH (400 MHz, D2O): 2.30 (2H, dd, 
J 9.6, 6.0 Hz, CH2), 2.67 (1H, dd, J 13.2, 8.8 Hz, CH), 2.85 (2H, dd, J 13.6, 6.0 Hz, CH2), 
3.05 (1H, dt, J 13.6, 6.0 Hz, C(NH2)H), 3.44 (1H, dd, J 8.8, 6.0 Hz, CH), 7.08-7.25 (5H, 
m, 5 x Ar-H); δC (100 MHz, D2O): 39.6 (CH2), 40.8 (CH2), 41.6 (CH2), 56.6 (CH), 127.0 
(ArCH), 128.7 (2 x ArCH), 129.3 (2 x ArCH), 137.1 (ArC), 176.6 (C=O); LRMS (CI+): 
208.3 ([M+H]+, 100%), 139.2 (13), 101.2 (46); HRMS calcd for C11H17N3O 208.1450, 
found 208.1447. 
3-Phenyl-2-(toluene-4-sulfonylamino)-N-[2-(toluene-4-sulfonylamino)-ethyl]-
propionamide (187) 
H
N
O
NH
NHTsPh
Ts
 
To a solution of p-toluenesulfonyl chloride (3.08 g, 16 mmol) in dry pyridine (9 mL) 
cooled to 0 oC, was added 186 (1.4 g, 6.7 mmol) dropwise. The solution was stirred at this 
temperature for 3 h, and then for a further 3 d at rt. The mixture was then poured onto an 
ice : H2O mixture (300 mL) and left overnight to precipitate which was then filtered off 
and dried in vacuo. The product was recrystallised from EtOH as white crystals (3.75 g, 
50%). mp: 169-171 oC; [α]D20 25.6 (c 0.5, CH2Cl2); νmax (KBr)/cm-1: 3334 (N-H), 3208 
(N-H), 3252 (N-H), 3029 (ArC-H), 1650 (C=O), 1596 (ArC=C), 1329 (SO2-N), 1307 (C-
N), 1162 (SO2-N); δH (400 MHz, CDCl3): 2.35 (3H, s, CH3), 2.36 (3H, s, CH3), 2.73 (1H, 
dd, J 14, 8.8 Hz, CH), 2.90-3.00 (3H, m, 3 x CH), 3.13-3.20 (1H, m, CH), 3.29-3.37 (1H, 
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m, CH), 3.66 (1H, dt, J 8.4, 5.6 Hz, CH), 4.85 (1H, d, J 5.2 Hz, NH), 5.12 (1H, t, J 6.4 Hz, 
NH), 6.69 (1H, t, J 6.0 Hz, NH) 6.82 (2H, d, J 7.2 Hz, 2 x Ar-H), 7.06-7.13 (5H, m, 5 x 
Ar-H), 7.25 (2H, d, J 8.4 Hz, 2 x Ar-H), 7.37 (2H, d, J 8.4 Hz, 2 x Ar-H), 7.69 (2H, d, J 
8.4 Hz, 2 x Ar-H); δC (100 MHz, CDCl3): 21.6 (2 xCH3), 38.2 (CH2), 39.7 (CH2), 42.6 
(CH2), 58.2 (CH), 127.1 (2 x ArCH), 127.3 (2 x ArCH), 127.4 (ArCH), 129.0 (4 x ArCH), 
129.8 (2 x ArCH), 129.9 (2 x ArCH), 134.8 (ArC), 135.1 (ArC), 137.0 (ArC), 143.6 (ArC), 
144.1 (ArC), 171.1 (C=O); LRMS (FAB); 516.2 ([M+H]+, 100%), 360.2 (7), 274.1 (24), 
154.9 (40), 138.1 (32), 92.8 (20); HRMS calcd for C25H29N3O5S2 516.1627, found 
516.1630. 
(2S)-2-Benzyl-2-(toluenesulfonylamino)-N-[2-(toluenesulfonylamino)ethyl]-
aminoethane (188) 
H
N
NH
NHTs
Ts
Ph
 
187 (500 mg, 0.97 mmol) was suspended in dry THF (7 mL) and cooled to 0 oC. BH3.THF 
(1M) (1 mL) was added dropwise, and then mixture stirred and heated at reflux for 6 d. 
The excess borane was then quenched by careful addition of MeOH (4 mL). Reaction 
mixture was then concentrated in vacuo. Conc HCl (7 mL) was added to the residue, and 
mixture stirred and heated under reflux overnight. The solution was then cooled using an 
ice bath, and product filtered, washed with Et2O (10 mL), and dried by rotary evaporation 
to give 188 as a white powder (375 mg, 77%). mp: 193-195 oC; νmax (KBr)/cm-1: 3434 (N-
H), 3063 (ArC-H), 3030 (ArC-H), 1599 (ArC=C), 1325 (SO2-N), 1157 (SO2-N), 1092 (C-
N); [α]D21 -17.32 (c 1.0, MeOH); δH (400 MHz, CD3OD): 2.56 (3H, s, CH3), 2.34 (3H, s, 
CH3), 2.48-2.65 (3H, m, 3 x CH), 2.76-2.93 (4H, m, 4 x CH), 4.54 (1H, br s, NH), 6.92-
6.94 (2H, m, 2 x Ar-H), 7.01-7.03 (3H, m, 3 x Ar-H), 7.10 (2H, d, J 8.0 Hz, 2 x Ar-H), 
7.30 (2H, d, J 8.0 Hz, 2 x Ar-H), 7.43 (2H, d, J 8.4 Hz, 2 x Ar-H), 7.61 (2H, d, J 8.4 Hz, 2 
x Ar-H). δC (100 MHz, CD3OD): 21.5 (2 x CH3), 39.5 (CH2), 40.0 (CH2), 48.9 (CH2), 52.7 
(CH2), 53.7 (CH), 128.0 (ArCH), 128.2 (2 x ArCH), 128.3 (2 x ArCH), 129.8 (2 x ArCH), 
130.1 (2 x ArCH), 131.0 (4 x ArCH), 137.2 (ArC), 137.7 (ArC), 138.4 (ArC), 145.2 (ArC), 
145.4 (ArC). LRMS (FAB): 502.3 ([M+H]+, 100%), 348.3 (9), 227.3 (13), 92.8 (42); 
HRMS calcd for C25H32O4N3S2 502.1834, found 502.1838. 
Caroline M. Reid, 2006  Chapter 7, 179 
(2S)-N-[2-[(toluenesulfonylamino)ethyl]-N-[2-(toluenesulfonyl)amino]-3-
phenyl-propyl-toluenesulfonamide (189) 
Ts
N
NH
NHTs
Ts
Ph
 
A solution of 188 (1.89 g, 3.8 mmol) in pyridine (10 mL) was added dropwise to a stirring 
solution of p-toluenesulfonyl chloride (869 mg, 4.56 mmol) in pyridine (30 mL) cooled to 
0 oC. The mixture was then stirred at rt for 7 d before being poured onto an ice : H2O 
mixture (150 mL), and left to precipitate overnight. The yellow solid 189 was then filtered 
and dried (2.17 g, 87%). mp: 73-76 oC (lit.120 no characterisation); [α]D21 23.9 (c 1.0, 
CHCl3); νmax (KBr)/cm-1: 3287 (-NH-), 1334 (SO2-N), 1160 (SO2-N); δH (400 MHz, 
CDCl3): 2.30 (3H, s, CH3), 2.32 (3H, s, CH3), 2.34 (3H, s, CH3), 2.49 (1H, dd, J 14.0, 7.8 
Hz, CH), 2.75 (1H, dd, J 14.0, 6.2 Hz, CH), 2.95-3.00 (4H, m, 4 x CH), 3.05-3.14 (1H, m, 
CH), 3.19 (1H, dd, J 14.0, 6.6 Hz, CH), 3.51-3.57 (1H, m, CH), 5.05 (1H, d, J 6.0 Hz, 
NH), 5.34 (1H, t, J 5.8 Hz, NH), 6.83 (2H, d, J 8.2 Hz, 2 x Ar-H), 7.01-7.08 (5H, m, 5 x 
Ar-H), 7.20 (4H, dd, J 8.2, 2.2 Hz, 4 x Ar-H), 7.47 (4H, dd, J 8.2, 3.8 Hz, 4 x Ar-H), 7.66 
(2H, d, J 8.2 Hz, 2 x Ar-H); δC (100 MHz, CDCl3): 21.6 (3 x CH3), 38.8 (CH2), 42.6 
(CH2), 51.3 (CH2), 54.4 (CH), 54.9 (CH2), 126.7 (ArCH), 127.1 (2 x ArCH), 127.2 (2 x 
ArCH), 127.5 (2 x ArCH), 128.7 (2 x ArCH), 129.1 (2 x ArCH), 129.8 (4 x ArCH), 130.0 
(4 x ArCH), 134.3 (ArC), 136.3 (2 x ArC), 136.8 (ArC), 143.4 (ArC), 143.5 (ArC), 144.2 
(ArC); LRMS (FAB): 656.1 ([M+H]+, 100%), 502.1 (6), 381.1 (11), 274.1 (13), 227.3 
(31), 92.8 (47); HRMS calcd for C32H38N3O6S3 656.1923, found 656.1921. 
2-(Benzyl)-1,4,7,10-tetrakis-(toluene-4-sulfonyl)-1,4,7,10-
tetraazacyclododecane  (190) 
N N
NN
Ts
TsTs
Ts
 
A solution of N,O,O'-Tri(p-toluenesulfonyl)diethanolamine 47 (433 mg, 0.76 mmol) in 
DMF (5 mL) added dropwise to a stirring solution of 189 (500 mg, 0.76 mmol) and 
caesium carbonate (743 mg, 2.3 mmol) in DMF (15 mL). The mixture was then stirred at rt 
for 14 d, before solvent was removed in vacuo and residue transferred to a separating 
funnel with CH2Cl2 (100 mL) and H2O (30 mL). The organic layer was separated, and the 
aq layer extracted with CH2Cl2 (2 x 25 mL). The organic layers were combined, dried over 
MgSO4 and concentrated under reduced pressure to yield a yellow solid (668 mg, 100%). 
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mp: 72-78 oC (lit.120 no characterisation); [α]D21 16.38 (c 1.0, CHCl3);  νmax (KBr)/cm-1: 
1597.7 (Ar), 1494.6 (Ar), 1339.3 (SO2-N), 1160.0 (SO2-N); δH (400 MHz, CDCl3): 2.25 
(3H, s, CH3), 2.60 (3H, s, CH3), 2.29 (3H, s, CH3), 2.32 (3H, s, CH3), 2.43-4.23 (15H, m, 
14 x CH, CHA), 6.79-7.72 (21H, m, 21 x Ar-H); δC (100 MHz, CDCl3): 21.5 (3 x CH3) 
21.7 (CH3), 38.8 (CH2), 48.5 (CH2), 51.0 (CH2), 54.5 (CH2), 54.7 (CH), 62.0 (CH2), 66.1 
(CH2), 68.4 (CH2), 127.1 (2 x ArCH), 127.1 (2 x ArCH), 127.2 (2 x ArCH), 127.5 (2 x 
ArCH), 128.0 (2 x ArCH), 128.5 (ArCH), 129.0 (2 x ArCH), 129.2 (2 x ArCH), 129.7 (2 x 
ArCH), 129.9 (2 x ArCH), 130.1 (2 x ArCH), 132.4 (ArC), 134.4 (2 x ArC), 136.7 (2 x 
ArC), 143.2 (2 x ArC), 143.4 (2 x ArC), 144.0 (2 x ArC), 145.3 (2 x ArC), 160.6 (2 x 
ArC), 162.7 (2 x ArC); LRMS (FAB): 900.9 ([M+Na]+, 24%), 787.8 (15), 678.0 (40), 
656.(12), 396.0 (7), 317.1 (7), 239.2 (15), 92.9 (100); HRMS calcd for C43H50N4O8S4Na 
901.2409, found 901.2412. 
2-Benzyl-1,4,7,10-tetraazacyclododecane (191) 
NH HN
HNNH .4HBr
 
190 (205 mg, 0.23 mmol) was added to H2SO4 (98%) (250 µL) heated to 165 oC in a 
conical flask. The solution was stirred vigorously at this t for six minutes. The mixture was 
then cooled in an ice bath before the liquid was added dropwise to a stirring flask of EtOH 
(2 mL). Et2O (1.2 mL) was then added and the solution cooled to 0 oC before the 
precipitate was collected by filtration. The solid was dissolved in hot H2O (200 µL) and 
HBr (48%) (200 µL) added. The tetrahydrobromide salts formed was filtered and dried in 
vacuo (111 mg, 83%). Due to time constraints, 191 was not converted to the free base and 
requires full characterisation. (lit.120 no characterisation). 
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7.4 Experimental to Chapter 5 
7.4.1 Experimental Details 
Tetrakis-(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane (220) 
N N
NN
OHHO
HO OH
 
36 (970 mg, 5.6 mmoles) was dissolved in H2O (10 mL) and the solution cooled to 0 oC. 
Ethylene oxide (2.66 mL, 560.0 mmol) was added via a cooling finger to a dropping funnel 
containing H2O (2 mL). The ethylene oxide solution was added to the cyclen solution, and 
the resulting mixture stirred for 2 h at 0 oC before the reaction was stopped by removal of 
excess ethylene oxide under vacuum. The product was dried in vacuo to leave a viscous 
yellow oil (1.92 g, 98%). This crude product was continually extracted with hexane for 30 
min to get 220 as white crystals (<1%). mp: 89-91 oC (lit.213 90-92 oC); νmax (neat)/cm-1: 
3350 (O-H stretching), 2811 (NCH2, CH2) cm-1; δH (400 MHz, D2O): 2.58 (8H, t, J 6.0 Hz, 
4 side chain NCH2), 2.69 (16H, s, 8 ring NCH2), 3.61 (8H, t, J 6.0 Hz, 4 side chain OCH2); 
δC (100 MHz, D2O): 49.9 (8 ring NCH2), 56.3 (4 side chain NCH2), 59.0 (4 side chain 
OCH2); LRMS (CI+): 349.3 ([M+H]+, 100%), 347.3 (7), 287.3 (44), 271.2 (8), 243.2 (6), 
216.2 (10); HRMS calcd for C16H36O4N4 349.2815, found 349.2815. 
1,4,7,10-Tetra-(2-chloroethyl)-1,4,7,10-tetraazacyclododecane 
dihydrochloride (209) 
N N
NN
ClCl
Cl Cl
 
220 (500 mg, 1.43 mmol) and SOCl2 (343 mmol, 25 mL) were added to a round-bottomed 
flask fitted with a water-cooled condenser and this was heated at 50 oC for 18 h. After this 
time, the excess thionyl chloride was removed by rotary evaporation. The product was 
recrystallised using hot propan-2-ol as white crystals. (47.7 mg, 34%). mp: 206-208 oC; 
NMR spectroscopy agreed with lit. values;209 δH (400 MHz, D2O): 3.28 (16H, s, ring 8 x 
CH2), 3.38 (8H, s, 4 x N-CH2), 3.84 - 3.90 (8H, m, 4 x Cl-CH2).; LRMS (FAB, glycerol): 
423.2 ([M+H]+, 100%), 421.2 (79), 387.3 (21), 359.2 (19), 211.2 (26), 197.1 (12), 161.1 
(9), 106.4 (39), 57.9 (12), 57.0 (11). 
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1,4,7,10-Tetrakis[(ethoxycarbonyl)methyl]-1,4,7,10-tetraazacyclododecane
 (222) 
N N
NN
EtO
O
EtO
O
OEt
O
OEt
O
 
A mixture of cyclen tetrahydrochloride 36 (364 mg, 1.14 mmol), ethyl chloroacetate (0.6 
mL, 5.7 mmol) and Na2CO3 (1.8 g, 17 mmol) in CH3CN (45 mL) was stirred and heated 
under reflux for 18 h. The solution was then cooled to rt before filtering, and the filtrate 
was concentrated in vacuo. The resulting brown residue was washed with hexane, then 
gave white hexagonal crystals (7 mg, 10%) from dichloromethane and hexane. mp: 
decomposition >150 oC (lit.217 decomposition 81 oC); νmax (neat)/cm-1: 2980 (N-CH2), 2826 
(N-CH2), 1724 (C=O), 1203 (CO-O), 1104 (CO-O); δH (400 MHz, D2O): 1.17 (16H, t, J 
7.1 Hz, 4 x CH3), 2.29 (16H, br s, 8 x ring CH2), 1.96 (8H, br s, 4 x arm CH2), 4.12 (8H, q, 
J 7.1 Hz, 4 x CH2-CH3); δC (100 MHz, D2O): 13.4 (4 x CH3), 55.2 (4 x CH2-O), 62.1 (12 x 
CH2-N), 175.0 (4 x C); LRMS (EI)+: 516.2 ([M+H]+, 5%), 443.2 (74), 374.2 (25), 271.1 
(46), 245.1 (100), 185.1 (52), 130.1 (80), 98.1 (34); HRMS calcd for C24H44N4O8, 
516.3159, found 516.3162. 
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (dota) (223) 
N N
NN
HO
O
HO
O
OH
O
OH
O
 
A solution of chloroacetic acid (876 mg, 9.3 mmol) in H2O (2 mL) was added to a stirring 
solution of cyclen 36 (0.2 g, 1 mmol) in H2O (3 mL), and the pH was adjusted to 9 with 
NaOH (5M). The t was raised to 70 oC and the pH maintained between 8.5 and 9 by the 
addition of NaOH (5M) as necessary. The mixture was stirred at this t for 48 h before 
cooling to rt and concentrating in vacuo. The residue was acidified with HCl (1M) to pH 
2.5 and the solution was passed through an cation exchange coloumn (Dowex 50W-8X 
(H+)). The column was washed with H2O until the eluent was neutral, and then the ligand 
was brought off the column using NH3 : H2O (20 mL : 100 mL). The basic eluent was 
reduced under reduced pressure to leave 223 as a white solid (143 mg, 23%). mp: 263-266  
oC (lit.280 265-267 oC); δH (400 MHz, D2O): 3.17 (16H, s, 8 x ring CH2), 3.51 (8H, s, 4 x 
arm CH2); δC (100 MHz, D2O): 49.7 (4 x CH2), 55.9 (8 x CH2), 171.82 (4 x C=O). 
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1,4,7,10-Tetrakis-(2-methoxyethyl)-1,4,7,10-tetraazacyclododecane (224) 
N N
NN
OMeMeO
MeO OMe
 
36 (1.0 g, 5.8 mmol), 2-chloroethyl-methyl ether (12 mL, 232 mmol), NaOH pellets (0.93 
g, 23 mmol), and aq EtOH (50%, 50 mL) were stirred and heated under reflux for 9 d. A 
pH greater than 11 was maintained by regular addition of NaOH pellets. After this time, 
the solvent was removed under vacuum. The solid residue was dissolved in H2O (30 mL) 
and made basic with conc NaOH (15 mL), before exhaustively extracting with CHCl3. The 
organic layer was then dried with Na2SO4 and concentrated, yielding product as yellow-
white crystals (3.44 g, 100%). νmax (neat)/cm-1: 2956 (CH), 2879 (CH), 2809 (O-CH3); 
NMR spectroscopy agreed with lit. values;218 δH (400 MHz, D2O): 2.56 (24H, m; 16 x ring 
N-CH2, 8 x side chain N-CH2), 3.34 (12H, s, 4 x O-CH3), 3.51 (8H, t, J 5.2, 4 x O-CH2); δC 
(100 MHz, D2O): 49.2 (8 x side chain CH2), 52.2 (8 x side chain CH2), 58.6 (4 x CH3), 
68.2 (16 x ring CH2); LRMS (CI+): 405.3 ([M+H]+, 51%), 373.4 (26), 316.3 (9), 290.3 
(31), 189.2 (59), 157.2 (19), 102.1 (100), 71.1 (58); HRMS calcd for C20H44N4O4 
405.3441, found 405.3440. 
Tetrakis-(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane (220) 
N N
NN
OHHO
HO OH
 
222 (185 mg, 0.36 mmol) was dissolved in Et2O (5 mL) and the solution stirred and cooled 
to -78 oC. Di-isobutyl aluminium hydride (3.2 mL, 3.2 mmol) was added drop wise, and 
then the mixture was stirred at this t for one h, before warming to rt and stirring for a 
further 24 h. The reaction was quenched by addition of a saturated ammonium chloride 
solution (5 mL) and the solution was stirred until a white precipitate formed. The solution 
was filtered through a pad of celite and washed with Et2O (30 mL). The organic phase was 
dried over MgSO4 before concentrating under reduced pressure to give 220 as a white solid 
(120 mg, 96%). mp: 89-91 oC (lit.213 90-92 oC); δH (400 MHz, D2O): 3.20 (8H, s, 4 side 
chain NCH2), 3.35 (16H, s, 8 ring NCH2), 3.92 (8H, t, J 6.0 Hz, 4 side chain OCH2). 
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tert-Butyl-(2-chloroethoxy)-dimethyl-silane (226) 
Cl O Si
 
To a stirred solution of dry THF (4 mL), was added tert-butyldimethylsilyl chloride (4.1 g, 
27 mmol) and imidazole (3.81 g, 56 mmol) at 0 oC. 2-Chloroethanol (1.5 mL, 22 mmol) 
was added dropwise at this t, and the solution warmed to rt and stirred for 6 d. A small 
amount of ice was added to quench the reaction and the solution was extracted with Et2O 
(5 x 30 mL). The ether layer was washed with H2O (10 mL) and brine (10 mL) before 
drying over MgSO4. The solvent was removed by rotary evaporation to leave the product 
as a clear colourless liquid (5 g, 100%). δH (400 MHz, CDCl3): 0.08 (6H, s, 2 x CH3-Si), 
0.82 (9H, s, 3 x CH3), 3.43 (2H, t, J 6.4 Hz, CH2-O), 3.75 (2H, t, J 6.4 Hz CH2-Cl); δC 
(100 MHz, CDCl3): –5.33 (2 x CH3-Si), 18.4 (C), 25.8 (3 x CH3), 45.1 (CH2), 63.6 (CH2); 
LRMS (CI+): 195.14 ([M+H]+, 100%), 137.07 (10); HRMS calcd for C8H19OSi35Cl 
195.0972, found 195.0976. 
7.5 Experimental to Chapter 6 
7.5.1 General Procedure (6A) 
A. Preparation of pyrazolidine derivatives.250 Phenyl-pyrazolidine-3,5-dione (1 eq), 
aldehyde (1 eq) and freshly fused sodium acetate (1 eq) were dissolved in glacial acetic 
acid (5 ml per mmol phenyl-pyrazolidine-3,5-dione). The solution was heated at reflux for 
2-19 h then cooled and filtered. The precipitate was rinsed with EtOAc (2 x 30 ml) and 
dried in vacuo to give the pyrazolidine as a mixture of geometric isomers. 
7.5.2 Experimental Details 
Phenyl-pyrazolidine-3,5-dione (241) 
N NH
OO
 
This method is adapted from the literature.246 
Sodium ethoxide (5.44 g, 81.6 mmol) was dissolved in dry EtOH (60 ml). Phenylhydrazine 
(4.02 ml, 40.8 mmol), and diethyl malonate (6.2 ml, 40.8 mmol) were added at rt with 
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stirring. The reaction mixture was heated at 110-120 oC for 1 h before the EtOH was 
removed by distillation. The residue was heated at this t for a further 2 h. The flask was 
cooled to 0 oC, and a small volume of distilled H2O (30 mL) was added. The flask was 
sonicated to dissolve all residues, and then the aq phase was extracted with Et2O (5 x 20 
ml) to remove any remaining starting material. The aq phase was acidified with HCl (6 M) 
to pH 1-2. The product precipitated as a yellow solid. The aq layer was then extracted with 
EtOAc (10 x 30 ml) to extract more of the product. The organic extracts were concentrated 
in vacuo to leave a yellow-brown residue. EtOH (200 ml) was added to dissolve all 
residues, and the flask was sonicated, before heating under reflux for 4 h, filtering 
occasionally to remove inorganic white salt. The product dissolved in EtOH was left to 
stand for 3 weeks to allow formation of any remaining salt, before filtering a final time. 
The organic extracts were concentrated in vacuo to leave phenyl-pyrazolidine-3,5-dione as 
a yellow solid. Re-crystallisation from EtOH gave 241 as yellow needles (3.55 g, 49%). 
mp: 190-191 oC (lit.246 192 oC); νmax(neat)/cm-1: 2910 (Ar), 1744 (amide), 1672 (amide); 
δH (400 MHz, DMSO-d6): 3.59 (2H, s, CH2), 7.18 (1H, t, J 7.4 Hz, Ar-H), 7.42 (2H, t, J 
8.0 Hz, 2 x Ar-H), 7.66 (2H, d, J 8.0 Hz, 2 x Ar-H), 11.46 (1H, br s, NH); δC (100 MHz, 
DMSO-d6): 38.1 (CH2), 118.8 (2 x ArCH), 124.87 (ArCH), 129.2 (2 x ArCH), 137.2 (C), 
166.4 (C=O), 167.9 (C=O); LRMS (EI+): 176.09 ([M]+, 100%), 108.09 (54), 77.05 (54); 
HRMS calcd for C9H8N2O2 176.0586, found 176.0587. 
1-Acetyl-1-phenylhydrazine (242) 
N
H
H
N
O
 
Phenyl hydrazine (3.0 mL, 0.03 mmol) was suspended in Et2O (30 mL) at 0 oC, and a 
solution of acetic anhydride (6.4 mL, 0.07 mmol) in Et2O (15 mL) was added dropwise 
over 10 min. The mixture was then stirred at this t for a further 10 min. The solution was 
then diluted with petroleum ether (30 mL) and filtered. The solid was washed with 
petroleum ether and Et2O, to give 242 as a white powder (4.43 g, 96%). mp: 127-129 oC 
(lit. 281 129 oC); δH (400 MHz, DMSO-d6): 1.91 (3H, s, CH3), 6.70-6.74 (3H, m, 3 x Ar-H), 
7.11-7.16 (2H, m, 2 x Ar-H), 7.64 (1H, s, NH), 9.61 (1H, s, NH); δC (100 MHz, DMSO-
d6): 21.0 (CH3), 112.4 (2 x ArCH), 118.7 (ArCH), 129.4 (2 x ArCH), 149.7 (ArC), 169.4 
(C=O). 
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4-(5-Bromo-2-furfurylidene)-1-phenyl-pyrazolidine-3,5-dione (240) 
1
2
35
4
N NH
OO
O
Br
 
4-5-Bromo-2-furfurylidene was synthesised as a 2:3 mixture of geometric isomers via 
general method 6A using phenyl-pyrazolidine-3,5-dione (250 mg, 1.4 mmol), 5-bromo-2-
furaldehyde (248 mg, 1.4 mmol) and sodium acetate (115 mg, 1.4 mmol). The reaction 
gave a brown/black precipitate (302.4 mg, 65%). mp: decomposition > 210 oC; δH (400 
MHz, DMSO-d6): 7.06 (1H, d, J 3.6 Hz, furan 4-H), 7.21 (1H, t, J 7.2 Hz, Ar-H), 7.45 (2H, 
dt, J 7.6, 2.4 Hz, 2 x Ar-H), 7.56 (0.4 H, s, vinylic CH), 7.58 (0.6 H, s, vinylic CH), 7.74 
(2H, dd, J 14.4, 8 Hz, 2 x Ar-H), 8.37 (0.6 H, d, J 3.2 Hz, furan 3-H), 8.45 (0.4 H, d, J 3.2 
Hz, furan 3-H); δC (100 MHz, DMSO-d6): 115.1 (C), 117.6 (CH-4), 118.6 (2 x ArCH), 
118.9 (CH), 125.1 (CH-3), 127.6 (ArCH), 129.3 (2 x ArCH), 131.7 (ArC), 152.4 (CH-2), 
152.3 (CH-5), 159.3 (C=O), 160.8 (C=O); LRMS (EI+): 332.0 ([M+H]+, 7%), 78.0 (80), 
63.0 (100); HRMS calcd for C14H9O3N279Br 331.9797, found 331.9800. 
4-(2-Furfurylidene)-1-phenyl-pyrazolidine-3,5-dione (243) 
N NH
OO
O
 
243 was synthesised as a 1:1 mixture of geometrical isomers using general method 6A, by 
reacting 241 (250 mg, 1.4 mmol) with furfuraldehyde (0.12 ml, 1.4 mmol) and sodium 
acetate (0.12 g, 1.4 mmol). 243 was produced as a gold/brown precipitate (276 mg, 77%). 
mp: decomposition >210 oC; νmax (neat)/cm-1: 3126 (Ar), 3011 (Ar), 1709 (C(O)N), 1652 
(C(O)N); δH (400 MHz, DMSO-d6): 6.93 (1H, dd, J 3.5, 1.21 Hz, CH-4), 7.20 (1H, dt, J 
7.4, 1.1 Hz, Ar-H), 7.45 (2H, dt, J 7.5. 1.9 Hz, 2 x Ar-H), 7.63 (0.5 H, s, vinylic CH), 7.65 
(0.5 H, s, vinylic CH), 7.75 (2H, dd, J 14.6, 8.0 Hz, 2 x Ar-H), 8.25 (1H, t, J 1.9 Hz, CH-
5), 8.43 (0.5 H, d, J 3.0 Hz, CH-3), 8.53 (0.5 H, d, J 3.7 Hz, CH-3), 11.5 (1H, br s, NH); δC 
(100 MHz, DMSO-d6): 114.8 (C), 115.4 (CH-4), 118.6 (2 x ArCH), 118.9 (CH), 125.0 
(CH-3), 125.8 (ArCH), 129.3 (2 x ArCH), 138.0 (ArC), 150.2 (CH-2), 151.1 (CH-5), 159.3 
(C=O), 160.8 (C=O). 
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4-(5-Methyl-2-furfurylidene)-1-phenyl-pyrazolidine-3,5-dione (244) 
N NH
OO
O
 
Analogue 244 was synthesised as a 1:1 mixture of geometric isomers by general method 
6A using 241 (150 mg, 0.85 mmol), 5-methyl-2-furaldehyde (0.08 ml, 0.85 mmol) and 
sodium acetate (70 mg, 0.85 mmol). 244 was produced as an orange solid (152 mg, 67%). 
mp: 201-203 oC; νmax (neat)/cm-1: 3126 (Ar), 3020 (CH3), 1709 (C(O)N), 1653 (C(O)N); 
δH (400 MHz, DMSO-d6): 2.53 (3H, s, CH3), 6.7 (1H, d, J 3.1 Hz, CH-4), 7.25 (1H, t, J 7.2 
Hz, Ar-H), 7.5 (2H, t, J 7.2, 2 x Ar-H), 7.6 (0.5H, s, CH), 7.62 (0.5H, s, CH), 7.79 (2H, dd, 
J 14.4, 8 Hz, 2 x Ar-H), 8.51 (0.5H, br s, CH-3), 8.57 (0.5H, d, J 3.6 Hz, CH-3), 11.3 (1H, 
br s, NH); δC (100 MHz, DMSO-d6): 14.5 (CH3), 112.5 (C), 113.0 (CH-4), 118.5 (2 x 
ArCH), 118.8 (CH), 124.9 (CH-3), 128.3 (ArCH), 129.2 (2 x ArCH), 138.0 (ArC), 149.2 
(CH-2), 149.3 (CH-5), 159.8 (C=O), 162.0 (C=O); LRMS (CI+): 269.1 ([M+H]+, 6%), 85.1 
(8), 79.1 (100); HRMS calcd for C15H13O3N2 269.0926, found 269.0929. 
4-(5-Nitro-2-furfurylidene)-1-phenyl-pyrazolidine-3,5-dione (245) 
N NH
OO
O
O2N
 
245 was prepared as a mixture of geometric isomers via general method 6A using 241 (150 
mg, 0.85 mmol), 5-nitro-2-furaldehyde (0.09 ml, 0.85 mmol) and sodium acetate (70 mg, 
0.85 mmol). 245 was produced as a dark brown solid (218 mg, 86%). mp: decomposition > 
230 oC; νmax (neat)/cm-1: 3138 (Ar), 1672 (amide), 1623 (amide), 1527 (C-NO2), 1344 (C-
NO2); δH (400 MHz, DMSO-d6): 7.24 (1H, t, J 7.6 Hz, Ar-H), 7.48 (2H, dt, J 8.8, 2.0 Hz, 2 
x Ar-H), 7.61-7.63 (1H, m, CH), 7.73-7.75 (2H, m, 2 x Ar-H), 7.90 (1H, t, J 4.0 Hz, CH-
3), 8.52 (1H, d, J 4.0 Hz, CH-4), 11.70 (1H, br s, NH). 
Caroline M. Reid, 2006  Chapter 7, 188 
4-(5-Hydroxymethyl-2-furfurylidene)-1-phenyl-pyrazolidine-3,5-dione (246) 
N NH
OO
O
HO
 
246 was synthesised as a 1:3 mixture of geometric isomers by general method 6A by 
reacting 241 (120 mg, 0.68 mmol), 5-hydroxymethyl-2-furaldehyde (86 mg, 0.68 mmol) 
and sodium acetate (70 mg, 0.68 mmol) to give 246 as a brown solid (93 mg, 48%). mp: 
175-179 oC; νmax (neat)/cm-1: 3070 (Ar), 1498.42 (C(O)N), 1344 (O-H), 1063 (C-O); δH 
(400 MHz, DMSO-d6): 4.62 (2H, s, CH2O), 5.24 (1H, s, OH), 6.83 (1H, d, J 3.7 Hz, CH-
4), 7.25 (1H, t, J 7.4 Hz, Ar-H), 7.5 (2H, t, J 8.6 Hz, 2 x Ar-H), 7.61 (0.25H, s, CH), 7.64 
(0.75H, s, CH), 7.79 (2H, dd, J 15.2, 8.2 Hz, 2 x Ar-H), 8.53 (0.75H, br s, CH-3), 8.58 
(0.25H, d, J 2.8 Hz, CH-3), 11.3 (1H, br s, NH); δC (100 MHz, DMSO-d6): 56.5 (CH2O), 
113.8 (C), 115.3 (CH-4), 118.6 (2 x ArCH), 118.8 (CH), 125.0 (CH-3), 127.2 (ArCH), 
129.2 (2 x ArCH), 138.0 (ArC), 149.5 (CH-2), 151.1 (CH-5), 161.0 (C=O), 164.6 (C=O); 
LRMS (EI+): 284.1 ([M+H]+, 9%), 150.0 (5), 44.0 (50), 28.1 (100); HRMS calcd for 
C15H12O4N2 284.0797, found 284.0799. 
4-(2-Pyrrolylidene)-1-phenyl-pyrazolidine-3,5-dione (247) 
N NH
OO
HN
 
Analogue 247 was prepared as a mixture of geometric isomers via general method 6A. 241 
(150 mg, 0.85 mmol), 2-pyrrolecarboxaldehyde (86 mg, 0.85 mmol) and sodium acetate 
(70 mg, 0.85 mmol) were reacted to give 247 as a brown solid (89 mg, 42%). mp: 
decomposition > 230 oC; νmax (neat)/cm-1: 3059 (Ar), 1653 (C(O)N), 1595 (C(O)N), 1496 
(NH); δH (400 MHz, DMSO-d6): 7.21 (1H, dd, J 15.6, 7.6 Hz, CH), 7.31 (1H, br s, NH), 
7.43-7.49 (2H, m, 2 x ArH), 7.68-7.70 (4H, m, 3 x ArH, CH), 7.74 (0.5H, s, CH), 7.78 
(0.5H, s, CH), 7.80 (1H, s, H) 11.45 (1H, br s, NH); δC (100 MHz, DMSO-d6): 107.9 (C), 
113.8 (CH), 113.9 (CH), 118.3 (2 x ArCH), 118.9 (CH), 124.2 (ArCH), 128.9 (2 x ArCH), 
129.4 (C), 136.9 (ArC), 161.8 (C=O), 1 x missing C=O; LRMS (EI+): 253.1 ([M+H]+, 
100%), 146.0 (44), 119.0 (38), 63.0 (41); HRMS calcd for C14H11O2N3 253.0851, found 
253.0849.  
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4-(5-Bromo-2-thiophenylidene)-1-phenyl-pyrazolidine-3,5-dione (248) 
N NH
OO
S
Br
 
248 was synthesised as a mixture of geometric isomers by general method 6A. 241 (150 
mg, 0.85 mmol), 5-bromothiophene-2-carboxaldehyde (0.1 ml, 0.85 mmol) and sodium 
acetate (70 mg, 0.85 mmol) were reacted to give 248 as a brown solid (243 mg, 82%). mp: 
> 250 oC; νmax (neat)/cm-1: 2958 (Ar), 1713 (C(O)N), 1659 (C(O)N), 741 (C-Br); δH (400 
MHz, DMSO-d6): 7.22 (1H, t, Ar-H), 7.46 (2H, t, J 8.0 Hz, 2 x Ar-H), 7.53 (1H, d, J 4.0 
Hz, CH-4), 7.72 (2H, dd, J 12.9, 8.1 Hz, 2 x Ar-H), 8.03 (0.5H, d, J 4.1 Hz, CH-3), 8.07 
(0.5H, d, J 4.1 Hz, CH-3), 8.13 (0.5H, s, vinylic CH), 8.16 (0.5H, s, vinylic CH), 11.3 (1H, 
br s, NH); δC (100 MHz, DMSO-d6): 118.5 (CH), 128.9 (2 x ArCH), 129.0 (2 x ArCH), 
131.9 (CH), 132.0 (CH), 137.4 (ArC), 137.7 (ArC), 2 x C=O missing; LRMS (EI+): 349.92 
([M+H]+, 15%), 255.1 (24), 78.0 (85), 63.0 (100); HRMS calcd for C14H9O2N281BrS 
349.9548, found 349.9550. 
4-Benzylidene-1-phenyl-pyrazolidine-3,5-dione (249)
 
N NH
OO
 
Analogue 249 was synthesised as a 2:1 mixture of geometric isomers using general method 
6A. 241 (150 mg, 0.85 mmol), benzaldehyde (0.09 ml, 0.85 mmol) and sodium acetate (70 
mg, 0.85 mmol) were reacted to give 249 as a vivid orange solid (145 mg, 65%). mp: 251-
253 oC; νmax (neat)/cm-1: 3068 (Ar), 1683 (C(O)N), 1658 (C(O)N); δH (400 MHz, DMSO-
d6): 7.22 (1H, t, J 7.2 Hz, Ar-H), 7.44-7.49 (2H, m, 2 x Ar-H), 7.55-7.59 (2H, m, 2 x Ar-
H), 7.62-7.66 (1H, m, Ar-H), 7.74-7.76 (2H, m, 2 x Ar-H), 7.9 (0.3H, br s, CH), 7.95 
(0.6H, s, CH), 8.56-8.61 (2H, m, 2 x Ar-H); δC (100 MHz, DMSO-d6): 118.3 (CH), 128.7 
(2 x ArCH), 128.8 (2 x ArCH), 128.9 (2 x ArCH), 129.0 (2 x ArCH), 132.3 (ArC), 133.4 
(ArCH), 134.0 (ArC), 134.1 (ArCH), 2 missing C=O; LRMS (EI+): 264.1 ([M+H]+, 
100%), 195.1 (26), 130.0 (33), 78.0 (71), 63.0 (85); HRMS calcd for C16H12O2N2 
264.0899, found 264.0898. 
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7.5.3 Biological Materials and Methods for Chapter 6 
7.5.3.1 Western Blotting 
Primary human pigment epithelial (RPE) cells were incubated with 1-20 µM of each drug 
compound for 24 h. The protein from whole cell extracts were separated by sodium 
dodecyl sulfate 12% poly-acrylamide gel electrophoresis (SDS-PAGE) and analysed by 
Western blotting with anti-p53 DO-1 (pharmingen), anti-HDM-2 AB1/AB2 (Oncogene 
Science), anti-phospho-p53 (serine 15) (Cell Signaling), anti-21WAF1CIP1 (Santa Cruz 
Biotechnology) antibodies. Blots were also probed with an anti-Cdk4 antibody (Santa Cruz 
Biotechnology) to monitor protein loading. Visual comparison of the intensity of the 
compound bands with the control bands gave an indication of biological activity. 
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